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Abstract 
Mycophenolic acid (MPA) is an immunosuppressant commonly used to prevent rejection 
following renal transplantation. MPA prevents graft rejection through selective inhibition of 
inosine monophosphate dehydrogenase (IMPDH) enzyme in lymphocytes. It displays 
considerable inter-individual pharmacokinetic (PK) variability, and many factors, other than 
dose or total plasma concentrations, may impact on lymphocyte MPA concentrations. There 
is evidence that the multidrug resistance-associated protein 2 efflux transporter may 
influence MPA PK in plasma and affect its distribution into lymphocytes. Therefore, the 
major aim of this thesis was to investigate the influence of ABCC2 genetic polymorphisms 
as a determinant of inter-individual variability in MPA treatment response, as well as clinical 
outcomes. This thesis also set out to investigate intra-lymphocyte pharmacokinetic-
pharmacodynamic analyses of MPA as predictors of graft rejection.  
The first major study of this thesis incorporated the development and validation of new LC-
MS/MS methods for the quantification of MPA concentrations in human kidney biopsies 
(Chapter 2) taken as part of routine clinical procedures, and lymphocytes (Chapter 4), and 
applying these new methods in a pilot prospective clinical study of the utility of determining 
intra-renal and lymphocyte MPA concentrations as predictors of graft rejection.  
For the second major study (Chapter 3) of this thesis, recipients (n = 60) prescribed MMF, 
tacrolimus and prednisolone-based immunosuppression, and their donors (n = 46) were 
retrospectively genotyped for three common single nucleotide polymorphisms (SNPs) of 
ABCC2 (-24 C > T, 1249 G > A, 3972 C > T), haplotyped and patients were divided into 
wild-type, low or high ABCC2 expressor group. Whilst no relationship was observed 
between donor expressor status and MPA PK parameters, recipients with the high ABCC2 
expressor haplotype (CAC, -24C/1249A/3972C, variant at 1249) had significantly higher 
Zaipul Md Dom, PhD Thesis 2016 xi 
MPA trough (C0) concentrations, presumably due to an increased enterohepatic recirculation 
of MPA, compared to recipients with low expressor haplotypes. The multivariate analyses 
indicated that MPA C0 concentrations were associated with recipient ABCC2 expressor 
phenotype, rejection incidence and peak panel reactive antibody.  
The third major study (Chapter 4) of this thesis investigated the concentrations of MPA and 
IMPDH activity in lymphocytes, as predictors of rejection in 48 renal transplant recipients. 
Lymphocyte MPA concentration was the only covariate independently associated with 
rejection incidence in the multivariate analysis, suggesting that lymphocyte concentrations 
may be the best indicator of MPA therapeutic efficacy compared to monitoring plasma 
concentrations alone. ROC curve analyses revealed that lymphocyte MPA concentration was 
a better predictor of severe (cellular/vascular) rejection compared to IMPDH activity or 
plasma concentrations. IMPDH activity was not a significant predictor of graft rejection, 
however, a single measurement of IMPDH activity at pre-dose may have accounted for the 
lack of significant relationship between IMPDH activity and rejection.  
In summary, ABCC2 genetic variability may be important in determining exposure to MPA 
and may have clinically significant impacts on MPA treatment response. Despite monitoring 
plasma concentrations to maintain MPA efficacy and minimise the consequences of over-
exposure, inter-individual differences in MPA plasma PK are still difficult to predict, but 
may be accounted for by directly measuring lymphocyte MPA concentrations.
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Chapter 1. General introduction 
This thesis addresses renal disease, in particular transplantation, the only curative therapy for 
patients with end-stage renal disease. Immunosuppressive drug therapy (mainly cyclosporine 
(CsA), tacrolimus (TAC), and mycophenolic acid (MPA) – the subject of this thesis) is a 
major contributor to successful management of transplant recipients. Whilst the use of 
immunosuppressants has markedly improved graft and recipient survival following 
transplantation, there remains substantial inter-individual variability in outcomes partly due 
to lack of understanding of their tissue pharmacokinetics (PK) and pharmacogenetics (PGx) 
– mainly the kidney and lymphocytes. Therapeutic drug monitoring (TDM) has been 
implemented to individualise dosage selection based on plasma concentrations, although this 
often inadequately explains the variability in outcomes. Consequently, there is a need for 
clinical tools that are better predictors of kidney and lymphocyte MPA concentrations, since 
they are not necessarily mirrored by plasma concentrations, as currently monitored with 
TDM alone. In addition, a better understanding of the factors determining MPA distribution 
into lymphocytes and kidney, and hence, clinical outcomes, is essentially important. 
The membrane efflux transporter, multidrug resistance-associated protein 2 (MRP2), is 
firmly established as a determinant of intestinal, biliary and renal transport, and hence, 
elimination of a broad range of substrates, including MPA, but also regulates drug 
distribution and affects drug response, an area still poorly researched. Therefore, the 
polymorphic ABCC2 gene, encoding MRP2, provides a promising potential source of 
variability in MPA response. 
Before outlining the hypotheses and aims of this thesis, this introduction will provide an 
overview on the clinical PK and pharmacodynamics (PD) of MPA, the potential role of PGx 
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for the individualisation of MPA therapy, and finally it will discuss areas where additional 
research is warranted. 
1.1 Renal transplantation in Australia 
According to the Global Burden of Disease Study in 2013 [1], renal disease is one of the 10 
leading causes or risk factors of fatal burden in Australia, with two therapeutic treatments 
currently available, dialysis and renal transplantation. Relative to dialysis, renal 
transplantation is the preferred option for renal failure due to improved long-term outcomes 
and cost-effectiveness, and prolonged patient lifespan [2, 3]. In Australia, a record 914 renal 
transplantations (the highest number ever) were performed in 2014, as compared to 883 
transplantations performed in 2013 [4]. Acute rejection episodes are still a major problem in 
renal transplant recipients especially in the early post-transplant period, with rejection rates 
of 13 – 24 % in the first six months of transplantation in 2013 [4].  
1.1.1 Immunosuppressive therapy 
To date, a range of immunosuppressant drugs has been developed and used in different 
combinations for induction and maintenance therapy, and for treatment of acute rejection 
episodes (Table 1.1). Antibody-based induction immunosuppression (such as anti-
interleukin-2 receptor monoclonal antibody drugs) is initiated in the early post-transplant 
period, and is followed by maintenance immunosuppression, which typically involves triple 
therapy with mycophenolate mofetil (MMF), prednisolone and either a calcineurin inhibitor 
(CNI) (such as TAC or CsA) or less frequently a mammalian target of rapamycin (mTOR) 
inhibitor (such as sirolimus or everolimus). In Australia, MMF, TAC and prednisolone were 
the most commonly prescribed immunosuppressants at initial treatment for deceased donor 
grafts, accounting for 60 %, 88 % and 90 %, respectively, of maintenance 
immunosuppression in 2014 [4].  
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When the initial phase of graft stabilisation is achieved, the doses of maintenance 
immunosuppression are usually tapered down (as opposed to early post-transplantation) by: 
(1) dose reduction or discontinuation of MMF; (2) dose reduction or withdrawal of 
corticosteroid; (3) dose reduction or elimination of CNI; or (4) substitution of CNI with 
sirolimus in transplant recipients who are primarily sensitive to the nephrotoxicity of CNI 
[5]. 
 
Table 1.1 Immunosuppressants used for induction and maintenance therapy, and for treatment 
of acute rejection episodes following renal transplantation [6-8]. 
 








Bind to the α-subunit (CD25) on activated T cells, 
which then inhibit IL-2 binding, resulting in 






Binds to and blocks T-cell membrane proteins, 




Binds to T-cell-associated CD3 complex, resulting 
in CD-3 cell death by inducing antibody-mediated 
cytotoxicity and apoptosis 
 Alemtuzumab Binds to CD52 antigen on all B- and T-cells, 




Azathioprine Blocks the de novo and salvage pathway of purine 




Inhibitor of inosine monophosphate 
dehydrogenase which is the rate-limiting enzyme 
in the de novo pathway of purine synthesis  
Calcineurin 
inhibitors2 
Tacrolimus Binds to immunophilin, FK506-binding protein 12 
(FKBP12), resulting in inhibition of calcineurin 
phosphatase and T-lymphocyte activation  
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 Cyclosporine Binds to cyclophilin, resulting in inhibition of 





Inhibit leukocyte infiltration and expression of 








Bind to immunophilin, FKBP12, resulting in 
formation of sirolimus- or everolimus- FKBP12 
complex, which inhibit the activation of mTOR 
and suppression of T-cell proliferation 
1Induction immunosuppression; 2Maintenance immunosuppression; 3Induction 
immunosuppression and treatment of acute rejection; 4Muromonab-CD3 has been 
discontinued and was unavailable from 2011.  
 
1.2 Mycophenolic acid 
Mycophenolic acid (MPA), originally isolated from a fermentation product of Penicillium 
[9], was initially developed as an anti-viral [10], anti-cancer [11] and anti-psoriasis [12] 
agent before its development as an anti-proliferative agent. Currently, two mycophenolate 
oral formulations are commercially available: (1) the 2,4-morpholinoethyl ester pro-drug of 
MPA, mycophenolate mofetil (MMF, a prodrug to enhance the oral bioavailability of MPA 
[13]) (CellCept®, Hofmann-La Roche Pharmaceuticals, Basel, Switzerland); and (2) the 
sodium salt of MPA, formulated as enteric-coated tablets of mycophenolate sodium (EC-
MPS, new formulation) (Myfortic®, Novartis, Basel, Switzerland).  
MMF (the main focus as MMF was used for the studies performed in this thesis, hence 
details on EC-MPS will not be further discussed) has been approved by the United States 
Food and Drug Administration (FDA) and the Therapeutic Goods Administration (TGA) in 
Australia as well as in many other countries worldwide (e.g. Europe, Canada, Japan), and is 
commonly used for prophylaxis of organ rejection in patients receiving renal, heart or 
hepatic transplants. As discussed in Section 1.1.1, MMF is administered in combination with 
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a CNI (TAC or CsA) or less frequently mTOR inhibitors and corticosteroids [6-8]. 
Currently, the manufacturer’s guidelines for MMF dosages are: (1) an oral dose of MMF 1 g 
twice daily in adult renal transplant recipients, and (2) in the paediatric transplant population, 
an oral dose of MMF suspension 600 mg/m2 administered twice daily [14]. 
1.2.1 Chemistry 
According to the manufacturer’s information [14], the chemical name for MMF is 2-
morpholinoethyl-(E)-6-(1,3-dihydro-4hydroxy-6-methoxy-7-methyl-3-oxo-5-iso-
benzofuranyl)-4-methyl-4-hexenoate, with an empirical formula of C23H31NO7 and a 
molecular weight of 433.50. The structural formula for MMF is shown in Fig. 1.1A. MMF is 
a white to off-white crystalline powder and is soluble in acetone, methanol and ethanol. The 
MMF solubility increases in acidic pH (4.27 mg/mL at pH 3.6), however its solubility is 
lower in water (0.043 mg/mL at pH 7.4). The pKa values for MMF are 5.6 and 8.5 for the 
morpholino and phenolic groups, respectively, and the apparent partition coefficient (log P) 
in 1-octanol/water (pH 7.4) is 238 [14]. 
The chemical name of MPA is 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-
methyl-4-hexenoic acid (Fig. 1.1B). MPA has an empirical formula of C17H20O6 and a 
molecular weight of 320.3 [15]. MPA is soluble in methanol (50 mg/mL), chloroform, 
dichloromethane, ethanol and sodium hydroxide (10 mg/mL), forming a colourless to a very 
faint yellow solution. The pKa values for MPA are 4.6 and 8.5 for the carboxylic acid [15] 
and phenolic [14] groups, respectively, and the apparent partition coefficient (log P) in 1-
octanol/water (pH 7.4) is 1.6 [15]. 
 
 















Figure 1.1 Chemical structures of (A) MMF, (B) MPA and its glucuronides: (C) the 
pharmacologically inactive phenolic glucuronide (MPAG) metabolite; and (D) the minor 
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1.2.2 Mechanism of action of MPA 
1.2.2.1 Inhibition of inosine monophosphate dehydrogenase 
Purine biosynthesis consists of two major pathways: the de novo and the salvage pathways 
(Fig. 1.2). The de novo purine pathway produces purine nucleotides that represent the 
building blocks of DNA synthesis and is fundamental to the production of DNA. 5-
Phosphoribosyl-1-pyrophosphate (PRPP) synthetase, a crucial rate-limiting enzyme in the 
pathway of purine synthesis, is allosterically regulated by nucleotides, whilst inosine 
monophosphate (IMP) is a common intermediate in purine nucleotide biosynthesis and can 
be converted to guanosine monophosphate (GMP) as required [16]. 
MPA is a potent, selective, reversible, and non-competitive inhibitor of inosine 
monophosphate dehydrogenase (IMPDH), which is the rate-limiting enzyme in the de novo 
guanosine nucleotide pathway, converting IMP to GMP (Fig. 1.2) [17]. The de novo purine 
synthesis is required for lymphocyte progression through the cell cycle and proliferation, and 
GMP is an important building block for DNA, RNA and proteins. Unlike other cell types 
that can use the salvage pathway as an alternative supply of guanosine, T- and B-
lymphocytes can only utilise the de novo pathway [16].  
There are two types of IMPDH isoforms, IMPDH type I, which is expressed in all cell types 
and IMPDH type II, which is expressed only in activated lymphocytes [18-20]. MPA inhibits 
both IMPDH isoforms [17], however, the inhibition of IMDPH type II by MPA is 
approximately 5-fold greater than the type I isoform of IMPDH with the Ki values of 0.007 
versus 0.033 μM, respectively [17]. Therefore, MPA has a more potent cytotoxic effect on 
lymphocytes than on other cell types, thereby preventing T- and B-lymphocyte proliferation, 
and inhibiting cell-mediated immune responses and antibody formation [21].  













Figure 1.2 Schematic representation of purine synthesis consisting of two major cellular 
pathways: (1) the de novo and (2) salvage pathways of guanosine nucleotides 
biosynthesis. MPA inhibits IMPDH, a crucial enzyme involved in the de novo pathway. 
ATP, adenosine triphosphate; dGDP, deoxyguanosine diphosphate; dGTP, 
deoxyguanosine triphosphate; GDP, guanosine diphosphate; GMP, guanosine 
monophosphate; GTP, guanosine triphosphate; HGPRTase, hypoxanthine guanine 
phosphoribosyltransferase; IMP, inosine monophosphate; IMPDH, inosine 
monophosphate dehydrogenase; PNP, purine nucleoside phosphorylase; XMP, xanthine 
monophosphate. 
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1.2.2.2 Prevention of graft rejection 
As discussed in Section 1.1.1, MPA is commonly administered in combination with CsA or 
TAC, and although TAC is structurally different to CsA, its mechanism of action is similar 
(Fig. 1.3). Similar to MPA, both CsA and TAC have potent immunosuppressive properties; 
CsA and TAC selectively bind to immunophilins; cyclophilin and FK506 binding protein, 
respectively, resulting in the formation of CsA-cyclophilin and TAC-FK506 complexes [22, 
23]. Both drug-complexes inhibit the phosphatase activity of calcineurin within 
lymphocytes, thereby suppressing nuclear translocation and subsequent activation of nuclear 
factor of activated T-cells (NFAT) transcription factors (Fig. 1.3) [22, 23]. NFAT is the 
transcription factor required for the synthesis of interleukins, including IL-2 which is 
produced by activated T-cells and involved in the growth and proliferation of lymphocytes 
[24], and consequently, inhibition of IL-2 production produces immunosuppression. As 
discussed in Section 1.2.2.1, MPA is a potent inhibitor of IMPDH and selectively inhibits T- 
and B-lymphocyte proliferation. The inhibition of lymphocyte proliferation results in 
decreased expression of adhesion molecules and reduced recruitment of lymphocytes into 
the sites of inflammation [25], thus suppressing the production of nitric oxide and the 

















Figure 1.3 Mechanisms of T-cell-mediated immunosuppression showing the sites of 
action of CNIs and how MPA fits in with the mechanism of action of CNIs to inhibit 
lymphocyte proliferation. FKBP, FK binding protein; G1, gap 1 phase; G2, gap 2 phase; 
IL-2, interleukin-2; M, mitosis phase; NFAT, nuclear factor of activated T-cells; PO4, 
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1.2.3 Clinical pharmacokinetics of MPA 
1.2.3.1 Absorption and oral bioavailability 
Following oral administration of MMF (Fig. 1.4), the drug is rapidly absorbed and 
completely metabolised by esterases in the liver, blood, stomach and small intestines to form 
the active entity, MPA [13]. Oral absorption of MMF is rapid and complete according to the 
manufacturer’s information [14]. Following administration of a single oral dose of 
radiolabelled [mycophenolate−14C] MMF to four healthy volunteers, a mean of 90.4 % of 
the total administered dose was recovered during the first 72 hours (hr) following 
administration. Following intravenous (IV) infusion over 48 hr, MMF rapidly disappears 
from the plasma and is undetectable after 10 – 30 minutes (min) [27]. In healthy volunteers 
receiving 1.5 g of MMF daily, the mean ± standard deviation (SD) absolute bioavailability of 
MPA following orally administered MMF relative to IV infusion of MMF based on MPA 
area under the plasma concentration-time curves over 24 hr (AUC0-24) was 94.1 ± 16.2 % 
[27]. Another study in 9 cardiac transplant patients comparing the bioavailability of MPA 
(based on MPA AUC0-12) between a 3 hr IV infusion (on day 3 and 5) with oral 
administration (on day 6 and 10) of MMF post-transplantation has reported the mean oral 
bioavailability of 95 % (range: 82.0 – 107.8 %) [28].  
1.2.3.2 Distribution 
The mean ± SD volume of distribution of MPA in healthy volunteers following oral and IV 
MMF administration was reported to be 3.6 ± 1.5 and 4.0 ± 1.2 L/kg, respectively [14]. In 
whole blood, 99.99 % of MPA is detected in plasma with only 0.01 % of MPA found in 
cellular elements [29, 30]. MPA is extensively bound to human serum albumin (97 – 99 %) 
in patients with normal renal and liver function [30, 31]. MPA does not bind significantly to 
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α1-acid glycoprotein (750 mg/L) [30]. The primary metabolite of MPA, MPAG also binds 











Figure 1.4 A graphical representation of pharmacokinetic behaviour of MMF. Pathways 
of enterohepatic circulation of MPA via the glucuronide conjugate metabolites are shown 
(red arrows). AcMPAG, mycophenolic acid acyl glucuronide; IMPDH, inosine 
monophosphate dehydrogenase; MMF, mycophenolate mofetil; MPA, mycophenolic 
acid; MPAG, mycophenolic acid phenolic glucuronide; MRP2, multidrug resistance-
associated protein 2; OATPs, organic anion transporter polypeptides; TDM, therapeutic 
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Only free or unbound MPA is pharmacologically active and capable of inhibiting IMPDH 
[33]. Furthermore, higher exposure to free MPA results in an increased risk of MMF-related 
adverse events (e.g. leukopenia, infection) [34]. The percentage of free MPA is well 
correlated with plasma albumin concentrations [35]. The free fraction of MPA is decreased 
from 53.3 to 0.92 % with increasing concentrations of serum albumin (from 0.7 to 69 g/L). 
In contrast, the free fraction of MPA increased approximately 3- and 8-fold with increasing 
concentrations of MPAG (up to 475 mg/L) and sodium salicylate (from 10 to 500 mg/L), 
respectively [30]. The binding of MPA to plasma albumin is influenced by several factors 
including the availability of albumin binding sites and competition for these sites by urea and 
MPAG, which have been shown to compete with MPA for binding sites on serum albumin 
[36]. In addition, the binding of MPA and MPAG to plasma albumin can also be altered in 
patients with chronic renal dysfunction [37] and hypoalbuminemia [35], and because MPA is 
a restrictively cleared drug (refer to Section 1.2.3.5), these clinical conditions may cause an 
increase in the MPA free fraction (hence may affect total plasma concentrations but unbound 
MPA concentrations (Cu) are likely to be unaltered), and consequently a rise in the clearance 
(CL) of total MPA. 
1.2.3.3 Metabolism 
MPA is mainly metabolised in the liver and to a lesser extent in the kidney and 
gastrointestinal tract [38] by uridine diphosphate-glucuronosyltransferase (UGT) enzymes 
primarily into its main inactive metabolite, the pharmacologically inactive phenolic-
glucuronide of MPA (MPAG, Fig. 1.1C and 1.4) [39, 40], important for enterohepatic 
recycling of MPA (refer to Section 1.2.3.4), and into the pharmacologically active acyl-
glucuronide of MPA (AcMPAG, Fig. 1.1D and 1.4) [41]. In humans, the UGT isoforms 
responsible for the formation of MPAG and AcMPAG are UGT1A9 and UGT2B7, 
respectively [40, 42]. UGT1A9 contributes 55 %, 75 % and 50 % to the formation of MPAG 
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by the liver, kidney and gastrointestinal tract, respectively [40] while UGT2B7 is the only 
isoform responsible for AcMPAG production [39, 40, 42]. UGT1A7, UGT1A8 and 
UGT1A10 are also involved in the production of MPAG [39, 42] but to a lesser extent than 
UGT1A9. However, UGT1A7, 1A8 and 1A10 are present only in the gastrointestinal tract 
and kidney [38] and therefore are not responsible for MPAG production in the liver.  
The pharmacologically inactive MPAG metabolite has been shown to have no inhibitory 
effect on IMPDH [33] however, the active AcMPAG metabolite (concentrations in plasma: 
5.6 – 32.5 μg/L) displayed somewhat variable inhibitory effect compared with that of MPA 
(median (range) inhibition/concentration ratio of AcMPAG to MPA = 0.91 (0.48 – 1.23), n = 
21) [43]. The AcMPAG metabolite has also been proposed to cause hypersensitivity and 
drug-related toxicity as a result of covalent binding to nucleic acids, proteins, and lipids in 
patients receiving MPA therapy [44]. However, the mechanisms involved in the 
development of these side effects are still not yet fully understood and thus requires further 
investigation. 
1.2.3.4 Enterohepatic recirculation 
MPA is subject to enterohepatic recirculation via biliary excretion of MPAG [45] where 
following its hepatic formation, MPAG is excreted into bile, deconjugated back to MPA 
through the action of bacterial β-glucuronidases in the gastrointestinal tract, subsequently 
returned to the circulation following reabsorption from the colon. The enterohepatic 
recycling of MPA, on average, contributes approximately 37 % (range 10 – 61 % in humans) 
of the total dose-interval MPA AUC and is reflected as a secondary MPA peak observed 6 – 
12 hr after oral administration [32]. The kidney, however, is the main organ responsible for 
the irreversible excretion of both MPAG and AcMPAG metabolites [32] and multidrug 
resistance-associated protein 2 (MRP2) has been shown to be involved in renal and biliary 
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excretion of MPAG [46] (refer to Section 1.3). However, it is yet to be clearly established 
whether AcMPAG metabolite is subjected to biliary excretion, resulting in enterohepatic 
recycling of MPA, therefore, the question of whether AcMPAG may be involved in the 
enterohepatic recirculation remains to be investigated.  
1.2.3.5 Clearance and elimination 
The liver is the main organ for MPA elimination via metabolism to MPAG and AcMPAG. 
The kidney plays a minor role in the elimination of MPA; however, it plays a major role in 
the irreversible elimination of MPAG and AcMPAG glucuronides. The clearance of MPA is 
correlated with the free fraction of MPA [34]. Following oral administration of radiolabelled 
[mycophenolate−14C] MMF (as discussed in Section 1.2.3.1), of the total radioactivity 
recovered (> 90 %), an average of 96.3 % and 5.5 % of the dose were recovered in the urine 
(almost exclusively as MPAG (Fig. 1.1) and faeces, respectively [32]. MMF was not 
recovered in urine and approximately 0.6 % and 0.3 % of MPA and AcMPAG (Fig. 1.1), 
respectively, were detected as minor urinary components [32]. Several renal excretory 
pathways for MPA and MPAG have been proposed, including reabsorption [27] or 
glomerular filtration [32] for MPA. MPAG and AcMPAG are thought to be mainly excreted 
into the urine and cleared predominantly via active tubular secretion, although it is yet to be 
clearly established and an area requiring further investigation. The MRP2 efflux transporter 
has recently been shown to be involved in renal excretion of MPAG and MPA has been 
identified as a substrate of MRP2 [46].  
Following IV administration, the mean ± SD elimination half-life and plasma CL of MPA 
were reported to be 16.6 ± 5.8 hr and 177 ± 31 mL/min, respectively. The mean ± SD 
apparent half-life and plasma CL of MPA were estimated to be 17.9 ± 6.5 hr and 193 ± 48 
mL/min, respectively, following oral administration [27]. Following IV and oral 
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administration, the mean ± SD apparent plasma CL of MPAG were estimated to be 44.7 ± 
14.3 and 40 ± 8.6 mL/min, respectively, which was 5- to 4-fold lower than that of MPA [27]. 
The apparent elimination half-life for MPAG was similar to MPA (mean ± SD: 16.1 ± 5.2 
(oral) and 21.8 ± 19 (IV) hr) [27]. 
1.2.4 Factors influencing MPA pharmacokinetics 
Demographic factors 
Previous studies reported a significant association between MPA PK parameters and patient 
gender. The MPA trough (C0) concentrations were significantly increased in female renal 
transplant recipients compared to males [47]. In a population PK model, males have been 
reported to have an 11 % increased MPA CL than females [48]. 
A number of studies have investigated the influence of ethnicity on the PK of MPA. The 
incidence of acute rejection was more frequent in African-American renal transplant 
recipients (31.8 %) receiving 1 g of MMF twice daily compared to Caucasian transplant 
patients (15.7 %) [49]. In addition, African-American patients administered with a higher 
dose of MMF (1.5 g twice daily) had increased efficacy, judged by a decreased rate of acute 
rejection (12.1 % vs. 31.8 %) compared to African-American patients receiving 1 g of MMF 
twice daily following renal transplantation [49]. In another study, there was no significant 
difference in dose-normalised MPA or MPAG AUC0-12 between African-American and 
Caucasian renal transplant recipients at 6 months following transplantation [50]. The 
influence of ethnicity on MPA PK parameters, however, is an area still poorly researched 
and thus requires further investigation.  
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Interactions with other immunosuppressive agents 
The influence of concomitant immunosuppressant drugs on the PK of MPA is shown in 
Table 1.2. Higher MPA concentrations (1.2 – 4-fold higher) were observed in transplant 
recipients receiving MMF in combination with TAC or sirolimus than those receiving CsA 
with MMF [34, 51-55]. MPA C0 was significantly higher in patients co-administered with 
TAC and interestingly, the second MPA peak as a result of the enterohepatic recirculation 
(as discussed in Section 1.2.3.4), is more pronounced in patients receiving TAC or sirolimus 
as compared to those receiving MMF in combination with CsA [53, 54]. One underlying 
mechanism was initially attributed to the inhibition of MRP2-mediated biliary excretion of 
MPAG by CsA, resulting in reduced enterohepatic recycling of MPAG back to MPA and 
subsequent accumulation of MPAG [56-58]. However, this is now thought to be due to the 
inhibition of MPAG uptake into hepatocytes by the organic anion transporting polypeptides 
(OATPs) [59]. 
Interactions with other co-medications 
In addition to the interaction with other immunosuppressant drugs, drug-drug interactions 
may also explain part of the inter- and intra-individual variability in the PK of MPA. In one 
case report, a novel, clinically drug interaction was reported between rifampicin and MMF; 
there was a two-fold reduction in MPA exposure when co-administered with rifampicin as a 
result of inhibition of enterohepatic recirculation of MPA [60]. This observation has been 
explained by an inhibitory effect of rifampicin on MRP2 transport activity, most likely due 
to the fact that rifampicin is a substrate for MRP2 [61], and this competitive mechanism 
could have contributed to the observed decrease in enterohepatic recycling of MPA. 
Therefore, failure to recognise this drug interaction could potentially lead to MPA 
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underexposure and loss of clinical efficacy. Other non-immunosuppressant drugs that may 
affect MPA disposition include iron supplements [62], antacids [63] and antiviral drugs [64].  
Other factors 
Impaired renal function (GFR < 25 mL/min) significantly reduces renal excretion of MPAG, 
causing concentrations to become markedly increased by 3- to 6-fold [65]. 
Hypoalbuminaemia decreases the number of binding sites available to MPA and MPAG. A 
previous study has identified a significant relationship between low serum albumin (≤ 31 
g/L) and increased free MPA percentage in renal transplant recipients [35].  
Dialysis (e.g. removal of MPAG by haemodialysis [66]) and other factors such as diet (e.g. 
food resulted in a 25 % reduction in maximum plasma concentration (Cmax) and a time to 
reach Cmax (tmax) of MPA was slightly delayed [63]), time after transplant (e.g. 30 – 50 % 
lower MPA AUC0-12 reported in the first few weeks compared to the 1 – 6 months post-
transplant [32]), and genetics (e.g. will be discussed in detail in Section 1.3.1.4), may also 
account for some of inter-individual differences in the PK of MPA. 
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≥ 3 weeks HPLC 2.8 ± 0.3 
1.2 ± 0.4* 
50 ± 3.9 






Month 3 EMIT 3.6 ± 2.6 








Day 5 HPLC 1.6 (1.4 – 3.0)2 
0.8 (0.6 – 1.3)2,* 
25.6 ± 11.13 







- HPLC 3.2 ± 2.2 
1.7 ± 1.0* 
23.2 ± 10.64 






≥ 6 months HPLC 4.7 ± 2.4 
2.8 ± 1.6* 
70.9 ± 19.3 






Week 2 EMIT 5.2 ± 3.0 
1.3 ± 0.5* 
81 ± 36 
43 ± 11* 
[51] 
All patients received MMF 1 g twice daily and *p < 0.05 versus TAC or SRL. Data are presented as mean (± SD) unless specified otherwise. 
1The different analytical assays for MPA quantification are shown as EMIT is less specific than HPLC for parent MPA [67]; 2Data are median 
(Inter-quartile range); 3Value calculated from AUC0-6 only; 4Value calculated from AUC0-4 only.  
AUC, area under the concentration-time curve; C0, trough; CsA, cyclosporine; EMIT, enzyme-multiplied immunoassay technique; HPLC, 
high-performance liquid chromatography; SRL, sirolimus; TAC, tacrolimus. 
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1.2.5 Pharmacokinetic parameter studies 
Numerous studies have investigated the concentration-time profile of MPA in renal 
transplant recipients with the most common PK parameters reported are the C0 
concentration, AUC, Cmax and tmax. Table 1.3 summarises the MPA PK parameters studies in 
renal transplant recipients. Following the administration of MMF, the MPA maximum 
concentration usually occurs around 1 – 2 hr post-dose. The concentration-time profile of 
MPA often shows two peaks [68], in which the secondary MPA peak, due to the 
enterohepatic recirculation of MPA, is observed 6 – 12 hr after oral administration and 
contributes approximately 10 – 61 % of the total dose-interval MPA AUC [32]. It has been 
shown that the enterohepatic recycling of MPA is reduced in patients co-administered with 
CsA due to the inhibition of biliary excretion of MPAG into the bile.  
As shown in Table 1.3, MPA displays complex and large between- and within- subject PK 
variability despite all patients receiving the same MMF dosage of 1 g twice daily. The 
variability in exposure to MPA is influenced by many factors and is discussed in Sections 
1.2.3.2 and 1.2.4. Despite considerable effort on the part of the manufacturer to introduce 
MMF as a “one-size-fits-all” drug, and although a fixed MMF dosage (1 g twice daily) may 
have contributed to the extensive use of MMF in organ transplantation, the data that continue 
to emerge in the literature suggest that this may not be the best optimal therapeutic option for 
MMF therapy. There has been heightened interest to consider individualisation of MMF 
therapy (refer to Section 1.2.8) as opposed to giving the standard MMF dosage as a means of 
improving clinical outcomes.  
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Table 1.3 Comparison of MPA pharmacokinetic parameters in Caucasian renal transplant recipients receiving 1 g MMF twice daily. 
No. of patients Follow-up 
time 
R2 between C0 and 
AUC0-12 
Cmax (mg/L)1 MPA C0 (mg/L)1 MPA AUC0-12 
(mg.hr/L)1 
Reference 
543,4 1 week 0.65 9.9 (1.5 – 42.3)2 1.1 (0.11 – 4.1)2 36 (3.1 – 95)2 [69] 
183,5 3 weeks 0.64  9.6 ± 5.6 1.8 ± 1.4 41± 19.4 [70] 
243,5 ≤ 30 days 0.72 13.8 ± 7.0 2.0 ± 1.2 47.6 ± 15.2 [71] 
103,4 2 days 
28 days 
0.36 11.1 ± 1.3 
14.9 ± 1.9 
- 
- 
42.3 ± 2.3 
37.5 ± 2.7 
[72] 
103,4 39 ± 451 
months 
0.39 – 0.66 12 ± 5.7 2.1 ± 1.2 49.8 ± 24.8 [73] 
313,4 6 days - 12 ± 3.8 - 40.8 ± 11.4 [74] 
313,5 ≤ 3 months 0.63 - 1.9 ± 1.3 44.8 ± 12.8 [75] 
334,6 1 week 0.57 10.3 (4.6 – 26.5)2 1.5 (0.1 – 5.0)2 43.8 (16.7 – 71.2)2 [76] 
1Values are presented as mean (± SD) unless specified otherwise. 2Values are median (range); 3CsA co-therapy; 4HPLC assay; 5EMIT assay; 
6TAC co-therapy. AUC, area under the concentration-time curve; C0, trough; Cmax, maximum drug concentration; CsA, cyclosporine; EMIT, 
enzyme-multiplied immunoassay technique; HPLC, high-performance liquid chromatography; MPA, mycophenolic acid; R2, coefficient of 
correlation; SD, standard deviation; TAC, tacrolimus. 
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1.2.6 Clinical pharmacodynamics of MPA 
1.2.6.1 Efficacy  
The pharmacodynamics (PD) of MPA have been extensively investigated in renal transplant 
recipients. Several studies have investigated the relationship between exposure to MPA and 
the incidence of acute rejection, with only a few studies failing to find any association 
between exposure to MPA and clinical efficacy (Table 1.4). The MPA concentration-effect 
relationship between AUC (and C0) with the risk of acute rejection has been investigated in 
two randomised concentration-controlled studies in renal transplant recipients receiving 
concomitant CsA therapy [77, 78]. Patients (n = 156 and 150, respectively) were randomised 
into three AUC target groups; low, intermediate or high, with AUC targets of 16, 32 and 60 
mg.h/L, respectively. Both studies reported similar observations; a higher proportion of 
patients experiencing acute rejection was observed in the low (31 % and 28 %) AUC group, 
as compared to intermediate (13 % and 15 %) and high (both at 12 %) AUC groups [77, 78]. 
These two pivotal concentration-controlled trials establishing a relationship between MPA 
exposure and the risk of rejection have provided the basis of the currently recommended 
therapeutic range of 30 – 60 mg.hr/L and 1 – 3.5 mg/L for MPA AUC0-12 and C0 
concentrations, respectively. 
In addition, a significant association between MPA AUC0-12 and the likelihood of rejection 
was observed in a retrospective study of 27 renal transplant recipients receiving CsA-based 
therapy [79]. The MPA AUC < 30 mg.hr/L was associated with a 1.3-fold increased risk of 
rejection (P = 0.02), however no relationship between MPA C0 concentration and rejection 
was observed (P = 0.21) [79].  
Although the relationship between low MPA AUC values and the incidence of rejection has 
been well established especially in transplant recipients receiving concomitant CsA, it has 
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Clinical Outcomes Reference 
156 CsA 6 months AUC0-12 HPLC Incidence of AR in low (16), intermediate (32), 
and high (60 mg.hr/L) AUC groups were 31, 13, 
and 12 %, respectively  
[77] 
150 CsA 6 months AUC0-12 HPLC Incidence of AR in low (16), intermediate (32), 
and high (60 mg.hr/L) AUC groups were 28, 15, 
and 12 %, respectively  
[78] 
27 CsA 1 month C0, AUC0-12 HPLC Increased risk of AR with AUC < 30 mg.hr/L; No 
significant association between AR and C0 
[79] 





1 year AUC0-12, 
Free AUC0-
12 
HPLC No significant concentration-effect relationship 




3 days C0, AUC0-12 HPLC AUC0-12 of 22 mg.hr/L was a threshold for 




1 year C0, AUC0-12 EMIT No significant concentration-effect relationship 
observed with either C0 or AUC0-12 
[82] 
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5 days AUC0-6, 
Free AUC0-6 
HPLC Neither free nor total AUC0-6 associated with AR [34] 
121 TAC 1 year C0 EMIT Higher risk of AR associated with C0 < 1.60 mg/L 






3 months C0, AUC0-12 HPLC AUC0-12 of 27.5 mg.hr/L and C0 of 1.1 mg/L were 




12 months AUC0-3 HPLC Increased risk (70 %) of AR with AUC < 30 
mg.hr/L, as compared to intermediate (30 %) and 
high (0 %) AUC groups 
[85] 
901 CsA (n = 
488), TAC 
(n = 413) 
12 months AUC0-12 EMIT Higher risk of AR in patients with AUC < 30 
mg.hr/L (19 %) compared to patients with AUC > 
30 mg.hr/L (13 %) 
[86] 
AR, acute rejection; AUC, area under the concentration-time curve; C0, trough concentration; CsA, cyclosporine; EMIT, enzyme-multiplied 
immunoassay technique; HPLC, high-performance liquid chromatography; ILAb, IL-2 antagonists; TAC, tacrolimus.
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been difficult to establish a similarly strong relationship between exposure to MPA and the 
likelihood of rejection in renal transplant recipients who received TAC as concomitant 
medication (Table 1.4). Neither AUC0-12 nor C0 concentrations (determined within the first 2 
weeks and 3 months after transplantation, and at the time of every rejection or side effect) 
was associated with rejection in a retrospective study of 51 renal transplant recipients 
receiving MMF in combination with TAC [80]. Consistent with this finding was the 
observation in a prospective study of 100 renal transplant recipients who received MMF, 
TAC and daclizumab (induction therapy). There was no significant difference in MPA 
AUC0-12 between patients who experienced rejection versus those who remained rejection-
free (56.4 ± 45.4 vs. 46.0 ± 22.8 mg.hr/L, P = 0.84) [82].  
Nevertheless, in TAC co-administered transplant patients, one study has reported positive 
findings [83]. Borrows et al. reported significantly lower MPA AUC0-12 and C0 values were 
associated with the incidence of rejection. In a retrospective study of 121 renal transplant 
recipients, the median (range) MPA C0 concentrations prior to rejection was significantly 
lower than patients who experienced rejection compared to those who did not experience 
rejection (1.1 (0.26 – 1.76) versus 1.85 (0.39 – 4.9) mg/L, P < 0.001) [83]. In addition, a 
threshold value of C0 < 1.60 mg/L with a diagnostic sensitivity of 91 % and specificity of 83 
% was chosen for discriminating patients with acute rejection [83].  
Two prospective randomised trials have also investigated the MPA concentration-effect 
relationship between AUC and the incidence of acute rejection. The first, Adaption de 
Posologie du MMF en Greffe Renale (APOMYGRE) study, was a 12-month, multicentre, 
randomised trial involving 137 renal transplant recipients, performed in 11 centres in France 
[85]. Of the 10 incidences of acute rejection occurring in the first 3 months post-
transplantation, a higher proportion of patients (70 %) experiencing acute rejection was 
associated with the MPA AUC < 30 mg.hr/L, as compared to intermediate (30 %) and high 
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(0 %) AUC groups. The second, Fixed-Dose versus Concentration-Controlled (FDCC) 
study, was a much larger trial involving 901 renal transplant recipients from 19 different 
countries [86]. In the FDCC study, there was a significant relationship between early MPA 
AUC values on day 3 and the incidence of acute rejection during the first month (P = 0.009) 
or the entire 12 months following transplantation (P = 0.006). Similar to APOMYGRE 
study, the risk of developing acute rejection was significantly higher (P = 0.018) in patients 
with a day 3 MPA AUC < 30 mg.hr/L (19 %), as compared to those with the MPA AUC > 
30 mg.hr/L (13 %). The APOMYGRE and FDCC studies were landmark randomised 
concentration-controlled trials investigated the added benefit of TDM for MPA and these 
findings have resulted in proposals for drug monitoring of MPA and dosage adjustments in 
renal transplant recipients (discussed in Section 1.2.8). 
1.2.6.2 Adverse events 
The use of MPA has been associated with the frequent occurrence of both haematological 
and gastrointestinal adverse effects including leukopenia and diarrhoea. In daily clinical 
practice, MPA toxicity leads to dose reduction or discontinuation and therefore places 
patients at higher risk of experiencing kidney rejection. Several studies have investigated 
relationships between MPA PK and adverse events [75, 79, 82, 87]. In a prospective study 
involving 100 renal transplant recipients who received MMF in combination with TAC, a 
significant association between high MPA exposure and adverse events was reported at 
different time points after transplantation [82]. Patients with leukopenia had significantly 
higher MPA AUC0-12 and C0 at 3 and 12 months: at 3 months AUC0-12: 61.4 ± 30.9 versus 
42.3 ± 25.3 mg.hr/L, P = 0.01; and C0: 4.1 ± 1.6 versus 2.9 ± 1.6 mg.hr/L, P = 0.01; and at 
12 months AUC0-12: 84.4 ± 45.6 versus 44.2 ± 21.9 mg.hr/L, P = 0.04; and C0: 8.7 ± 7.9 
versus 3.4 ± 1.9 mg.hr/L, P = 0.04. Similar observations were reported in anaemic patients 
(higher AUC0-12 and C0) at 3 and 12 months post-transplantation [82]. Another prospective 
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study in 31 CsA co-treated transplant recipients reported that MPA AUC was significantly 
higher in patients who presented with side effects (e.g. leukopenia, anaemia, diarrhoea) with 
mean ± SD AUC0-12 of 62.1 ± 21.1 versus 39.8 ± 15.2, P = 0.0005 [75].  
In addition to investigating the relationship between MPA AUC and C0 concentrations with 
the risk of rejection and adverse events, some studies have investigated relationships 
between the free or unbound (Cu) MPA concentration and clinical outcomes (both efficacy 
and adverse events). Although the monitoring of MPA Cu concentration is not widely used, 
it has been proposed to better predict immunosuppressive effect than total MPA AUC or C0 
as a risk factor for acute rejection or side effects, since only free or unbound MPA is 
pharmacologically active and capable of inhibiting IMPDH [33]. No previous studies have 
reported a relationship between MPA Cu concentration and the risk of rejection. In a study of 
42 renal transplant recipients receiving concomitant CsA (n = 32) or TAC (n = 10) and 
induction therapy, there was no significant difference in the MPA Cu AUC0-6 between 
patients (median = 1.4 mg/hr/L) with and without rejection (0.9 mg/hr/L, P = 0.07) [34]. In 
addition, an open-label longitudinal study in 54 pediatric renal transplant recipients who 
received MMF in combination with CsA, there was no association between the risk of acute 
rejection and MPA Cu AUC0-12 values (P = 0.40) [88].  
However, MPA Cu concentration was associated with adverse events, as reported in two 
clinical studies in both adult and pediatric renal transplant recipients [34, 88]. Significantly 
higher MPA Cu AUC0-6 values were observed in patients who experienced one or more 
adverse events (e.g. leukopenia, thrombocytopenia, or infection) in the first month post-
transplantation (mean ± SD = 1.9 ± 0.3 mg/hr/L versus 1.1 ± 0.1 mg/hr/L, respectively, P = 
0.004) [34]. Similar observations were reported in pediatric renal transplant recipients with 
higher MPA Cu AUC0-12 levels associated with an increased risk of developing adverse 
events (leukopenia or infection). A cut-off value of MPA Cu AUC0-12 > 0.4 mg.hr/L 
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(sensitivity of 92 % and specificity of 61 %) chosen for discriminating patients with 
leukopenia or infection [88], further supporting the utility of measuring the active, unbound 
concentration of MPA in comparison to total concentrations. 
1.2.7 Summary 
The PK of MPA have been extensively studied in renal transplant recipients, however, the 
findings from previous studies of concentration–effect and –toxicity relationships are 
inconclusive and demonstrated considerable inter-patient variability in the PK of MPA. The 
reported conflicting results are most likely due to: (1) the small population size and (2) low 
number of rejection episodes and adverse events, therefore some of these studies may not 
have been sufficiently powered to detect a difference; (3) the use of induction therapy (e.g. 
basiliximab and daclizumab); (4) the time after transplant (ranging from day 3 – 1 year post-
transplant); (5) the majority of studies not assessing TAC or CsA concentrations; and finally 
(6) the different analytical assays (EMIT versus HPLC) used for determination of MPA 
plasma concentrations, as EMIT is less specific than HPLC and cross-reacts with AcMPAG 
[67], hence potentially overestimating MPA concentrations.  
In addition, the therapeutic range of MPA co-administered with TAC had not been well 
defined and the effect of CsA on inhibiting enterohepatic recirculation reflects the two 
different C0 concentration target ranges that have been proposed with 1.3 – 3.5 mg/L 
(associated with the AUC target of 30 – 60 mg.hr/L) when co-administered with CsA, but a 
higher C0 concentration target range of 1.9 – 3.5 mg/L when co-administered with TAC to 
attain the same target AUC. The C0 concentration range is higher (at least at the low end) 
when MMF is administered with TAC because a greater proportion of the exposure to MPA 
is in the latter part of the dosing interval (C0 concentration may overestimate AUC), due to 
the greater enterohepatic recirculation compared to patients receiving MMF and CsA.  
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Exposure to MPA is essential to assess, as there is a large variability in C0 concentrations or 
AUC measured in renal transplant recipients administered standard doses of MMF. The 
majority, but not all, of the clinical studies show a significant association between exposure 
to MPA with clinical efficacy and/or safety. MPA PK parameters such as C0 concentration 
or AUC are generally the most commonly used tools for investigation of the MPA 
concentration-effect relationship in renal transplant recipients for the risk of rejection and 
adverse events. Based on the wide variability in the PK of MPA and the reported 
relationships between exposure to MPA and the incidence of rejection and/or adverse events, 
therapeutic drug monitoring (TDM) strategies have been implemented and this is discussed 
in the next section of this thesis. 
1.2.8 Therapeutic drug monitoring of MPA 
Maintenance of adequate exposure to MPA is very crucial especially in the early post-
transplant period for prevention of acute rejection. Although strong relationships between 
MPA AUC0-12 and clinical outcomes had been reported previously, the application of TDM 
to MPA would provide clinical benefits in increasing the therapeutic potential of MPA 
(improved efficacy and reduced adverse events) in the early post-transplantation period, as 
compared to a fixed-dosage regimen. In current clinical practice, a fixed MMF dose of 1 g 
twice a day has been recommended for renal transplant recipients [14] in the early transplant 
period, and then monitored (tapered or maintained) accordingly at the time of major clinical 
events (rejection episode or adverse events). However, there are several reasons to consider 
individualisation of MMF doses (as opposed to giving a fixed dosage) as a tool in the 
management of transplant recipients: (1) MPA PK show a large inter-patient variability; (2) 
graft rejection relates to low MPA exposure; (3) adverse events relate to high concentrations; 
and (4) blood concentrations are poorly predicted by standard body measures (e.g. weight, 
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body mass index). Two approaches for MMF dose individualisation have been taken into 
consideration: (1) the PK approach (e.g. AUC0-12 or limited sampling strategy); and (2) PD 
monitoring (e.g. IMPDH activity).  
Several analytical methods have been developed for the determination of MPA 
concentrations including the EMIT [89-91], HPLC [91-93] and HPLC with mass 
spectrometric detection [94]. In the clinical setting, determination of MPA concentrations by 
EMIT assay may be less laborious and time-consuming than HPLC, however, because of the 
cross-reactivity between the anti-MPA antibody used with the pharmacologically active 
AcMPAG metabolite, measurement of MPA concentrations are generally higher (5 – 40 % 
higher) compared to those measured from HPLC-based methods [67, 89, 91], suggesting that 
HPLC may be more suitable to provide the most accurate measurement of the parent 
compound MPA as compared to EMIT.  
In 2001, a roundtable meeting to discuss the use of TDM to guide immunosuppressive 
therapy provided recommendations and strategies for applying TDM of MMF in solid organ 
transplantation [95]. Based on the roundtable discussion, the therapeutic window of 30 – 60 
mg.hr/L and 1 – 3.5 mg/L for total MPA AUC0-12 and C0 concentrations, respectively, have 
been proposed to minimise the risk of rejection, based mostly on findings in patients with 
MMF co-administered with CsA. Another roundtable discussion was held in 2004 to update 
and revise previous guidelines since TAC had since become the predominant CNI in renal 
transplantation [96]. The total MPA AUC0-12 of 30 – 60 mg.hr/L, MPA C0 ≥ 1.3 mg/L (CsA-
based regimen) and C0 ≥ 1.9 mg/L (TAC-based regimen), measured using HPLC, was 
recommended in renal transplantation.  
With the need for individualisation of MPA therapy, the question arises regarding which 
parameter is the most suitable as a marker for total MPA exposure. The most frequently used 
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means of MPA monitoring is C0 concentration measurements in plasma. However, MPA C0 
concentrations correlate weakly with AUC0-12, with R2 values ranging from 0.23 to 0.63 in 
renal transplantation (no difference with regard to AUC and concomitant 
immunosuppression (e.g. CsA or TAC)) [75, 97-101], suggesting that the estimation of a full 
MPA AUC0-12 monitoring may be the most useful assessment of total MPA exposure than C0 
concentrations, to establish that adequate MPA exposure is present in the early post-
transplantation period. Although low MPA exposure, as estimated by the AUC0-12, has been 
shown to better correlate with the risk of rejection (refer to Section 1.2.6.1), MPA AUC0-12 
monitoring requires multiple blood samples during a 12 hr dose interval, hence the use of 
full MPA AUC0-12 is restricted due to its impracticality in an out-patient clinical setting, 
time-consuming and costly. Therefore, there is a need for alternative limited sampling 
strategies (LSS) to allow full estimation of MPA AUC0-12 based on abbreviated AUC.  
Several LSS have been published to estimate MPA AUC0-12 without taking multiple blood 
samples in the full 12 hr dose interval, based on multiple regression methods and mostly 
involving 3 or 4 blood samples drawn during the first 6 hr post-dose [97, 98, 100, 101]. 
However, some disadvantages of abbreviated LSS are that samples drawn during the first 6 
hr of the dosing interval are likely to miss the enterohepatic recirculation as the 
concentration-time profile of MPA includes a secondary peak as a result of enterohepatic 
recycling, occurring 6 – 12 hr following administration. In addition, abbreviated LSS 
requires strict adherence regarding the timing of blood samples. Alternatively, a method of a 
maximum a posteriori (MAP) Bayesian estimation has been developed [102], which allows 
estimation of MPA AUC0-12 by combining a patient’s own data with a population-PK model 
to estimate dosage prediction for each individual. One advantage of MAP Bayesian 
estimation is the flexibility with respect to the timing of sample collection [102], although 
the use of Bayesian estimation requires specific software programs to perform the analysis. 
Zaipul Md Dom, PhD Thesis 2016 33 
1.2.8.1 Pharmacodynamic monitoring of MPA 
As previously discussed in Section 1.2.2, MPA produces potent, reversible and non-
competitive inhibition of IMPDH, thereby suppressing the proliferative responses of T- and 
B-lymphocytes [16], antibody formation and the generation of cytotoxic T-cells are inhibited 
[21]. This is the principal mechanism by which MPA exerts immunosuppressive effects. 
Therefore, PD monitoring by measurement of IMPDH activity directly in lymphocytes may 
be a useful biomarker as it may correlate more closely to the biological response of MMF 
than MPA concentrations.  
Determination of the activity of IMPDH in isolated peripheral blood mononuclear cells 
(PBMCs) has been investigated previously in renal transplant recipients, and is based on the 
chromatographic determination of the produced XMP [103-108]. However, there have been 
only two studies investigating relationships between MPA concentrations and IMPDH 
activity [103, 104]. A weak inverse correlation between post-transplant pre-dose IMPDH 
activity and MPA concentrations (R2 = 0.24, P = 0.17) has been reported in 35 renal 
transplant recipients under MMF therapy [103]. In addition, this was the first study 
establishing a relationship between IMPDH activity and clinical outcome. Two main 
observations were made: (1) that a higher percentage of patients (63 %) with MMF dose 
reductions had lower pre-transplant IMPDH activity; and interestingly (2) that patients with 
high pre-transplant IMPDH activity (above a threshold value of 8.5 nmol/mg protein/hr) and 
MMF dose reduction had a higher risk of rejection (82 % versus 36 %, P < 0.01). In a 
prospective study involving 40 renal transplant recipients, there were significant inverse 
correlations between individual IMPDH activities and MPA plasma concentrations, taken at 
1.5 and 3.5 hr on different days (2, 4 and 10) following transplantation [104]. However, 
there was no correlation found between MPA C0 concentrations and pre-dose IMPDH 
activities. These observations suggest that determination of IMPDH activity may better 
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reflect clinically relevant information on the immunosuppressive efficacy of MPA and 
provides an additional tool in the future for MMF dose individualisation. 
1.2.9 Summary 
The inhibition of graft rejection by immunosuppressants is a key factor in successful 
transplant outcomes, in particular long-term graft survival is influenced by the incidence of 
acute rejection especially in the early post-transplantation period. Therefore, minimising, or 
preferably eliminating early acute rejection typically benefits graft survival. The PK of MPA 
are characterised by large inter-individual variability and due to its narrow therapeutic index, 
the application of TDM may help to overcome its PK variability, ensuring sufficient 
concentrations to prevent rejection but not too high to cause toxicity. To overcome this PK 
variability, relationships between plasma MPA concentrations and clinical outcomes have 
been demonstrated and target plasma concentration ranges have been proposed for dosage 
individualisation.  
However, plasma MPA concentrations may be a relatively poor predictor of the target tissue 
concentration. There has been debate as to whether C0 plasma concentrations are sufficient 
as an index of exposure to MPA (assumed to relate to AUC0-12) for routine monitoring 
purposes and whether they relate to indices of clinical efficacy and safety. This discrepancy 
between plasma and tissue concentrations is most likely due to the presence of the efflux 
transporter MRP2, which at the two major effector sites of MPA, lymphocytes and kidney, 
may result in significant inter-individual variability in tissue concentrations and 
consequently overall PD of MPA, despite the use of TDM to overcome variability in 
bioavailability and clearance. Furthermore, time after transplant, co-medication and the 
binding of MPA to plasma albumin, may also add to the variability in total MPA response. 
Any PGx factor influencing the PK or PD pathways of MPA has the potential to affect a 
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patient’s response to MPA treatment. This is discussed in the next section of this 
Introduction from the perspective of the genetic variability considered in this study, the 
MRP2 efflux transporter. 
1.3 Drug transporters 
Over the last decades, extensive work has been undertaken to identify single nucleotide 
polymorphisms (SNPs) in the genes encoding drug transporters to determine their allelic 
frequencies in different ethnic populations, and importantly to characterise their functional 
impact, if any, towards inter-individual variability in drug disposition and transport activity. 
Genetic polymorphisms in the genes encoding transporter proteins may potentially affect the 
function and/or expression of a given drug transporter, thereby contributing to the inter-
individual variability in drug disposition [109, 110]. Members of the ATP-binding cassette 
(ABC) transporter family, especially MRP2, have an overlapping and remarkably broad 
substrate spectrum that are now increasingly recognised to play an important role in the 
absorption, distribution and elimination of several drug substrates. MRP2 is depicted in 
uppercase letters when the human protein is described, whereas Mrp2 (only the first letter is 
uppercase) is used in rodent species.  
1.3.1 Multidrug resistance-associated protein 2 
The multidrug resistance-associated protein 2 (MRP2) or canalicular multispecific organic 
anion transporter (cMOAT), encoded by ABCC2 gene located on chromosome 10q24, is a 
member of the ABC transporter superfamily with a molecular weight of 190 – 200 kDa and 
comprised of 1545 amino acids spanning approximately 45 kb containing 32 exons [111, 
112].  
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MRP2 has a very broad substrate specificity [113] and actively exports a wide variety of 
endogenous compounds as well as both conjugated and non-conjugated anionic drugs into 
bile including: gluthathione conjugates (e.g. reduced gluthathione and glutathione 
disulphide) [114, 115]; glucuronide conjugates [116]; bile salts conjugates [117]; non-
conjugated anionic drugs (e.g. pravastatin) [118]; and anticancer drugs (e.g. cisplatin and 
methotrexate) [119]. Therefore, altered ABCC2 functional activity would potentially affect 
the clearance of many clinically important drugs.  
1.3.1.2 Localisation and function of MRP2  
The membrane transporter MRP2 is predominantly expressed in the apical membrane of 
hepatocytes [120] and renal proximal tubule cells of the kidney [121]. MRP2 efflux 
transporter is also expressed in the apical membrane of enterocytes [122], lymphocytes 
[123], human placenta [124] and gall bladder epithelia [125]. Transport activities of ABCC2 
have been extensively studied using membrane vesicles and transfected mammalian cells 
[126] and also by comparing the Mrp2 transport activity between normal and Mrp2-deficient 
rats (e.g. such as Groningen yellow (GY) Eisai hyperbilirubinemic (EHBR) rats) [127] as a 
model to investigate the pathogenesis of Dubin-Johnson syndrome (DJS) in humans.  
Alterations of MRP2 expression and/or function could potentially have clinically important 
effects. MRP2 is best known for its role in the hepatobiliary transport of conjugated bilirubin 
(a yellow-coloured bile pigment) and the absence of functional MRP2 from the hepatocytes 
results in DJS, an autosomal recessive disorder that is characterised by conjugated 
hyperbilirubinemia, which can result in clinically apparent jaundice (e.g. yellow colouring of 
skin, deposition of dark pigments in the liver) [128, 129]. The difference in the expression of 
MRP2 results in large inter-individual differences in MRP2 function. The expression of 
MRP2 was approximately 15-fold higher in patients undergoing surgical resection of liver 
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metastasis compared to controls (no histological evidence of liver disease) [130]. Inter-
individual differences in the expression level of MRP2 have also been demonstrated in 
duodenal biopsies taken from 16 healthy volunteers who received 600 mg rifampicin daily 
[131]. There were 6- and 8-fold differences in the mRNA and protein levels, respectively. In 
addition, the administration of rifampicin induced duodenal mRNA and MRP2 protein levels 
in 14 (88 %) and 10 (63 %) individuals, respectively, out of 16 healthy volunteers.  
Previous animal studies have suggested that MPAG is a substrate for Mrp2 and CsA 
inhibited Mrp2-mediated transport through inhibition of MPAG biliary excretion via 
interaction with rat Mrp2 on the bile canalicular membrane [56, 58, 132]. The cumulative 
biliary excretion of MPAG-derived MPA was significantly decreased by approximately 20 
% when MPA was co-administered with CsA compared to MPA alone [56, 132], suggesting 
that Mrp2 was important for MPAG biliary excretion and therefore the glucuronide is a 
likely substrate of Mrp2. Patel et al. has demonstrated that MPAG is a substrate of MRP2 (a 
Km value of 224.2 ± 42.7 μM and Vmax value of 2.7 ± 0.2 μmol/min) [133]. These findings 
indicate that MRP2-mediated transport for MPAG biliary excretion is an essential 
mechanism governing MPAG disposition, and therefore the MRP2 transporter may play a 
role in the enterohepatic recirculation of MPA (as discussed in Section 1.2.3.4) and renal 
excretion of MPAG. 
A recent study using human embryonic kidney (HK293) cells has shown that MPA is a 
substrate of MRP2 (MRP2 transported MPA with a Km value of 16 ± 4 μM and Vmax value 
of 4.7 ± 0.7 μmol/min) [46]. In addition, the effect of different immunosuppressants has been 
tested on MRP2-mediated (3H)-methotrexate transport using membrane vesicles isolated 
from HEK293 cells overexpressing MRP2. MPA, CsA and TAC inhibited MRP2-mediated 
transport with IC50 values (mean ± SD) of 0.065 ± 0.001, 41 ± 1 and 15.2 ± 0.1 μM, 
respectively [134]. Interestingly, the inhibition of MRP2-mediated transport by MPA, CsA 
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and TAC may suggest possible interactions at the renal and tubular efflux levels, however, 
since MPA is eliminated mainly in urine as MPAG (as discussed in Section 1.2.3.5) [134], 
the presence of a possible interaction between this glucuronide and MRP2 expression needs 
further investigation.  
In summary, MRP2, located in the apical membrane of hepatocytes, kidney proximal tubules 
and intestinal epithelia, plays an important role in the detoxification and disposition by 
transporting a wide range of compounds and clinically relevant drugs including the 
immunosuppressant MPA, as a consequence, MRP2 is important in determining the 
pharmacological and side effects of drug substrates. 
1.3.1.3 Genetic polymorphisms of ABCC2 
Over the last few years, extensive work has been undertaken to identify SNPs in the ABCC2 
gene encoding MRP2 to determine its allelic frequencies in different ethnic populations, and 
importantly to characterise their functional impact, if any, towards inter-individual 
variability in drug disposition and transport activity. Genetic polymorphisms of the ABCC2 
gene may potentially affect the function and/or expression of the MRP2 efflux transporter, 
thereby contributing to inter-individual variability in drug disposition.  
Several SNPs have been identified in both coding and non-coding regions of ABCC2, with 
significant linkage disequilbrium, some of which affect MRP2 transporter expression and/or 
function (Table 1.5) (based on information found in http://www.pharmgkb.org and 
http://www.ncbi.nlm.nih.gov/projects/SNP). These polymorphisms include deletions, 
nonsense mutations, premature stop codons and frame shift mutations. Among the ABCC2 
SNPs, the most commonly studied ABCC2 SNPs are the promoter (-24 C > T, rs717620), 
exon 10 (1249 G > A, rs2273697) and exon 28 (3972 C > T, rs3740066) due to their high 
allelic frequency in Caucasian population [135, 136]. The 1249 G > A SNP is associated 
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with amino acid substitution from Valine to Isoleucine at 417 (Val417Ile), whilst 3972 C > T 
is a “silent” SNP (Ile1324Ile) in linkage disequilibrium with the -24 C > T SNP [137, 138]. 
In Caucasians, combinations of these SNPs make up 5 haplotypes (Table 1.6), the three most 
common being H1 (homozygous wild-type (WT)), H2 (variant at position 1249) and H9 
(variant at position 3972) [139-141]. The functional effects of ABCC2 polymorphisms on 
MRP2 expression and functional activity remain unclear, however, the -24 T allele has been 
associated with lower ABCC2 mRNA expression in normal renal tissues (P = 0.03) and a 19 
% reduction in transcriptional activity in HepG2 cells (P = 0.003) [135].  
A recent study assessing in vitro expression and function of ABCC2 haplotypes in 
transfected HEK293T/17 cells, has conclusively demonstrated that in comparison to ABCC2 
WT haplotype H1 (CGC; -24C/1249G/3972C), haplotype H2 (CAC; variant at 1249) 
resulted in increased protein expression and transport activity, haplotype H10 (TGC; variant 
at -24) resulted in lower protein expression, whilst haplotype H9 (CGT; variant at 3972) and 
H12 (TGT; variant at -24 and 3972) resulted in lower protein expression and transport 
activity (Table 1.6) [140]. Furthermore, to elucidate the impact of the most common ABCC2 
haplotypes, the same study has investigated the bioavailability and AUC of talinolol (an anti-
hypertensive agent, β-blocker) in vivo in 24 healthy volunteers exhibiting at least one of the 
investigated haplotypes H1, H2, H9 and H12 [140]. Haplotype H2 decreased the 
bioavailability of talinolol, whilst haplotypes H9 and H12 increased the bioavailability of 
talinolol, however because of low number of individuals homozygous for defined 
haplotypes, this study may not have been sufficiently powered to detect a difference between 
these haplotype groups.  
Recently, the effects of ABCC2 polymorphisms on the PK of the TAC were investigated in 
102 renal transplant recipients in a haplotype-specific manner [141]. The effect of individual 
ABCC2 SNPs on TAC concentrations were initially investigated; the 1249 G > A and 3972 
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C > T SNPs was significantly associated with reduced dose-normalised TAC C0 by 1.4- and 
1.3-fold, respectively. Further investigation of the effects of ABCC2 polymorphisms was 
then carried out in a haplotype-specific manner as reported previously [140]. It was shown 
that patients in the MRP2 high-activity group (H2/H2 and H1/H2 carriers) had significantly 
1.5-fold lowered dose- corrected C0 TAC concentrations (P = 0.007), in comparison to those 
patients in the low-activity and WT groups [141], further supporting the efficacy of 
employing an haplotype approach in place of individual SNPs.  
In summary, the effects of ABCC2 polymorphisms are variable and substrate specific. The 
MRP2 efflux transporter has an overlapping and remarkably broad substrate spectrum that is 
now increasingly recognised to play an important role in the absorption, distribution and 
elimination of several clinically important drug substrates. Genetic polymorphisms in the 
gene encoding MRP2 have been shown to cause significant inter-individual variations in 
drug disposition; however further investigations in a larger cohort are still required to 
elucidate and re-confirm the functional consequences of ABCC2 haplotypes. 
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Table 1.5 Genetic polymorphisms in both coding and non-coding regions of ABCC21.  
SNP Nucleotide
position 
rs number Amino acid 
change 
Allelic frequency2 Effect on mRNA or 
protein level 
Reference 
-1549 G > A 







Cau: 0.43  As: 0.10  Af: 0.49 





-24 C > T Promoter rs717620  Cau: 0.19  As: 0.10  Af: 0.06 Ð mRNA expression [135] 
1249 G > A Exon 10 rs2273697 Val417Ile Cau: 0.47  As: 0.10  Af: 0.17 no change [142] 
1446 C > G Exon 10 rs113646094 synonymous Cau: 0.013 As: 0.00  Af: 0.00 Ï mRNA expression [143] 
2366 C > T Exon 18 rs56220353 Ser789Phe Cau: 0.00  As: 0.12  Af: 0.00 unknown  
3542 G > T Exon 25 rs8187692 Arg1181Leu Cau: 0.00  As: 0.00 Af: 0.09 unknown  
3563 T > A Exon 25 rs17222723 Val1188Glu Cau: 0.08  As: 0.00  Af: 0.07 Ï mRNA expression [144] 
3972 C > T Exon 28 rs3740066 synonymous Cau: 0.38  As: 0.20  Af: 0.27 unknown  
4348 G > A Exon 31 rs56296335 Ala1450Thr Cau: 0.00  As: 0.02  Af: 0.00 unknown  
4544 G > A Exon 32 rs8187710 Cys1515Tyr Cau: 0.08  As: 0.00  Af: 0.20 Ï mRNA expression [144] 
1Adapted and updated from Haufroid et al. [145]. 2Based on http://www.ncbi.nlm.nih.gov/projects/SNP and http://www.pharmgkb.org. 
3As reported by Lévesque et al. [139] - 1446 C > G SNP for Caucasian. 
Ï: increase; Ð, decreased; Af: African; As: Asian; Cau: Caucasian population. 
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Table 1.6 Frequencies (%) of ABCC2 haplotypes [139-141] in Caucasians and their corresponding expressor phenotypes [140]. 
Haplotype -24 C > T 1249 G > A 3972 C > T Frequency Influence on protein expression and transport 
activity1 
Phenotype 
H1(WT) C G C 31 – 54 % Normal                                  Normal - 
H2 C A C 20 – 23 % Ï Protein expression          Ï Transport activity High expressor 
H9 C G T 12 – 16 % Ð Protein expression          Ð Transport activity Low expressor 
H10 T G C 7 – 19 % Ð Protein expression          = Transport activity Low expressor 
H12 T G T 4 – 18 % Ð Protein expression          Ð Transport activity Low expressor 
1In comparison to wild-type H1. The variant alleles are underlined. WT, wild-type; =, No significant difference; Ï, Increased ABCC2 
expression/activity; Ð, Decreased ABCC2 expression/activity. 
Zaipul Md Dom, PhD Thesis 2016 43 
1.3.1.4 Influence of ABCC2 on MPA exposure and effects 
These sections will discuss the clinical studies conducted to date on the role of the MRP2 
efflux transporter, aimed at elucidating the effect of ABCC2 genetic variability on the PK of 
MPA and hence, clinical outcomes. As mentioned earlier in this thesis, the MRP2 efflux 
transporter is a major focus of this thesis and the functional significance of ABCC2 genetic 
polymorphisms on MPA exposure are discussed in the context of Caucasians only, as this is 
the only ethnic population studied in this thesis. 
1.3.1.4.1 Impact of ABCC2 polymorphisms on MPA exposure 
As discussed in Section 1.1.2.4, the MRP2 efflux transporter is involved in the enterohepatic 
recirculation of MPA and the biliary excretion of MPAG, therefore ABCC2 genetic 
polymorphisms may affect the PK of MPA. There have been numerous studies investigating 
the association between the different ABCC2 polymorphisms and the PK of MPA and/or 
clinical outcomes with some conflicting results. The majority of the studies have failed to 
find any significant association of the individual ABCC2 SNPs with MPA PK parameters (or 
clinical outcomes) [146-150], however, there have been at least three positive studies [136, 
139, 151] which will be discussed in detail below.  
One study was conducted in 95 renal transplant recipients co-administered MMF and TAC 
using two doses of MMF, either 1 g (n = 63) or 2 g (n = 32) daily, with monitoring at days 7, 
42, 90 and 360 after transplantation [136]. At day 7 post-transplant, under steady-state 
conditions, patients with mild liver disease and not carrying the -24 C > T SNP had 
significantly 2-, 3.2- and 2.4-fold lower dose-normalised MPA C0 (P = 0.045), AUC6-12 (P = 
0.002) and AUC0-12 (P = 0.0007) concentrations, respectively, and a 2.3-fold increased MPA 
CL (P = 0.0007), compared to those patients without liver dysfunction [136]. Their 
observations are consistent with a previous study in liver transplant recipients [152], in 
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which mild liver disease is associated with a decreased in exposure to MPA and a higher 
MPA CL. The authors reported that this effect is partly due to a lower enterohepatic 
recirculation, which is depicted by a reduction in the partial AUC6-12 [136]. An alternative 
explanation for the overall decrease in MPA AUC6-12 and AUC0-12 is that liver inflammation 
may affect the expression and transport activity of organic anion transporters via complex 
cytokine-mediated down-regulating signaling networks [153]. In addition, a similar 
observation was also reported in patients carrying the WT 3972 C > T SNP, where 
significantly decreased dose-normalised MPA C0, AUC6-12 and AUC0-12 concentrations were 
observed in patients with mild liver dysfunction. As previously discussed in Section 1.3.1.3, 
the 3972 C > T is a “silent” SNP without any amino acid substitution, it is unlikely that this 
SNP affects the MRP2 expression or function, suggesting that the effect observed between 
the 3972 C > T SNP and MPA exposure may be mediated via linkage disequilibrium with 
the -24 C > T SNP [135, 137]. There were no significant effects of other ABCC2 SNPs (-
1549 G > A, -1023 G > A, -1019 A > A, 1249 G > A and 4544 G > A) on the PK of MPA in 
patients with or without liver dysfunction. However, the findings in this study may have 
been biased by the use of an EMIT assay for determination of MPA concentrations because 
of the cross-reactivity between MPA and AcMPAG measurement (as discussed in Section 
1.2.8). 
In a retrospective study involving 47 healthy volunteers who received a single 1.5 g dose of 
MMF, Lévesque et al. showed that, in comparison to the WT carriers (n = 27), individuals 
who were heterozygous carriers (n = 20) of the -24 C > T SNP had a 25 % increased 
AcMPAG AUC0-12 (P ≤ 0.05 in multivariate analysis), suggesting the -24 T allele carriers 
may be exposed to higher concentrations of AcMPAG resulting in an increased risk of 
intestinal toxicity [139]. However, two of the patients also carried the UGT1A9*3 variant, 
which was previously shown to be associated with an 85 % increased exposure to AcMPAG 
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[154], and therefore may suggest a potentially synergistic effect of the combined 
polymorphisms. This study provides evidence of the involvement of human MRP2 in the 
disposition of AcMPAG; MRP2/Mrp2 has previously been shown to be involved in the 
biliary excretion of MPAG (as discussed in Sections 1.2.3.4 and 1.3.1.2), and also in the 
canalicular excretion of AcMPAG in Wistar rats [132]. There were no significant differences 
between MPA and MPAG AUC0-12 values in patients carrying the -24T variant and the WT 
carriers [139]. 
Finally, in a group of 66 renal transplant recipients who received MMF in combination with 
CsA (n = 30), TAC (n = 13) or SRL (n = 23) with monitoring at day 7, and months 1 and 3 
after transplantation, Lloberas et al. showed that under steady-state conditions, at month 3, 
heterozygous carriers (n = 16) of the -24 C > T SNP had significantly 1.4-fold lower (P = 
0.023) MPA AUC0-12 than the WT carriers [151]. Their findings confirmed previous 
observations between the -24 C > T polymorphism and the oral CL of MPA in patients with 
mild liver dysfunction [136]. Patients with mild liver disease and carrying the -24 C > T SNP 
were protected from a reduction in exposure to MPA, suggesting a relationship between this 
SNP and lower oral CL of MPA under steady-state conditions [136]. At Day 7, free MPA 
AUC0-12 was statistically significantly 1.5-fold higher (P = 0.008) in the heterozygous 
carriers of the -24 C > T SNP [151]. In addition, a separate analysis of MPA PK parameters 
in the presence or absence of the -24 C > T SNP for each concomitant CNI (CsA versus 
TAC and SRL) was also investigated. The heterozygous carriers of the -24 C > T SNP co-
administered with TAC and SRL had significantly lower free and total MPA AUC0-12 at 
month 3 (P = 0.001 and 0.003, respectively) compared to the WT carriers [151]. In contrast, 
at day 7, significantly higher free and total MPA AUC0-12 (P = 0.003 and 0.03, respectively) 
was observed in the heterozygous carriers under CsA co-treatment than the WT carriers 
[151]. However, this study has a relatively small number of patients, thus further 
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investigation in a larger prospective study is needed to reconfirm the presented differences 
observed in patients with the -24 C > T SNP co-treated with CsA or TAC. 
1.3.1.4.2 Impact of ABCC2 polymorphisms on clinical outcomes 
In contrast to PK studies, data regarding the effects of ABCC2 polymorphisms on MPA PD 
variability (adverse events) is relatively limited. A number of studies have investigated 
relationships between ABCC2 polymorphisms and clinical outcomes [136, 148, 155, 156], 
however only one study has reported positive findings [136]. Naesens et al. demonstrated 
that patients carrying the variant -24 C > T SNP had a significantly higher incidence of 
diarrhoea compared to the non-carriers (29 % (12/41) versus 13 % (7/54), P = 0.049) in the 
first year post-transplantation [136]. The pathogenesis of MPA-associated diarrhoea is still 
unknown, however, it is believed that AcMPAG metabolite could have played a role in the 
incidence of diarrhoea through a secondary immunological mechanism [157]. There was no 
significant difference in the incidence of leukopenia or haematological disorders between the 
-24 C > T carriers and non-carriers [136].  
Data on the effects of ABCC2 SNPs on MPA PK parameters are limited with most studies 
considering only the impact of recipient genotype. Importantly, previous findings have been 
conflicting due to the lack of haplotype analysis and small patient groups. However, one 
study investigating the influence of both donor and recipient ABCC2 polymorphisms on 
transplant outcome has been published [158], which reported that a donor haplotype 
CGACA (-24C/1249G/3563A/3972C/4544A, variant at 3563 and 4544) was more prevalent 
in patients with delayed graft function (DGF) (P = 0.004) compared to those patients without 
DGF. Multivariate regression analysis revealed that the donor 3563 T > A and 4544 G > A 
SNPs but none of the other polymorphisms (-24 C > T, 1249 G > A and 3972 C > T SNPs) 
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or clinical covariates tested were significantly associated with DGF (P = 0.006) [158], 
further confirming the superiority of haplotype analysis in predicting the incidence of DGF. 
1.3.1.5 Summary  
In summary, a full understanding of the findings in previous studies is hampered by the fact 
that the role of common ABCC2 SNPs on exposure of MPA and MRP2 expression and 
function has not been extensively evaluated to date. In addition, although there are a large 
number of clinical studies on the effects of ABCC2 polymorphisms on MPA PK, results are 
conflicting due to the lack of a haplotype approach and small patient numbers. Importantly, 
the majority of studies have investigated only the genotype of the recipient. The MRP2 
efflux transporter is of particular clinical importance given its pivotal role in the biliary and 
renal excretion of MPAG, therefore transplant donor genotypes are likely to have the 
greatest impact on MPAG PK. While there are conflicting data regarding the impact of 
ABCC2 polymorphisms on MPA PK, very limited studies have investigated the influence of 
ABCC2 gene variants on clinical outcomes in particular the risk of rejection and adverse 
events. 
 
1.4 Lymphocyte and kidney MPA concentrations 
In addition to determining the effect ABCC2 polymorphisms on the PK of MPA, membrane 
transporter expression in lymphocytes and the kidney may affect MPA PD despite targeting 
patients to narrow blood concentration ranges. Therefore, there is a need to move beyond 
individualising MPA dose to attain target plasma concentrations to the situation whereby 
distribution into target tissue is also factored into dosage adjustments. Due to a narrow 
therapeutic index (1.0 – 3.5 mg/L) and large inter-individual PK variability [96, 159], TDM 
has been recommended to individualise MPA dosing, ensuring sufficient concentrations to 
Zaipul Md Dom, PhD Thesis 2016 48 
prevent kidney rejection but not too high to cause toxicity. Routine MPA monitoring is 
performed by measuring C0 concentrations in plasma, or even better by AUC 
determinations. The immunosuppressive site of action for MPA, however, is inhibition of 
IMPDH within lymphocytes. Therefore, obtaining intracellular MPA concentrations within 
lymphocytes may provide a better understanding of MPA distribution into target tissue and 
may have greater relevance for predicting MPA efficacy or toxicity than plasma 
concentrations. 
The importance of this concept has been highlighted in a previous clinical study of 20 renal 
transplant recipients, which reported that intra-lymphocyte concentrations of CsA, another 
immunosuppressant that targets lymphocytes, decreased significantly 3 days before acute 
rejection was recognised clinically, and there was a significantly lower intracellular exposure 
to CsA in patients experiencing rejection (265 ± 18.2 versus 747 ± 221 ng/106 cells, P = 
0.004) [160]. A similar observation between clinical rejection and decreased intra-
lymphocyte concentrations of TAC (1.9 – 4.4-fold, P < 0.05) has also been reported in 90 
liver transplant recipients [161], with this study further confirming the importance of 
obtaining intra-lymphocyte immunosuppressant concentrations in predicting acute rejection 
compared to measuring systemic concentrations alone.  
In addition to intra-lymphocyte concentrations, tissue immunosuppressant concentrations 
within the transplanted organ may provide more clinically relevant information for 
predicting immunosuppressant efficacy than plasma or whole blood concentrations, as has 
been reported in previous studies with CsA [162, 163] and TAC [164, 165]. Although there 
was no significant association between blood concentrations and graft rejection, intra-renal 
immunosuppressant concentrations were found to be significantly lower (1.9 – 5.8-fold, P ≤ 
0.02) in patients experiencing rejection versus those who did not experience rejection in both 
liver [163-165] and renal [162] transplantations.  
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At the time of commencing this PhD project in 2011, no previous studies had investigated 
the concentrations of MPA in human kidney biopsies, and there have been only two clinical 
studies investigating the utility of measuring lymphocyte MPA concentrations in renal 
transplant recipients. One study failed to find a relationship between trough lymphocyte 
(C0L) and plasma (C0P) MPA concentrations [166], however, another study reported some 
associations between lymphocyte and plasma MPA concentrations determined at 1.5 and 3.5 
hr on days 2, 4 and 10 following transplantation, but not between MPA C0P and C0L 
concentrations [104]. Despite these two studies, the factors that determine lymphocyte MPA 
concentrations and variables predictive of rejection had not been previously investigated and 
thus remain unknown. Two important modulators of lymphocyte MPA concentration may 
include the binding of MPA to plasma albumin (hence unbound concentrations need to be 
used) and the possible role of uptake and efflux (e.g. MRP2) transporters in lymphocytes in 
modulating concentrations. There is yet to be a similar study investigating IMPDH activity 
and lymphocyte MPA concentrations, as predictors of graft rejection and importantly, 
including for the first time, establishing methods capable of measuring intracellular MPA 
concentrations in the human kidney biopsies and lymphocytes in renal transplant recipients – 
this will be a novel and innovative feature of this thesis. 
1.5 Summary, Aims and Hypotheses 
The application of TDM has been proposed to maximise the effectiveness of MPA to 
achieve target plasma concentrations that suppress rejection and minimise MPA-related 
toxicity. Whilst the use of TDM of plasma concentrations has been put forward to 
individualise MPA dosages, previous studies have shown that effective target plasma MPA 
concentrations are still highly variable between individuals. Consequently, there is a need for 
clinical tools that are better predictors of tissue, and lymphocyte, MPA concentrations that 
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are not necessarily mirrored by plasma concentrations as currently monitored with TDM 
alone. In addition, the application of PGx approaches to identify factors that affect the MPA 
concentration-effect relationship may explain some of the additional inter-individual 
variability in response to MPA. Therefore, knowledge of the multiple PGx factors that may 
influence an individual patient’s response to immunosuppressants such as MPA and 
determine overall success of renal transplantation is needed.  
 The ABCC2 gene provides a good candidate for this PGx approach, as its product, the 
MRP2 efflux transporter, plays an important role in determining MPA distribution into 
lymphocytes and kidney graft tissue, and hence, clinical outcomes. Furthermore, the gene is 
highly polymorphic with some genetic polymorphisms having a clinically relevant impact on 
MPA exposure.  
Prior to commencing this PhD, several major gaps in the published knowledge of genetic 
polymorphisms in modulating MPA response were identified.  
Firstly, the majority of research into the PGx of MPA had concentrated on genetic 
polymorphisms affecting MPA metabolism, not MPA distribution into lymphocytes and 
kidney graft tissue (Fig. 1.5) – an area still poorly researched.  
Secondly, although there are numerous studies on the effects of MRP2 PGx on MPA PK 
and/or PD, reported findings are conflicting due to lack of haplotype analysis, with the 
majority of the studies considering only the impact of recipient genotype. 
Thirdly, drug transporter genetic polymorphisms influencing MPA distribution into 
lymphocytes and kidney graft tissue had not been previously investigated, nor had the 
potential association (e.g. intra-lymphocyte and intra-renal concentrations) with clinical 
outcomes following renal transplantation.  











Figure 1.5 Summary of the proposed factors determining distribution of MPA in plasma, 
circulating lymphocytes and the kidney graft tissue. AcMPAG, mycophenolic acid acyl 
glucuronide; MPA, mycophenolic acid; MPAG, mycophenolic acid phenolic 
glucuronide; MRP2, multi-drug resistance protein 2; OATPs, organic anion transporter 
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Finally, at the time of commencing this PhD, no studies had investigated the intracellular 
MPA concentrations in the human kidney and lymphocytes to determine whether these 
concentrations are better predictors of the incidence of rejection in renal transplant 
recipients. 
Based on the existing literature, the major hypotheses to be tested for this PhD project were: 
Hypothesis 1: Recipient ABCC2 expression influences the plasma concentration of MPA 
(hence MMF dose): recipients with low expressor ABCC2 haplotypes would have lower 
MPA concentrations as a result of decreased enterohepatic recirculation. 
Hypothesis 2: Donor graft ABCC2 haplotype expression or function influences the plasma 
concentration of MPAG: donors with high expressor ABCC2 haplotypes would have 
decreased plasma concentrations of MPAG as a result of increased renal excretion of MPAG 
as renal excretion is the primary clearance mechanism for MPA metabolites.  
Hypothesis 3: Lymphocyte MPA concentrations may have greater relevance for predicting 
IMPDH activity and the risk of graft rejection as compared to plasma MPA concentrations. 
Hypothesis 4: Recipient ABCC2 expressor status may influence the distribution of MPA 
into lymphocytes, therefore affecting lymphocyte MPA concentrations (hence the incidence 
of graft rejection). 
Therefore, the main aims of this thesis were: 
Aim 1: To develop and validate methods capable of accurately quantifying MPA 
concentrations in human kidney biopsies and human peripheral blood mononuclear cells 
(PBMCs), and intracellular IMPDH enzyme activity in PBMCs, from renal transplant 
recipients. Assay development and validation are presented in Chapters 2 and 4, for renal 
biopsies and PBMCs, respectively. 
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Aim 2: To investigate the influence of donor and recipient ABCC2 haplotypes (formed by 
the common -24 C > T, 1249 G > A and 3972 C > T SNPs) on plasma MPA concentrations 
and clinical outcomes in renal transplant patients. This aim was addressed in a retrospective 
investigation of ABCC2 genetic polymorphisms in patients receiving standard 
immunosuppression therapy consisting of MMF, TAC and prednisolone (Chapter 3).  
Aim 3: To apply methods developed from Aim 1 to a pilot clinical investigation of the utility 
of determining lymphocyte MPA concentrations and intracellular IMPDH enzyme activity, 
as predictors of early graft rejection in renal transplant recipients (Chapter 4).  
 
Zaipul Md Dom, PhD Thesis 2016 
 
54 
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Mycophenolic acid (MPA) has a low therapeutic index and large inter-individual 
pharmacokinetic variability necessitating therapeutic drug monitoring to individualise dosing 
after transplantation. There is an ongoing discrepancy as to whether plasma MPA 
concentrations sufficiently predict kidney rejection or toxicity and whether 
immunosuppressant concentrations within the graft tissue may better predict transplant 
outcomes. The aim of the study was to develop an LC-MS/MS method for the quantification 
of MPA concentrations in human kidney biopsies taken as part of routine clinical 
procedures. A total of 4 surplus human kidney biopsies obtained from 4 different kidney 
transplant recipients were available to use for this study. MPA was also quantified in 2 
kidney samples from rats administered MPA to assess tissue extraction reproducibility. 
Human kidney biopsies and rat kidneys were homogenized mechanically and underwent 
liquid-liquid extraction before analysis by LC-MS/MS. MPA-free human kidney tissue was 
used in calibrators and quality control samples. Analyte detection was achieved from 
multiple reaction monitoring of the ammonium adducts of both MPA (m/z 321.1 → 207.3) 
and N-phthaloyl-L-phenylalanine (PPA, internal standard, m/z 296.2 → 250.2) using 
positive electrospray ionisation. The method was linear (calibration curves R2 > 0.99, n = 
10), precise, and accurate with coefficients of variation and bias less than 15%. Extraction 
efficiencies for MPA and PPA were approximately 97 % and 86 %, respectively, and matrix 
effects were minimal. In 4 kidney transplant recipients, tissue MPA concentrations ranged 
from 1.3 – 7.7 ng/mg of tissue, however, the correlation between blood (C0) and tissue MPA 
concentrations could not be established. The method was successfully applied to the 
quantification of MPA in human kidney biopsies without the need to alter current clinical 
protocols.  
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Mycophenolic acid (MPA) is a widely prescribed immunosuppressant for the prevention of 
rejection following kidney transplantation (Fig. 2.1) [167], usually in combination with other 
immunosuppressant drugs, most commonly a calcineurin inhibitor (cyclosporine or 
tacrolimus) and prednisolone. Due to a narrow therapeutic index and significant inter-subject 
pharmacokinetic variability [96, 159], MPA requires therapeutic drug monitoring (TDM) to 
individualize dosing, ensuring optimal plasma concentrations to prevent organ rejection and 
minimize the incidence of adverse events such as leukopenia and diarrhea [96, 168]. MPA 
pre-dose trough (C0) concentrations are a relatively good indicator of total drug exposure 
[169] and the acceptable plasma therapeutic range for MPA C0 is 1.0 to 3.5 mg/L [96]. 
Lower plasma C0 MPA concentrations have been shown to correlate significantly with the 
risk of rejection whereas high MPA C0 values were associated with an increased risk of 
toxicity [5, 47, 75]. Although TDM from plasma is necessary for individualization of MPA 
dosage, both acute rejection and adverse events still occur after kidney transplantation [170], 
further reinforcing that TDM alone may be inadequate in predicting target tissue 
concentrations and consequently therapeutic efficacy and/or safety. In contrast, MPA 
concentrations within lymphocytes or the graft tissue may provide more clinically relevant 
information on the immunosuppressive efficacy of MPA. Previous studies in liver and 
kidney transplant recipients suggest that rejection was associated with low concentrations of 
tacrolimus [161, 164, 165] and cyclosporine [162, 163, 171] within the graft tissue, but not 
with those in whole blood. To our knowledge, no previous studies have examined tissue 
MPA concentrations in human kidney biopsies and determined if the concentrations within 
the graft tissue correlate to the outcomes of rejection and toxicity compared to plasma 
concentrations. 
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The aim of this study was to develop and validate a liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) method capable of accurately quantifying MPA concentrations 
in human kidney biopsies from kidney transplant recipients taken as part of routine clinical 
procedures. The overall design of the method was primarily to assess whether MPA 
concentrations could be quantified in very small samples of kidney biopsy tissues, which are 
shared for histological assessments. In addition, we also assessed whether the potential in-
source ion fragmentation of the metabolites of MPA (ether- and acyl-glucuronides) to MPA 
[172, 173] would result in an overestimation of MPA concentrations by LC-MS/MS.  
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2.3 Materials and Methods  
2.3.1 Chemicals and reagents 
Mycophenolic acid (MPA), tacrolimus, ammonium acetate, formic acid, tertiary-butyl 
methyl ether (t-BME) and N-phthaloyl-L-phenylalanine (PPA, internal standard (IS)) were 
sourced from Sigma-Aldrich (Castle Hill, NSW, Australia). MPA ether- (MPAG) and acyl- 
(AcMPAG) glucuronides were purchased from Roche Pharmaceuticals (Palo Alto, CA, 
USA). Cyclosporine and everolimus were purchased from Novartis Pharmaceuticals 
Australia Pty. Ltd. (North Ryde, Australia). Sirolimus was provided by Wyeth Research (NJ, 
USA). HPLC-grade methanol (MeOH) was purchased from Thermofisher Pty Ltd (Scoreby, 
VIC, Australia). Sodium chloride (NaCl), sodium dihydrogen orthophosphate 
(NaH2PO4.H2O) and hydrochloric acid (HCl) were supplied by Ajax Finechem Pty Ltd 
(Taren Point, NSW, Australia). Sodium dihydrogen phosphate (NaH2PO4) and ethanol were 
obtained from Chem Supply (Gillman, SA, Australia). Potassium chloride (KCl) and 
potassium dihydrogen phosphate (KH2PO4) were purchased from Ajax Chemicals (Auburn, 
NSW, Australia). Ultrapure, de-ionized water (≥ 18.2 mOhms, Cascada AN-water 
Purification system, Pall, Cheltenham, VIC, Australia) was used throughout the assay.  
2.3.2 Human and animals tissues  
Human kidney tissue obtained from a non-transplant nephrectomy patient (The Queen 
Elizabeth Hospital Ethics of Human Research Committee, approval number 2008178) who 
was not administered MPA, was used to prepare the calibrators and quality control (QC) 
samples. Two rat kidney samples used as biological QCs in this study were obtained from a 
previous study [58]. Briefly, adult male transport-deficient (TR-) Wistar rats (HRD-AMC 
Abcc2) had been purchased from Harlan (Horst, the Netherlands) and ethics approval had 
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been obtained from the Animal Experiments Committee of the Eramus Medical Center. The 
rats received 20 mg/kg bodyweight mycophenolate mofetil (the prodrug of MPA; Cellcept®, 
Roche Bioscience, Palo Alto, CA, USA) in combination with 4 mg/kg bodyweight 
tacrolimus daily (oral microemulsion formulation, 10 mg/mL; Prograf®, Fujisawa 
Pharmaceutical Co. Ltd., Osaka, Japan), starting on day 7 and continuing through day 14 
before being sacrificed. Kidney samples were then harvested and immediately stored at -80 
°C until the day of assay. All harvested tissues were divided and assayed as biopsy-sized 
samples thereafter.  
2.3.3 Measurement of tissue MPA concentrations 
On the day of assay, frozen human and rat kidney specimens were thawed at room 
temperature and cut into biopsy-sized pieces as required (approximately 0.5-1.0 mm3), using 
a clean scalpel blade and placed in a clean eppendorf tube (Sarstedt AG & Co, Nümbrecht, 
Germany). Patient biopsy specimens stored in TissueTek® solution (ProSciTech, 
Thuringowa, QLD, Australia) were removed from aluminium packaging and placed in an 
empty eppendorf tube to thaw. The biopsy specimens were displaced from the TissueTek® 
solution with a clean, unused pipette tip to the top of the eppendorf tube. The biopsy 
specimens were then rinsed with 2-3 drops of water, blotted dried on lint-free tissue and 
transferred to clean eppendorf tubes. Each tissue specimen was weighed before undergoing 
mechanical homogenisation. Briefly, a chilled mortar and pestle was used to grind the 
specimens to a fine powder. At this stage, 200 µL of phosphate buffered saline (pH 7.4) was 
added to each tissue specimen and was mixed thoroughly around the mortar with the pestle 
before being transferred into a 5 mL disposable glass tube, appropriately labeled. To each 
sample, 5 µL of PPA internal standard (0.1 mg/L), 60 µL of HCl (0.4 M) and 1 mL of t-
BME were added. Samples were mixed on a roller mixer for 10 minutes at a gentle speed 
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ensuring that the samples were not mixed too vigorously as this may result in the formation 
of an emulsion. The tubes were then centrifuged at 4000 rpm (1900 x g) at 4 ºC for 10 
minutes. The aqueous layer was then snap-frozen in an ethanol/dry ice bath, the organic 
layer removed and evaporated using an evacuated centrifuge at 45 ºC for approximately 20 
minutes. The dried residues were reconstituted with 50 µL of 50/50 methanol/water, 
vortexed and transferred to vial-inserts. Ten microlitres of the reconstituted solutions were 
injected onto the LC-MS/MS for analysis.  
2.3.4 Preparation of calibration curve standards and QC samples 
All calibrators and quality control (QC) samples were prepared using a blank, MPA-free, 
human kidney tissue obtained from the non-transplant nephrectomy patient. MPA working 
solutions for calibration curve standards were prepared from MPA stock solution (100 mg/L 
in 100 % MeOH) and were then used to spike blank human kidney tissue in homogenisation 
buffer, to final concentrations of 0.6, 1.0, 2.0, 5.0, 10.0 and 20.0 ng/mL. Similarly, QC 
samples were prepared by spiking blank human kidney sample in homogenisation buffer 
with an independently prepared MPA stock solution (100 mg/L in 100 % MeOH) to final 
concentrations of 0.6, 2.0 and 10.0 ng/mL.  
As well as spiked controls, two kidney samples obtained from rats administered MPA were 
initially assayed in replicates of 3 – 6 to determine the concentrations of MPA. Samples 
from these kidneys were then used consistently during method development as biological 
QCs to ensure tissue extraction reproducibility. 
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2.3.5 LC-MS/MS conditions 
Detection of MPA and PPA IS in rat kidneys and human kidney biopsies was achieved using 
an API 3200 tandem mass spectrometer (AB Sciex, Mount Waverley, VIC, Australia) 
operating in positive electrospray ionization mode. The spectrometer was coupled to a 
Shimadzu UPLC system (Shimadzu USA Manufacturing Inc, Canby, OR, USA) consisting 
of a dual Shimadzu LC pump, a degasser (DGU-20A3), an autosampler (SIL-20AC) and a 
column oven (CTO-20AC). The analytical column used was a 2 x 30 mm Luna phenyl-
hexyl, 5 μm particle size column (Phenomenex, Lane Cove, NSW, Australia) maintained at 
60 ºC. Mobile phases A and B consisted of 100 % water or 100 % methanol, respectively, 
with both solutions also containing 2 mM ammonium acetate and 0.1 % formic acid, which 
assisted the formation of positive ammonium adducts used for MPA and PPA detection by 
the mass spectrometer. The mobile phases were filtered, degassed and pumped at a flow rate 
of 0.5 mL/min with the ratio of mobile phase A:B at 50:50 for 0.0 – 1.2 minutes and then 
changed to the ratio of 5:95 (A:B) for the remaining 1.2 – 2.2 minutes of the sample run 
time. The analytical column was washed using 50 % mobile phase A for a further 30 seconds 
prior to the next sample injection. Ten microlitres of reconstituted solutions were injected 
onto the analytical column and Analyst v1.5.1 software (AB Sciex, Mount Waverley, VIC, 
Australia) was used for data acquisition and quantitation.  
The collision energy was set at 25 V, the ionspray voltage was set at 5500 V and the 
declustering potential was set at 25 V and 15 V for MPA and PPA IS, respectively, allowing 
optimal detection of MPA and PPA by the mass spectrometer. The desolvation temperature 
was set at 375 ºC with nitrogen as both the curtain and collision gas. Analyte detection was 
obtained from multiple reaction monitoring (MRM) of the ammonium adducts of both MPA 
(m/z 321.1→207.3) and PPA IS (m/z 296.2→250.2), and calibration curves were constructed 
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using weighted 1/X least-squares linear regression analysis of peak area ratios (MPA/PPA 
internal standard) versus MPA concentrations. MPA tissue concentrations were converted 
from ng/mL of MPA in digestion buffer to ng/mg of MPA in tissue for all unknown human 
kidney biopsies and rat kidney samples. 
2.3.6 Method validation 
The assay development and validation were performed following the principle of the Food 
and Drug Administration (FDA) guidelines for bioanalytical methods [174]. The method 
was assessed for accuracy, precision, linearity, extraction efficiency, matrix effects and 
stability. 
2.3.6.1 Accuracy, precision and linearity 
The highest and lower limit of quantification (LLOQ) calibrators and QC samples were 
assayed in replicates of 6 in a single analytical run to obtain intra-day inaccuracy and 
reproducibility as well as over 6 consecutive days to obtain inter-day inaccuracy and 
reproducibility. The assay was deemed reproducible if intra- and inter-day inaccuracy and 
imprecision for calibrators and QC samples were both within 15 % (or 20 % for the LLOQ). 
Linearity was assessed and acceptable if the coefficient of determination (R2) for each of the 
calibration curves was greater than 0.99 and calibrator concentrations did not differ by more 
than 15 % (or 20 % for the LLOQ) from the nominal concentrations. Tissue weighing 
accuracy and reproducibility had been assessed previously [171]. Two rat kidney tissues 
were also assayed in 6 replicates within a single analytical run as well as over 6 separate 
days to ensure intra- and inter-day tissue extractions were reproducible. Results were 
accepted if these biological QCs had a coefficient of variation below 15 %.  
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2.3.6.2 Extraction efficiency and matrix effects 
Extraction efficiency and matrix effects were estimated using a post-extraction analyte 
addition approach, as previously described [175]. Three sets of samples were prepared at low 
(2 ng/mL) and high (20 ng/mL) concentrations. Samples in set 1 consisted of standards 
containing the analytes at concentrations of 2 and 20 ng/mL prepared in 50/50 
methanol/water; samples in set 2 consisted of MPA-free tissue acquired from rat kidney and 
human kidney tissues, which were spiked with 100 μL of spiking solution to give final 
analyte concentrations of 2 and 20 ng/mL, thereafter, the samples were extracted, as 
described previously, and the dried residues were reconstituted in 100 μL of 50/50 
methanol/water; samples in set 3 consisted of MPA-free tissue from the same source as used 
in set 2 that were first extracted followed by reconstitution of the dried residues with 100 μL 
of 50/50 methanol/water containing the analytes of interest at amounts of equivalent to the 2 
and 20 ng/mL calibrators. Extraction efficiency was estimated by comparing MPA and 
internal standard peak areas from the samples of set 3 to those from the corresponding 
samples of set 2. Matrix effects were determined by comparing the peak areas of the samples 
of set 1 to those from the corresponding samples of set 2. Process efficiency was determined 
by comparing sets 3 and 1. 
Potential interference from other immunosuppressants that may be co-administered with 
MPA was also investigated using post-extraction addition. Based on previous measurement 
of cyclosporine [171] and tacrolimus [176] concentrations in human kidney biopsies, 
duplicate samples (0.7 mg) of drug-free human kidney tissue were homogenised and spiked 
with 100 μL of 50/50 methanol/water alone or methanol/water containing cyclosporine (50 
ng/mg tissue), tacrolimus, sirolimus and everolimus (all at 1 ng/mg tissue). The samples 
were then extracted as described above, and spiked with MPA and PPA during reconstitution 
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using 50 μL of a 50/50 methanol/water solution containing the equivalent concentrations of a 
2 ng/mL calibrator. MPA and PPA peak areas in the reconstituted extracts were also 
compared to direct injection of the methanol/water spiking solution. 
Assessment of matrix effects was also estimated using a post-column analyte infusion 
technique [175, 177] that involves post-column infusion of MPA and internal standard 
against injections of reconstituted blank tissue extract. The sample was mechanically 
extracted and reconstituted in 50/50 methanol/water. Pure solutions of MPA and internal 
standard were introduced separately onto the LC-MS/MS system by an infusion syringe 
placed after the chromatographic column and before mass spectrometer ionization source in 
a constant flow [175]. The reconstituted tissue sample without added analyte was injected 
into the LC-MS/MS system, and the response from the analyte was recorded and compared 
to direct injection of pure 50/50 methanol/water.  
2.3.6.3 Stability 
The stability of MPA in tissues was investigated over a 2 month period in biological QCs 
that were stored at -80 °C, with replicate samples (n = 3 – 6) thawed and analysed at 0, 1 and 
2 months together with freshly prepared calibration curves. The stability of MPA during 
chromatographic analysis was investigated by repeated injection of an extracted calibrator 
sample over 24 hr. 
Stability of MPA glucuronide metabolites was checked using authentic MPA ether- (MPAG) 
and acyl- (AcMPAG) glucuronides. Three separate sets of samples were prepared for each 
MPA glucuronide. Samples in set 1 consisted of pure solutions containing each of the 
glucuronides at a concentration of 100 ng/mL prepared in 50/50 methanol/water and kept at  
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-20 ºC until ready for injection onto the LC-MS/MS; samples in set 2 consisted of MPA-free 
tissue spiked with AcMPAG or MPAG before being homogenized mechanically; samples in 
set 3 consisted of MPA-free tissue spiked with AcMPAG or MPAG after undergoing 
mechanical homogenisation; thereafter, samples in sets 2 and 3 were extracted as described 
previously and the dried residues were reconstituted in 50 μL of 50/50 methanol/water.  
2.3.7 Clinical application of the method to biopsy specimens from kidney 
transplant recipients 
A total of 4 excess biopsy specimens obtained from 4 different kidney transplant recipients 
were available for use in this study. Three of the 4 kidney transplant recipients were taking 
MPA, everolimus and prednisolone-, and the other, sirolimus and prednisolone-based 
immunosuppression. The kidneys were transplanted from living (n = 1) and deceased (n = 3) 
donors between February 2006 and April 2010. Informed written consent was obtained from 
the recipients and living donor, and where the kidney was obtained from a deceased donor, 
the recipient was asked to provide consent for the use of the biopsy specimen. The study was 
approved by the Ethics of Human Research Committee of the Queen Elizabeth Hospital 
(approval number 2008178). Biopsies were taken in cases of suspected rejection, with 1 of 4 
biopsies taken at 8 days post-transplant, 2 taken within the first year post-transplant, and 1 
taken after 4 years post-transplant. Rejection was defined according to Banff 2007 criteria 
[178]. Fine core needle kidney biopsies were routinely divided by pathology staff and part 
embedded in paraffin for histological assessment with the remaining biopsy tissue snap 
frozen at -80 ºC in TissueTEK® solution until the day of the assay.  




2.4.1 Assay performance 
PPA and MPA eluted at 1.80 and 1.83 minutes, respectively, and total chromatographic 
analysis time was 2.2 minutes. Figure 2.2 (A) shows a representative chromatogram of an 
extracted patient kidney biopsy tissue, with added internal standard (light grey). The 
calibration curves were linear over the concentration range of 0.6 to 20.0 ng/mL, with 
coefficients of determination, R2, greater than 0.997 (mean ± SD; 0.999 ± 0.00096, n = 10) 
routinely obtained. Intra- and inter-day inaccuracy and reproducibility for calibration curves 
and QC samples was less than 15 % (Table 2.1). Tissue extraction reproducibility was 
determined using two rat kidneys from abcc2-deficient rats administered MPA. The mean (± 
SD) kidney MPA concentrations (n = 3 – 6 replicates) were 0.35 (± 0.04) and 3.5 (± 0.26) 
ng/mg of tissue. Tissue extraction from the rat kidney samples was considered reproducible 
and within acceptable limits (CV < 13 %, n = 6) (Table 2.1). These rat kidneys were used 
consistently during method development and validation as biological QCs. 
Extraction efficiency, matrix effects and process efficiency were all acceptable, as shown in 
Table 2.2. There was no evidence for a matrix effect in human kidney tissue. However, for 
rat kidney, a small matrix effect in the form of ion enhancement was observed at a higher 
concentration of MPA (Table 2.2), although it was well within the acceptable limit of ± 15 
% as discussed previously [175, 179], and was similar for both MPA and PPA. Other 
immunosuppressants likely to be co-administered with MPA had no significant effects on 
either MPA or PPA peak areas, except sirolimus, which appeared to interfere with the 
detection of MPA, decreasing peak area by 39 %. In the post-column infusion technique, 
Fig. 2.3 shows a comparison of an injection of analyte-free human kidney tissue extract 
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(light grey) and mobile phase (black) for MPA (A) and PPA IS (B). MPA and PPA IS co-
eluted outside of the area of ion suppression.  
The stability of MPA glucuronide metabolites was checked by comparing the peak areas of 
both metabolites in pure solution, before and after undergoing mechanical homogenisation. 
There was no difference in the peak areas of MPA metabolites before and after mechanical 
homogenisation and no MPA peak was observed at its retention time on the chromatograms 
(Fig. 2.2). In contrast, a peak was observed in the MPA MRM corresponding to the retention 
times of MPAG or AcMPAG, 1.51 and 1.63 minutes, respectively, as shown in Fig. 2.2 (B) 
and (C), respectively. This could be due to in-source ion fragmentation of the glucuronides 
to MPA during the ionization procedure inside the mass spectrometer. However, since we 
were able to separate both glucuronide metabolites from MPA chromatographically; this in-
source fragmentation did not interfere with quantification of MPA.  
2.4.2 Method application to biopsy specimens from kidney transplant 
patients 
Mean (± SD, range) patient biopsy weights were 0.18 (± 0.1, 0.11 to 0.33) mg, and tissue 
MPA concentrations measured in each patient biopsy from 4 kidney transplant recipients 
were 1.25 (biopsy taken at 8 days post-transplant; co-administered with everolimus), 1.77 
(524 days post-transplant; co-administered with sirolimus), 6.67 (693 days post-transplant; 
co-administered with everolimus) and 7.67 (1651 days post-transplant; co-administered with 
everolimus) ng/mg of tissue, as shown in Fig. 2.4. Tissue MPA concentrations were all 
within the calibration curve range. Two of the 4 MPA biopsy concentrations were of a 
similar magnitude to the plasma therapeutic range for C0 (1 – 3.5 mg/L) and the other two 
biopsies concentrations were above this range. Plasma MPA C0 concentrations were not 
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available for all patients and therefore the correlation between plasma (C0) and tissue MPA 
concentrations could not be established in this study. 




Figure 2.1 The chemical structures of (A) mycophenolic acid (MPA) and (B) N-
phthaloyl-L-phenylalanine (PPA, internal standard). Sites for MPA glucuronidation are 
shown by the arrow. 


















Figure 2.2 Representative LC-MS/MS chromatograms from (A) an extracted patient 
kidney biopsy tissue (weight 0.33 mg) with a measured MPA concentration of 11.0 
ng/mL in extraction buffer, equating to 6.7 ng/mg in the biopsy; and MPA-free human 
kidney tissues spiked with (B) MPA ether-glucuronide (MPAG) at the retention time of 
1.51 min, or (C) MPA acyl-glucuronide (AcMPAG) at the retention time of 1.63 min. In 
panels (B) and (C) the MPAG or AcMPAG MRMs are shown in light grey.  
 
 











Figure 2.3 Post-column infusion traces of (A) MPA and (B) PPA IS following injections 
of analyte-free human kidney tissue extract (light grey) and mobile phase (black). 
Expected analyte peak widths are indicated by double arrow on the chromatograms.  




Figure 2.4 Kidney (y) MPA concentrations measured in 4 kidney transplant recipients 
over 8 – 1651 days post-transplantation. Numbers in parenthesis indicate the time 
biopsies were taken post-transplantation (days) and the shading (1.0 to 3.5 mg/L) 
indicates the plasma therapeutic range for C0. 
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Table 2.1 Intra- and inter-day inaccuracy (bias) and imprecision of the lowest and highest 
calibration and low, middle and high QC samples for MPA, and two kidney samples obtained 
from rats administered MPA (Biological QCs). 
 Intra-day (n = 6) Inter-day (n = 6) 




      
0.6 0.61 ± 0.07 10.7 2.2 0.59 ± 0.05 4.6 -0.4 
20 20.1 ± 0.66 3.3 0.6 19.9 ± 0.87 4.4 -0.5 
QCs (ng/mL)       
0.6 0.60 ± 0.05 8.6 0.1 0.57 ± 0.05 9.5 -5.4 
2 1.86 ± 0.25 13.3 -7.3 2.0 ± 0.11 5.5 1.9 
10 10.5 ± 0.82 7.8 5.1 10.3 ± 0.49 4.8 2.8 
Biological QCs  
(ng/mg) 
 
      
A 0.35 ± 0.05 12.8 - 0.35 ± 0.04 12.9 - 
B 3.5 ± 0.26 7.3 - 3.6 ± 0.22 6.1 - 
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Table 2.2 Extraction efficiency, matrix effects, and process efficiency of the LC-MS/MS assay 
in human and rat kidney samples using the post-extraction analyte addition approach [175] at 
MPA concentrations of 2 (low) and 20 (high) ng/mL.  
  Human Kidney Rat kidney  
  Low  High  Low  High  
Extraction efficiency MPA 97 % 98 % 94 % 89 % 
 PPA 88 % 86 % 83 % 86 % 
 MPA/PPA 103 % 104 % 100 % 103 % 
Matrix effect MPA - 4 % 2 % 0 % 10 % 
 PPA - 2 % 9 % - 5 % 10 % 
 MPA/PPA - 2 % - 6 % 5 % 0 % 
Process efficiency MPA 94 % 99 % 95 % 98 % 
 PPA 94 % 95 % 92 % 95 % 
 MPA/PPA 101 % 105 % 103 % 105 % 
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2.5 Discussion and Conclusions 
The quantification of MPA concentrations within the graft tissue may provide a better 
understanding of MPA distribution during kidney rejection. Previous studies in liver and 
kidney transplant recipients showed that intra-graft tacrolimus [161, 164, 165] and 
cyclosporine [162, 163, 171] concentrations are better predictors of transplant outcomes 
compared to whole blood concentrations. No study to date has examined tissue MPA 
concentrations in kidney transplant recipients to determine whether MPA concentrations 
within the graft tissue may better reflect or predict transplant outcomes. This study aimed to 
develop a method suitable for the quantification of MPA in human kidney biopsies from 
kidney transplant recipients taken as part of routine clinical care. Several analytical methods 
have been reported for the quantification of MPA concentrations in plasma [92, 93, 180-
182]; however, to our knowledge, this is the first study to measure tissue MPA 
concentrations in human kidney biopsies taken as part of routine clinical procedures.  
The method has been comprehensively assessed following the principle of the FDA criteria 
for industry on bioanalytical methods [174] and several aspects of this method are based on 
our previous method for the quantification of the calcineurin inhibitor tacrolimus in human 
kidney biopsy specimens [176]. Like tacrolimus, detection of MPA was also based on MRM 
monitoring of the ammonium adducts, similar to a several other published MPA methods 
measuring MPA in plasma [94, 183, 184] to enhance greater overall immunosuppressant 
assay flow-through on the LC-MS/MS system. However, several changes to the tacrolimus 
method were also necessary to maximise analyte peak intensity and improve the sensitivity. 
This method employed mechanical homogenisation using a mortar and pestle followed by 
liquid-liquid extraction of the drug in biopsy samples. Enzymatic tissue digestion had been 
used previously for the tacrolimus method [176] and has some advantages over mechanical 
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homogenisation particularly minimizing sample handling and analyte loss that may occur in 
the process. However, the solubilisation is carried out at alkaline pH and may hydrolyse the 
relatively unstable AcMPAG during sample preparation. This study demonstrated that the 
mechanical homogenisation technique prevented degradation of the glucuronides and 
produced excellent extraction efficiency (approximately 97 %) and high process efficiency, 
and therefore can be considered as an alternative sample preparation technique for the 
analysis of small biopsy-sized samples. Furthermore, the use of biological QCs obtained 
from rats administered MPA also provided additional assessment and validation of the 
reproducibility of the tissue extraction procedures. Liquid-liquid extraction has been used in 
our sample preparation as it has been shown to minimize potential matrix interference in 
comparison to the solid-phase extraction technique [185] and this method demonstrated no 
significant matrix effects in human samples and practically negligible ion enhancement (d 
10 %) in rat kidney samples. Initially, carboxy-butoxy ether mycophenolic acid (MPAC) had 
been selected as the internal standard, however MPAC produced an interfering peak in the 
MPA trace (most likely due to in-source fragmentation) and was replaced by PPA, which 
provides overall accuracy, precision and specificity well within acceptable limits in both 
human and rat tissues. The use of stable labeled internal standards (MPA-d3) is highly 
recommended to adequately compensate for matrix effects, and may contribute to the 
improved performances, however deuterated internal standard was not available at the time 
of developing the method.  
We have demonstrated no interference in the quantification of tissue MPA concentrations by 
cyclosporine, tacrolimus and everolimus, the other commonly co-administered 
immunosuppressants. However, sirolimus appeared to cause underestimation of MPA and 
the method may require further validation before MPA concentrations can be measured in 
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tissues also exposed to sirolimus. Regarding potential analytical interference from the 
metabolites of MPA, the in-source ion fragmentation of drug metabolites to their respective 
parent analyte has been discussed previously [172] and a previous study by Vogeser and 
colleagues [173] has demonstrated that the in-source ion fragmentation of MPAG can 
interfere with the quantification of MPA. We have checked with pure MPAG and AcMPAG 
solutions that both metabolites did not interfere with the detection and quantification of 
MPA. Although in-source ion fragmentation of the glucuronides into MPA was observed at 
the retention times of MPAG and AcMPAG, the chromatographic separation of the two 
MPA glucuronides from MPA resulted in no interference with the quantification of MPA. 
This factor must be assessed critically during method development to ensure a correct 
detection and quantification of the actual MPA peak, since falsely high MPA concentrations 
could lead to lower dose administration and potentially an increased risk of rejection in 
kidney transplant recipients. 
The LC-MS/MS method has allowed for the accurate and precise quantification of MPA in 
biopsy-sized tissue samples taken as part of routine clinical care. As same-day plasma MPA 
C0 concentrations were not available for the biopsy specimens in this small study, we were 
unable to investigate any relationships between kidney MPA concentrations and those in 
plasma. However, it appears that graft MPA concentrations were of a similar magnitude to 
the C0 therapeutic range for MPA. In comparison, we have previously reported tissue to 
blood concentration ratios of 4 and 20 for cyclosporine [171] and tacrolimus [176], 
respectively, with no correlation between their concentrations in whole blood and those 
within the kidney, consistent with other published studies [163-165]. However, small sample 
size was a limitation for this and our two previous studies [171, 176]. In addition, this study 
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may also have been limited by the age of the biopsy samples, as the stability of MPAG and 
AcMPAG during long-term storage could not be assessed. 
In summary, this method has been successfully used for quantification of MPA 
concentrations in core needle biopsies from kidney transplant recipients taken as part of 
routine clinical care. In contrast to previously published studies [162, 165], clinical practice 
in this study did not allow prospective acquisition of excess biopsy specimen. In addition, 
due to shared histological assessments and processing of biopsy specimens, this method was 
primarily designed to quantify MPA in routine core needle biopsies of kidney transplant 
recipients weighing as little as 0.1 mg. Nonetheless, these limitations have ensured that our 
assay benefits unaltered biopsy sampling and handling to fit into current clinical practice, 
and therefore will allow further investigations on the immunosuppressant MPA 
concentrations in the transplanted organ and their relationship with clinical outcomes 
following kidney transplantation.  
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This retrospective study aimed to investigate whether donor and recipient ABCC2 
haplotypes (formed by the common -24 C > T, 1249 G > A and 3972 C > T SNPs) influence 
MPA and MPAG concentrations, and the potential associations between ABCC2 genetic 
polymorphisms and kidney transplant outcomes. Sixty patients gave informed consent 
having been prescribed mycophenolate mofetil, tacrolimus and prednisolone-based 
immunosuppression. Blood or graft tissue was collected for ABCC2 genotyping, and 
pharmacokinetic analysis was based on therapeutic drug monitoring data from recipients in 
whom abbreviated AUC (0 – 6 hr) monitoring had been carried out within 14 days of 
transplantation. ABCC2 genotyping (-24 C > T, 1249 G > A, 3972 C > T) was performed 
with PCR-RFLP. ABCC2 haplotypes were inferred using PHASE v2.1.1 and patients were 
classified as low, wild-type or high expressors. MPA trough (C0) concentrations were 2.3-
fold higher in recipients with high- (n = 5) compared to low-expressor (n = 30) ABCC2 
haplotypes (P = 0.04). In addition, a significant gene-dose effect was observed with an 
inverse step-wise relationship between ABCC2 expression and MPA C0 concentrations 
(Jonckheere-Terpstra test, P = 0.01). There was also a significant gene-dose effect between 
ABCC2 expression and MPAG/MPA C0 ratio (P = 0.04). In contrast, there was no effect of 
donor expressor status on either MPA or MPAG plasma concentrations. Multivariate 
analyses indicated that MPA C0 was associated with recipient ABCC2 expressor haplotype-
inferred phenotype, rejection and peak panel reactive antibody (P = 0.008), whilst MPAG 
exposure was associated with delayed graft function and cold ischemia time (P = 0.0002). 
Recipient ABCC2 haplotypes are associated with variability in MPA concentrations and 
rejection and may be an important factor to consider in dosage adjustment. 
Keywords: MPA, MRP2, ABCC2, mycophenolic acid, haplotype, pharmacogenetics, 
pharmacokinetics, rejection, renal transplantation.  
 




Mycophenolic acid (MPA), administered either as the morpholinoethyl ester prodrug or as 
the sodium salt, is now the principal immunosuppressive agent used concomitantly with 
calcineurin inhibitors, either tacrolimus (TAC) or cyclosporine (CsA), to prevent rejection 
following renal transplantation [4]. MPA produces potent, selective and noncompetitive 
inhibition of inosine monophosphate dehydrogenase (IMPDH), which catalyses the de novo 
synthesis of guanosine nucleotides required for T and B lymphocyte proliferation [16]. MPA 
is mainly metabolised in the liver and to a lesser extent in the kidney and gastrointestinal 
tract [38] by UDP-glucuronosyltransferase enzymes primarily into its main inactive 
metabolite, the phenolic-glucuronide of MPA (MPAG) and the pharmacologically active 
acyl-glucuronide of MPA (AcMPAG) [41]. MPA is also subject to enterohepatic 
recirculation via biliary excretion of MPAG [45] and its deconjugation back to MPA through 
the action of bacterial β-glucuronidase in the gastrointestinal tract, and subsequent 
reabsorption into the circulation. The enterohepatic recycling of MPA, on average, 
contributes approximately 37 % (range 10 – 61 % in humans) of the total dose-interval MPA 
area under the concentration-time curve (AUC) and is reflected as a secondary MPA peak 
observed 6 – 12 hours (hr) after oral administration [32].  The kidney, however, is the main 
organ responsible for the irreversible excretion of both MPAG and AcMPAG metabolites 
[32] and multidrug resistance-associated protein 2 (MRP2) has been shown to be involved in 
renal and biliary excretion of MPAG [46].  
Relationships between plasma MPA concentrations (trough (C0) or AUC) with both 
rejection [78, 83] and adverse events [82, 83] have been demonstrated in various studies. 
Increased rejection rates and higher incidence of adverse events are associated with low and 
high MPA concentrations, respectively, with proposed target ranges to avoid these effects of 
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30 – 60 mg.hr/L for AUC0-12 [78] corresponding to C0 concentration targets of 1.3 – 3.5 
mg/L (when co-administered with CsA) or 1.9 – 3.5 mg/L (when co-administered with 
TAC), determined by high-performance liquid chromatography assay [96]. Because of the 
narrow therapeutic index and large inter-individual variability in pharmacokinetics (PK) 
[32], therapeutic drug monitoring (TDM) [96] has been proposed to individualise doses of 
MPA based on the above target ranges. The large variability in MPA PK has been at least 
partially explained by differences in the type of concomitantly used calcineurin inhibitor 
(TAC or CsA) [186], kidney graft [187] or hepatic [188] function, plasma protein binding 
[35] and drug-drug interactions [60]. In addition, there is a growing awareness that multiple 
genomic factors may also influence the PK and pharmacodynamics (PD) of 
immunosuppressants such as MPA [189], and therefore determine the overall success of 
renal transplantation.  
The membrane transporter MRP2, encoded by the ABCC2 gene, is a member of the ABC 
membrane transporter superfamily and the protein is predominantly expressed in the apical 
membrane of hepatocytes and renal proximal tubular epithelium [111]. This efflux 
transporter is of particular clinical importance given its pivotal role in the biliary and renal 
excretion of MPAG [46]. Several single nucleotide polymorphisms (SNPs) in the ABCC2 
gene have been identified and among them, the SNPs most frequently observed in 
Caucasians are the promoter (-24 C > T, rs717620, 20 % frequency), exon 10 (1249 G > A, 
rs2273697, 16 %) and exon 28 (3972 C > T, rs3740066, 30 %) [135, 136]. The functional 
effects of ABCC2 polymorphisms on MRP2 expression and functional activity remain 
unclear. For instance, the promoter polymorphism has been shown to increase [190], 
decrease [135, 136] or have no influence [148] on MRP2 expression and/or functional 
activity. However, a recent report assessing in vitro expression and function of haplotypes 
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demonstrated that in comparison to ABCC2 wild-type (WT) haplotype H1 (CGC; -
24C/1249G/3972C), haplotype H2 (CAC; variant at 1249) resulted in increased protein 
expression and transport activity, haplotype H10 (TGC; variant at -24) resulted in lower 
protein expression, while haplotypes H9 (CGT; variant at 3972) and H12 (TGT; variant at -
24 and 3972) resulted in lower protein expression and transport activity [140]. These 
outcomes suggest that consideration of ABCC2 haplotypes in place of individual SNPs is 
more likely to accurately reflect MRP2 protein expression and/or transport activity.  
Although there are a large number of clinical studies evaluating the influence of individual 
ABCC2 SNPs on MPA and/or MPAG PK [136, 146, 148-151], results have been conflicting 
due to lack of haplotype analysis and small patient cohorts. Importantly, previous studies of 
the effects of ABCC2 SNPs on clinical outcomes have focused mostly on the impact of 
recipient genotype. Only one study investigated the influence of both donor and recipient 
ABCC2 genotype variants on kidney transplant outcomes [158]. Two main observations of 
this study were: i) a donor haplotype CGACA (-24C/1249G/3563A/3972C/4544A, variant at 
3563 and 4544) was more frequent in patients with delayed graft function (DGF) compared 
to those without DGF; and ii) variant alleles (A/A) at 3563/4544 of the donor genotype were 
strongly related to the incidence of DGF but not with any of the other genetic or clinical 
parameters tested [158]. Since enterohepatic recirculation, involving biliary MPAG 
excretion, is an important component of MPA PK, recipient ABCC2 expression and/or 
function may influence the PK of MPA. In contrast, donor ABCC2 expression and/or 
function may have the greatest impact on MPAG PK, as renal excretion is the primary 
clearance mechanism for MPA metabolites [32]. 
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Therefore, the aims of this retrospective study were to investigate the influence of donor and 
recipient ABCC2 haplotypes (formed by the common (-24 C > T, 1249 G > A and 3972 C > 
T SNPs) on MPA and MPAG PK, and the potential associations between ABCC2 genetic 
polymorphisms and kidney transplant outcomes. It was hypothesised that recipients with low 
expressor ABCC2 haplotypes (H9, H10 and H12) would have lower MPA concentrations as 
a result of decreased enterohepatic recirculation, whilst high expressor donor ABCC2 
haplotypes would decrease the plasma concentrations of MPAG as a result of increased renal 
excretion of MPAG.  
 




3.3.1 Study population, pharmacokinetic data and blood/graft collection 
In total, 60 kidney transplant recipients, and 46 donors, who had undergone kidney 
transplantation between May 2004 and March 2011, were included in this retrospective 
study. Each recipient and living donor gave written informed consent to participate in this 
study. Where the kidney graft was from a deceased donor, consent for the use of tissue 
sample for genotyping was obtained from transplant recipients at the time of surgery. The 
study protocol was approved by the Royal Adelaide Hospital Research Ethics Committee 
(approval number 100117) and the Queen Elizabeth Hospital Human Research Ethics 
Committee (approval number 2008178). All transplant recipients received a fixed dose of 
MMF (1 g twice daily) maintenance immunosuppression in combination with TAC and 
prednisolone. Patient clinical notes were used to obtain demographic data (sex, age and 
ethnic background), MMF dose, TAC pre-dose (C0) concentrations and transplant-related 
data including albumin and bilirubin concentrations, human leukocyte antigen (HLA) 
mismatch, cold ischemia time, panel reactive antibody (PRA) and donor type (living or 
deceased). The incidence of rejection within 0 – 26 days post-transplantation was defined 
based on clinical assessment and/or histology (e.g. protocol or for-cause biopsies) and 
classified for severity according to Banff 2007 criteria [178], as no rejection, subclinical 
borderline, clinically evident, or severe vascular rejection. The incidence of DGF was 
identified by the lack of spontaneous fall in serum creatinine or haemodialysis within 7 days 
post-transplantation.  
MPA and MPAG plasma concentrations for TDM were determined by high-performance 
liquid chromatography (HPLC) [93]. Pharmacokinetic analyses were based on TDM data 
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from transplant recipients in whom abbreviated AUC monitoring had been carried out within 
14 days of transplantation. In brief, blood samples (patients were on a fixed dose at the time 
of sampling) were collected at pre-dose, 1, 2, 3, and either 4 or 6 hr after daily MMF 
administration. Because of the differences in the last sampling time between individuals, the 
MPA and MPAG average plasma concentrations (Cav) were used in the data analysis and 
determined as follows: Cav= AUC0
n (mg/L) ÷ sampling time (n), where n is the time of the 
last sample (4 or 6 hr). Same-day TAC C0 concentrations were also obtained from TDM 
data.  
3.3.2 ABCC2 genotyping 
Blood samples from all 60 kidney transplant recipients and 15 living donors were available 
for ABCC2 genotyping. For transplants from deceased donors (n = 31), a small sample of 
excess donor kidney blood vessel was collected at the time of surgery for genotyping. Of the 
46 donor blood/graft and 60 recipient blood samples, 24 and 26, respectively, had already 
been genotyped as part of a previous study aimed to develop a primer extension denaturing 
HPLC (PE-dHPLC) assay to determine the common variants (-24 C > T, 1249 G > A and 
3972 C > T SNPs) of the ABCC2 gene [191]. The remaining samples were genotyped by the 
use of polymerase chain reaction (PCR) – restriction fragment length polymorphism (RFLP) 
assays as previously described [136]. In brief, genomic deoxyribonucleic acid (DNA) was 
isolated from 400 μL of whole blood collected in EDTA tubes, or ≤ 25 mg of donor tissue 
samples by use of a QIAamp® DNA mini kit according to manufacturer’s protocol 
(QIAGEN, Clifton Hill, Australia). The primer sequences and the size of the amplified 
fragments for PCR-RFLP assay are shown in Table S3.1 (see Supplementary Tables). All 
PCR reactions were prepared on ice to prevent premature polymerisation and primer binding 
and were carried out in a 30 μL volume containing: 50 ng purified genomic DNA; 50 μM 
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dNTPs (Finnzymes, distributed by Genesearch, Arundel, QLD, Australia); 0.1 μM of -24 C 
> T and 1249 G > A or 0.5 μM of 3972 C > T forward and reverse primers; 2.5 U of Taq 
DNA Polymerase (New England Biolabs, distributed by Genesearch) for the -24 C > T SNP 
or 1 U of Taq DNA Polymerase for the 1249 G > A and 3972 C > T SNPs; and 1 X 
ThermoPol Reaction Buffer, (New England Biolabs). All PCR reactions were run in a PTC-
100 or PTC-200 Peltier Thermal Cycler (MJ Research Inc., distributed by GeneWorks, 
Thebarton, SA, Australia) at optimal temperature programs for the specific PCR assay. PCR 
cycling conditions were as follows: 12 min at 95 °C; 35 cycles of a) 30 sec at 93 °C, b) 35 
sec at 55 °C (-24 C > T), 63 °C (1249 G > A) or 58 °C (3972 C > T), and c) 30 sec at 72 °C; 
and 5 min at 72 °C. All PCR assays incorporated a negative (no DNA template) control to 
ensure no contamination of reagents and random samples were sequenced (BigDye v3.0 
sequencing kit with analysis on an ABI Prism 7700 DNA sequencer (Applied Biosystems, 
Scoresby, VIC, Australia) at SA Pathology (Adelaide, SA, Australia) to confirm the 
presence of SNPs and subsequently used as positive controls (WT or variant) for each PCR 
assay. 
After amplification, the PCR products were separated and visualised on a 4 % 2:1 (w:w) 
Omnigel-Sieve (Adelab Scientific Pty Ltd., Thebarton, SA, Australia):Agarose I 
(AMERSCO Inc., distributed by Adelab Scientific Pty Ltd.) gel containing ethidium 
bromide. A pUC19/HpaII DNA molecular weight marker (GeneWorks) was used as 
reference. PCR products were then digested with the restriction enzymes and their optimal 
digestion conditions for each PCR-RFLP assay are shown in Table S3.2 (see Supplementary 
Tables). Digested fragments were visualised by gel electrophoresis on a 4 % 3:1 Omnigel-
Sieve:Agarose I gel containing ethidium bromide, with a pUC19/HpaII DNA molecular 
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weight marker as reference. A comparison of the ABCC2 genotypes was performed between 
PCR-RFLP and PE-dHPLC assays, and the results were 100 % concordant between assays. 
3.3.3 Data analysis 
Chi-squared analyses were performed to test for genotype deviations from Hardy-Weinberg 
equilibrium. ABCC2 haplotype predictions were inferred by the use of PHASE software 
version 2.1.1 [192], which allows the estimation of haplotypes from population genotype 
data. The validity of PHASE haplotype estimations was checked as per PHASE 
recommendations, and a PHASE case-control permutation test was run to detect any 
significant differences in inferred ABCC2 haplotypes between the recipient and donor 
groups. If the permutation test gave a significant result, post-hoc analysis of individual 
ABCC2 haplotype frequencies was performed using Odds Ratios and Fisher’s Exact Tests. 
Pairwise linkage disequilibrium was assessed using the Arlequin program (Version 3.5) 
[193] which was able to calculate the D’ and R2 coefficients of linkage disequilibrium as 
well as perform a test of linkage disequilibrium for statistical significance for each pairwise 
comparison of loci. Odds Ratios and Fisher’s Exact Test were used to examine any 
differences in ABCC2 SNP allele, genotype and haplotype frequencies between recipients 
and donors.  
The associations between donor or recipient ABCC2 haplotypes with MPA and MPAG 
pharmacokinetics (C0, Cav and the corresponding MPAG/MPA ratios) were investigated in 
the first two weeks following transplantation using the Kruskal-Wallis test (with Dunn’s 
multiple comparisons post hoc). The recipients and donors were divided into three groups 
according to the ABCC2 haplotypes analysis as reported previously by Laechelt et al. [140]: 
ABCC2 high expressor group (H2/H2 and H1/H2), low expressor group (H9/H9, H10/H10, 
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H12/H12, H1/H9, H1/H10 and H1/H12) and WT group (H1/H1). Gene-dose effects were 
analysed using Jonckheere-Terpstra Test (SPSS, version 19, IBM).  
The associations between MPA and MPAG PK with genetic and clinical parameters were 
investigated using a general linear model of multivariate regression with step-wise addition 
of factors. The variables included in the step-wise addition procedure were: age, sex, genetic 
(donor and recipient phenotypes), rejection, DGF, MMF dose, human leukocyte antigen 
(HLA) mismatches, cold ischemia time (CIT), panel reactive antibody (PRA) and TAC C0 
concentration. Data are presented showing the overall P value and also individual P values 
for each covariate. A P > 0.05 for an individual covariate included in the model indicates 
that, whilst not independently associated with the outcome being investigated, the variable 
significantly improved the overall final linear model. Analysis was performed using R [194]. 
Data are presented as median (range) (unless indicated otherwise) and P < 0.05 (two-tailed) 
was considered statistically significant for all analyses. 
 
 




3.4.1 Frequency distribution of the ABCC2 polymorphisms 
Patient characteristics and transplant-related data are shown in Tab1e 3.1. The allele and 
genotype frequencies of ABCC2 genetic polymorphisms in recipients and donors are 
summarised in Table 3.2. Genotype frequencies in both recipient and donor groups did not 
deviate from Hardy-Weinberg equilibrium (P ≥ 0.13). There were no significant differences 
between the recipient and donor groups in either allele (P ≥ 0.2) or genotype (P ≥ 0.1) 
frequencies at each locus. Five and six ABCC2 haplotypes were identified in recipients and 
donors, respectively, with no significant difference in population ABCC2 haplotype 
frequency distributions between the recipient and donor groups (P = 0.34, Table 3.3). 
However, only 37 % of donor-recipient pairs (n = 17) had identical ABCC2 haplotypes. The 
four most common ABCC2 haplotypes in recipients and donors, respectively, were H1 CGC 
(-24C/1249G/3972C, both at 48 %, WT), H12 TGT (18 and 21 %, low expressor), H2 CAC 
(both at 14 %, high expressor) and H9 CGT (13 and 12 %, low expressor) (Table 3.3). In 
addition, haplotype TAT has also been observed in our study cohort and was present in 4 % 
of donors. 
3.4.2 Linkage disequilbrium 
Significant linkage disequilibrium was observed between the -24 C > T and 3972 C > T 
SNPs which had moderate-to-high values for both D’ and R2 (Recipient: D’ = 0.64, R2 = 
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3.4.3 Effects of ABCC2 haplotypes on MPA and MPAG pharmacokinetics 
Recipient ABCC2 haplotypes. MPA C0 concentrations in the recipient ABCC2 high 
expressor group (n = 5) were 2.3-fold higher than those in the ABCC2 low expressor group 
(n = 30, P = 0.04); but not different to those in the WT group (n = 8, P > 0.99), respectively 
(Fig. 3.1A). There was no significant difference between the ABCC2 low expressor groups 
and WT group (P = 0.36). However a significant gene-dose effect relationship was observed 
among the three ABCC2 haplotype groups (Fig. 3.1A, Jonckheere-Terpstra test, P = 0.01), 
with an inverse step-wise relationship between ABCC2 expression and MPA C0 
concentrations. ABCC2 haplotypes did not significantly affect MPAG C0 concentrations (P 
= 0.74) (Fig. 3.1B). There was also a significant gene-dose effect between ABCC2 
expression and MPAG/MPA C0 ratio (Fig. 3.1C, Jonckheere-Terpstra test, P = 0.04). There 
were no significant differences in either MPA (P = 0.74) or MPAG (P = 0.62) Cav 
concentrations, or the MPAG/MPA Cav ratio (P = 0.99) between the three ABCC2 haplotype 
groups (Fig. 3.1D-F), respectively.  
Donor ABCC2 haplotypes. Donor ABCC2 haplotypes had no effect on MPA and MPAG C0 
(P = 0.28 and 0.90, respectively) or Cav (P = 0.12 and 0.22, respectively) concentrations 
(Fig. 3.2A, B, D and E). In addition the ratios of C0 or Cav MPAG/MPA were not different 
between donor ABCC2 haplotypes (P = 0.31 and 0.51) (Fig. 3.2C and 3.2F). 
3.4.4 Effects of demographics, genetic and clinical covariates on MPA and 
MPAG pharmacokinetics 
Rejection occurred in 22 kidney transplant recipients, giving an overall incidence of 37 %. 
Of these, 18 were biopsy-proven defined by Banff 2007 guidelines (Banff grade IA or 
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higher) and four were borderline or suspicious rejection and were treated with methyl-
prednisolone. The overall incidence of DGF was 7 %.  
A step-up linear regression model selection procedure was used to identify variables 
associated with MPA and MPAG PK. Of the variables examined (refer to Section 3.3.3), 
MPA C0 was significantly associated with rejection, PRA peak and recipient ABCC2 
expression phenotypes (explaining 23 % of variance, P = 0.008). Patients who experienced 
rejection had a 1.1 unit increase in MPA C0 concentrations (P = 0.017) compared to those 
who had no rejection (given all other predictors were held constant). MPA C0 values 
increased as PRA peak increased (P = 0.096). Recipients with low and WT ABCC2 
expressor haplotypes had 1.1 and 0.2 units, respectively, lower MPA C0 concentrations (P = 
0.10 and 0.79, respectively), compared to high expressor recipients.  
MPAG C0 was significantly associated with the incidence of DGF (explaining 46 % of 
variance, P = 7.9 x 10-7); patients who had DGF had a 181 unit increase in MPAG C0 values 
compared to those who had no DGF. There were no significant associations between the 
MPAG/MPA C0 ratio and clinical parameters, hence no modelling of the data was 
performed.  
Of the demographic variables tested, age was the only significant variable associated with 
MPA Cav (explaining 44 % of variance, P = 1.0 x 10-5). As the age of the patient increased 
by 1 year, MPA Cav decreased by 1.4 units.  
MPAG Cav was significantly related with DGF and CIT; these variables explained 36 % of 
variance in MPAG values (P = 0.0002). Patients who experienced DGF had a 168 unit 
increase in MPAG Cav concentrations (P = 0.00014) compared to those who had no DGF. In 
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addition, patients with optimal CIT (≤ 18 hr) had a 118 unit decrease in MPAG Cav 
concentrations (P = 0.039) compared to those with non-optimal CIT.  
Finally, the ratio of MPAG/MPA Cav was also significantly associated with DGF and CIT 
(explaining 22 % of variance in the ratio of MPAG/MPA Cav concentrations, P = 0.006). 
Patients who experienced DGF had a 1.2 unit increase in log (MPAG/MPA Cav) values (P = 
0.01) compared to those who did not experience DGF, and as CIT increased by 1 unit, 
patients had a 0.04 unit increase in log (MPAG/MPA Cav) values (P = 0.087).  
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Table 3.1 Demographic, pharmacokinetic and transplant related data for the study population. 
 Patients 
n = 60 
Sex 
      Male 







56 (19 – 72) 
MMF dose (gram/day) 
 
2 (1.5 – 3) 
TAC C0 (μg/L) 
 
9.4 (2.5 – 21.2) 
HLA mismatches 
 
4 (0 – 6) 
PRA 
      At transplantation 
      Peak 
 
 
0 (0 – 98) 
0 (0 – 98) 
Cold ischemia time (hr) 
 
9.8 (3 – 23.3) 
Donor graft 
      Living 






      Yes 






      Yes 





DGF, delayed graft function; HLA, human leukocyte antigen; MMF, 
mycophenolate mofetil; PRA, panel reactive antibody; TAC C0, tacrolimus 
trough whole blood concentration. 
Data are given as absolute values with percent data in parentheses or median 
(range). 
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Table 3.2 Recipient and donor allele and genotype frequencies (%) for the -24 C > T, 1249 G > A and 3972 C > T SNPs of ABCC2. 
   Allele Frequency (%)                       Genotype Frequency (%)    







1.1 (0.56 – 2.0) 
 

































OR (95 % CI), Odds ratio (95 % confidence interval); V, Variant; WT, Wild-type; F², Chi-square. P-value from Fisher’s exact test. 
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Table 3.3 ABCC2 haplotype frequencies (%) in 60 kidney transplant recipients and 46 donors. 
ABCC2 haplotype -24 C > T 1249 G > A 3972 C > T Frequency (%) 
    Recipient Donor 
H1  C G C 47.5 47.8 
H2 C A C 14.2 14.1 
H9 C G T 13.3 12.0 
H10 T G C 7.5 1.1 
H12 T G T 17.5 20.7 
 T A T 0.0 4.3 
H1, wild-type; H2, high expressor; H9, H10 and H12, low expressor [140]. 
The variant nucleotides in each haplotype are underlined. 
 
Zaipul Md Dom, PhD Thesis 2016 
 
99 































































































Figure 3.1 Influence of the recipient ABCC2 haplotypes on (A) MPA, (B) MPAG and 
(C) ratio of MPAG/MPA trough (C0) concentrations (mg/L), and (D) MPA, (E) MPAG 
and (F) ratio MPAG/MPA average (Cav) plasma concentrations (mg/L). Notes: Lines 
indicate median values. Open squares and triangles are homozygous high- and low-
expressor ABCC2 haplotypes, respectively. P-values are shown for both Kruskal-Wallis 
analysis (plain text) and Jonckheere-Terpstra (trend) test (bold text). 















 P = 0.01 in trend test 
  
P = 0.04 
P = 0.74 
 P = 0.04 in trend test 
  
P = 0.07 
P = 0.62 
P = 0.74 
P = 0.99 
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Figure 3.2 Influence of the donor ABCC2 haplotypes on (A) MPA, (B) MPAG and (C) 
ratio of MPAG/MPA trough (C0) concentrations (mg/L), and (D) MPA, (E) MPAG and 
(F) ratio of MPAG/MPA average (Cav) plasma concentrations (mg/L). Notes: Lines 
indicate median values. Open squares and triangles are homozygous high- and low-
expressor ABCC2 haplotypes, respectively. P-values are shown for Kruskal-Wallis 
analysis. 















































P = 0.28 
P = 0.90 
P = 0.31 
P = 0.22 
P = 0.12 
P = 0.51 
 




Table S3.1 Primer sequences and the amplified fragment size for PCR-RFLP assays. 
SNP Region Primer Sequences Fragment 
size 
-24 C>T Promoter F   5’-CTGTTCCACTTTCTTTGATGA-3’ 
 
R   5’-TCTTGTTGGTGACCACCCTAA-3’ 
 
211 bp 
1249 G>A Exon 10 F   5’-GGGCAAAGAAGTGTGTGGAT-3’ 
 
R   5’-ACATCAGGTTCACTGTTTCTCCCA-3’ 
 
303 bp 
3972 C>T Exon 28 F   5’-AACTTACTTCTCATCTTGTCTCCTTGC-3’ 
 
R   5’-CTCCACCTACCTTCTCCATGCTATC-3’ 
 
184 bp 
bp, base pair; F, forward primer; R, reverse primer.
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Table S3.2 Restriction enzymes and digest conditions used for restriction fragment length 









-24 C>T BbsI 5’-GAAGACNN⌃NNN-3’ 2.5 U: 16 hr at 37 
°C, 20 min at 65 °C 
 
WT: 151 + 60 
V: 211 
 
1249 G>A NcoI 5’-AT⌃CG_AT-3’ 5 U: 16 hr at 37 °C, 
20 min at 65 °C 
 
WT: 208 + 95 
V: 208 + 69 + 
26 
 
3972 C>T ClaI 5’-C⌃CATG_G-3’ 1 U: 16 hr at 37 °C, 
20 min at 65 °C 
 
WT: 158 + 26 
V: 184 
bp, base pair; N, can be any nucleotide; U, unit; V, variant fragment; WT, wild-type fragment; ⌃ , 
cleavage site. 
 




Previous pharmacogenetic studies of ABCC2 genetic variability on MPA and MPAG PK 
have reported conflicting findings with the majority of studies having investigated only the 
genotype of the recipient and the influence of ABCC2 genetic polymorphisms in isolation.  
To our knowledge, this is the first study to investigate the role of ABCC2 haplotypes of both 
the donor graft and the transplant recipient on MPA and MPAG pharmacokinetics and 
kidney transplant outcomes.  
In the present study, the three SNPs investigated (-24 C > T, 1249 G > A and 3972 C > T) 
are the most commonly observed in the Caucasian population. The allele and genotype 
frequencies observed were not significantly different between the recipients and donors, and 
variant allele frequencies were comparable to those previously published in healthy 
Caucasians [135] and in Caucasian kidney transplant recipients [136]. As reported in 
previous studies [135, 140], the four most common ABCC2 haplotypes identified were the 
CGC (WT), CAC (high expressor), CGT (low expressor) and TGT (low expressor). In 
addition, although there was no significant difference in overall haplotype frequencies 
between donor and recipient groups, only 37 % of recipients had identical ABCC2 haplotype 
to their donor graft. This mismatching on the basis of ABCC2 haplotype indicates that 
ABCC2 expression and/or functional activity may differ significantly between the transplant 
recipient and the donor graft. Although previous studies have investigated the frequencies of 
ABCC2 haplotypes [135, 140, 158, 195], comparison across studies is limited due to the 
different combinations of ABCC2 SNPs included in the analyses. Despite this, the 
frequencies of the WT (CGC) (48 % versus 39 % [140] and 47 % [135]), CAC (14 % versus 
20 % [140] and 21 % [135]) and TGT (18 – 21 % versus 18 % [140] and 17 % [135]) 
haplotypes (combination of -24 C > T, 1249 G > A and 3972 C > T SNPs) were comparable 
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to those reported previously. In agreement with previous findings [135, 195], significant 
linkage disequilbrium was observed between the -24 C > T and 3972 C > T SNPs and 
although the 3972 C > T SNP results in a silent mutation, this linkage may be inferred in 
altered MRP2 expression and/or functional activity.  
The investigation of the possible associations between ABCC2 haplotypes and MPA PK 
revealed new and significant findings. Of the prior investigations that have focused on 
individual ABCC2 SNPs, conflicting observations on the influence on MPA PK have been 
reported [136, 146, 149, 151]. To our knowledge, the present study provides the first 
evidence that the recipient’s MRP2/ABCC2 affects the PK of MPA in a haplotype-specific 
manner. This study has demonstrated for the first time that recipient haplotype CAC (-
24C/1249A/3972C), exhibiting significantly higher protein expression [140], is associated 
with 2.3-fold higher MPA C0 concentrations, compared to recipients with low expressor 
haplotypes. This association was also confirmed in the multivariate analysis, and is 
consistent with increased enterohepatic recirculation due to increased biliary excretion of 
MPAG and reabsorption of MPA after deglucuronidation of MPAG in the gastrointestinal 
tract. The lack of significant differences in MPA C0 concentrations between recipients with 
the WT (CGC) and low expressor haplotypes (CGT, TGC and TGT) may suggest that the 
variant A at position 1249 could have accounted for the high levels of MPA C0 
concentrations. In addition, significant gene-dose effects were observed between recipient 
ABCC2 expression with MPA C0 concentrations and MPAG/MPA C0 ratio.  
 
In contrast, ABCC2 recipient haplotypes were not associated with MPA Cav concentrations. 
The concentration-time profile of MPA includes a secondary peak as a result of 
enterohepatic recirculation, occurring 6 – 12 hr following administration [32]. Thus, 
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recipient ABCC2 gene variants are most likely to affect this later part of the dosing interval, 
which in this study is seen as differences in C0 concentrations, rather than the early-hour 
samples (C1-3), which are more closely related to the rate of absorption. These findings are of 
practical clinical interest and may be informative for groups assessing MPA exposure 
through abbreviated AUC monitoring rather than MPA C0 monitoring. In addition, the 
calcineurin inhibitor co-administered with MMF may also influence the enterohepatic 
recirculation of MPA and should be taken into consideration. CsA, but not TAC, decreases 
MPA and increases MPAG plasma concentrations [54, 186]. Although this interaction was 
initially attributed to the inhibition of MRP2-mediated biliary excretion of MPAG by CsA 
[58], this is now thought to be due to the inhibition of MPAG uptake into hepatocytes by the 
organic anion transporting polypeptides (OATPs) [59]. However, this was not expected in 
the present study as all patients were receiving TAC as part of their immunosuppressant 
therapy.  
There was no association between recipient ABCC2 haplotypes with either MPAG C0 or Cav 
concentrations. This seems contradictory to expectations as recipients with low expressor 
ABCC2 haplotypes, associated with lower protein expression and transport activity [140], 
may be expected to have higher plasma MPAG concentrations than high expressor 
recipients. These findings, however, are not unexpected since hepatic clearance only plays a 
minor role in the clearance of MPAG.  
This is the first study investigating the potential influence of donor ABCC2 genetic 
polymorphisms on the PK of MPA and MPAG. The efflux MRP2 transporter is expressed in 
the apical membrane of kidney proximal tubules [111], hence the donor ABCC2 genotypes 
determine kidney graft MRP2 expression and/or function, and consequently influence the 
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renal clearance (CLR) of MPAG. However, in the present study, no association was observed 
between donor ABCC2 haplotypes and either MPA or MPAG PK. The renal clearance of 
MPAG may involve passive filtration from plasma and active tubular secretion (potentially 
MRP2-mediated) and/or reabsorption. In healthy subjects, the mean unbound fraction of 
MPAG in plasma (fu) is approximately 0.18 [30], and the CLR of MPAG was reported 
between 25 – 34 mL/min [27]. Assuming an average glomerular filtration rate (GFR) of 120 
mL/min in healthy subjects, active tubular secretion may be inferred if CLR is greater than 
GFR x fu (approximately 22 mL/min). Thus, for MPAG, the contribution of active tubular 
secretion to overall CLR may be relatively small, and a large change in ABCC2 expression 
and/or MRP2 functional activity may be necessary to significantly affect MPAG plasma 
concentrations.   
In addition to identifying associations between ABCC2 haplotypes and MPA PK, the present 
study also investigated the effects of demographics and other clinical covariates on MPA and 
MPAG PK using a step-up linear regression model selection procedure. Recipient 
MRP2/ABCC2 expression phenotypes, PRA peak and rejection contributed individually 
towards the association with MPA C0 values, and collectively explained 23 % of MPA C0 
variability. Supporting our initial findings, the multivariate analysis revealed that higher 
MPA C0 concentrations were associated with high recipient MRP2 expression phenotype 
and, somewhat surprisingly, also related to the risk of rejection and high PRA peak. It is 
unclear whether rejection may have played a role to cause higher MPA C0 concentrations, or 
whether having a high expressor MRP2 phenotype per se may predispose patients to 
rejection, particularly in patients with high PRA peak, who are already at greater risk of 
rejection [196]. Alternatively, the effect of MPR2 phenotype on the enterohepatic 
recirculation of MPA may alter the relationship between C0 and AUC, as previously 
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suggested for the interaction between MPA and CsA or TAC [96], such that a slightly higher 
C0 concentration target range may be necessary for patients who are high MRP2 expressors 
compared to those who are low MRP2 expressors.  
Interestingly, the multivariate analysis did not show an association between MPA Cav 
concentrations and the incidence of rejection, potentially reflecting the importance of 
incorporating MPA concentrations between 6 – 12 hr post-dose to accurately determine total 
MPA exposure in patients co-administered with TAC. Age of the patients was the only 
significant variable associated with MPA Cav concentrations, in agreement with another 
recent study, which revealed that higher recipient age was associated with increased 
clearance of MPA [197]. As expected, DGF and CIT were associated with MPAG 
concentrations as renal clearance is the final irreversible clearance of the glucuronide. DGF 
was associated with increased MPAG C0 and Cav concentrations and conversely, CIT 
(optimal CIT ≤ 18 hr) was linked to decreased MPAG Cav concentrations. CIT plays an 
essential role in the success of renal transplantation and prolonged CIT is a risk factor for the 
development of DGF [198]. Recent studies have shown a correlation between longer CIT 
(20 – 30 hr and > 30 hr) and increased incidence of DGF [199] and each additional hour of 
CIT can increase the risk of graft failure [200].  
Despite the novel observations from this study, several limitations need to be discussed. 
Firstly, blood samples were only collected up to 6 hr post-dose and therefore may have 
underestimated the effects of ABCC2 haplotypes on the enterohepatic recycling of MPA. 
Furthermore, the use of Cav concentrations based on the last sample taken at either 4 or 6 hr 
post-dose may potentially confounding the results, such that the 6- but not the 4-hr sample, 
may be picking up the secondary peak on the enterohepatic recirculation of MPA. The use of 
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an AUC0-12 would be a more reliable tool to adequately reflect changes in total MPA 
exposure but remains an impractical barrier. For example, a decrease in the partial AUC6-12 
may have better indicated changes in the enterohepatic recycling of MPA, which could result 
in MPA under-exposure and altered dosage requirements. Secondly, it is possible that 
detecting associations between ABCC2 haplotypes (e.g. MRP2 expressor groups) and PK or 
clinical outcomes may have been limited by the relatively small sample size and low 
frequency of the high expressor phenotype (approximately 15 %). In addition, both recipient 
and donor ABCC2 haplotypes could have a combined effect on the PK of MPAG and 
MPAG/MPA ratio, however, combining recipient/donor haplotype expressor groups would 
result in extremely small numbers in some groups. Finally, this study was limited to 
examination of only three SNPs, and it is possible that other functionally relevant SNPs (e.g. 
3563 T > A and 4544 G > A) [201] are associated with clinical outcome [158] and also 
contribute to interindividual variability in MPA PK.  
In conclusion, recipient ABCC2 haplotypes impacted on MPA C0 concentrations and may be 
useful to optimise the starting dose of MMF, resulting in faster achievement of target 
concentrations. In our study, there was no significant influence of donor ABCC2 haplotypes 
on kidney transplant outcomes and matching of the ABCC2 haplotypes between recipients 
and donors was uncommon, suggesting that haplotype analysis of donors may be of limited 
additional benefit in patients already undergoing TDM. In contrast, the previously reported 
association between donor haplotype and DGF, and the combined contribution of rejection 
and recipient high expressor ABCC2 haplotype on MPA C0 concentrations warrants further 
investigation in a larger and internationally collaborative validation cohort. 
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Although therapeutic drug monitoring of mycophenolic acid (MPA) concentrations in 
plasma has been recommended to individualise MPA doses in transplant recipients, little is 
known regarding MPA concentrations at the site of action within lymphocytes, where MPA 
inhibits inosine monophosphate dehydrogenase (IMPDH). This study investigated the utility 
of measuring trough lymphocyte MPA (C0L) concentrations and IMPDH activity, as 
predictors of graft rejection in renal transplant recipients. Forty-eight patients commencing 
mycophenolate mofetil (1 g twice daily) for maintenance immunosuppression in 
combination with tacrolimus and prednisolone were recruited. Blood was collected for 
determination of total (C0P) and unbound (C0u) plasma MPA concentrations. Lymphocytes 
were isolated for determination of C0L concentrations and IMPDH activity. The incidence of 
rejection within 2 days of sample collection was determined histologically and classified 
according to the Banff 2007 criteria. There was no significant correlation between MPA C0L 
and C0P concentrations (Spearman r = 0.18, P = 0.22), however, MPA C0L concentrations 
were significantly correlated with MPA C0u concentrations (Spearman r = 0.36, P = 0.034). 
Multivariate analysis indicated that MPA C0L concentration was the only covariate 
independently associated with rejection incidence (33 % of patients had rejection, P = 0.03), 
whilst MPA C0P concentration was the only significant variable associated with MPA C0L 
concentration (P = 0.009). The ROC area under the curve (AUC) for the prediction of severe 
rejection using MPA C0L concentrations was 0.71 (P = 0.045), with a C0L threshold of 0.5 
ng/107 cells providing 71 % sensitivity and 70 % specificity. However, the ROC analysis for 
IMPDH activity was not significant (AUC = 0.66, P = 0.12). MPA C0L measurement within 
the early post-transplant period may be one factor to facilitate early titration of MPA dosing 
to significantly reduce rejection.  
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Mycophenolic acid (MPA), one of the primary immunosuppressants administered to prevent 
rejection following renal transplantation [4], exerts anti-proliferative effects on lymphocytes 
[17]. MPA is a potent, selective, reversible, and non-competitive inhibitor of inosine 
monophosphate dehydrogenase (IMPDH), a rate-limiting enzyme involved in de novo purine 
synthesis that is selectively required for lymphocyte proliferation [17]. Inhibition of this 
pathway prevents the proliferation of lymphocytes and the activation of T-cells, which 
consequently contributes to the prevention of graft rejection. Similar to MPA, calcineurin 
inhibitors such as cyclosporine (CsA) and tacrolimus (TAC), also produce 
immunosuppression by targeting lymphocytes and causing selective inhibition of the nuclear 
transcription factor calcineurin, thus preventing the formation and secretion of interleukin-2 
[22, 23].  
Immunosuppression following renal transplantation typically involves triple therapy with 
mycophenolate mofetil (MMF), prednisolone and a calcineurin inhibitor (TAC or CsA) [4]. 
The clinical use of immunosuppressants, such as MPA, however, is complicated by a narrow 
therapeutic index and large inter-patient variability in pharmacokinetics (PK) [5, 96]. 
Numerous studies have investigated the plasma MPA concentration-effect relationships, and 
in general have reported relationships between MPA exposure and the risk of graft rejection 
[77, 78, 80, 82, 83]. Consequently, MPA may benefit from therapeutic drug monitoring 
(TDM) to individualise MPA dosing in order to achieve target plasma concentration ranges 
that suppress graft rejection and minimise MPA-related toxicity [96]. Routine MPA 
monitoring is performed using either trough plasma (C0P) concentrations, or even better, 
using the area under the plasma concentration-time curve (AUCP) determinations [96]. 
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Without TDM, patients are at greater risk of either inadequate immunosuppression resulting 
in graft rejection, or over-exposure and subsequent immunosuppression toxicity [96].  
Despite application of TDM strategies that target patients to narrow plasma concentrations 
ranges (1.9 – 3.5 mg/L for C0P or 30 – 60 mg.hr/L for AUC0-12P, when co-administered with 
TAC) [95], rejection rates in Australian renal transplant recipients remain high (13 – 24 % in 
the six months post transplantation) [4]. This suggests that only monitoring of plasma 
concentrations may be inadequate to predict graft rejection and may not be the most 
appropriate predictor for target tissue concentrations, and hence, clinical outcomes. 
Consequently, there is a need for clinical tools that are better predictors of target tissue 
concentrations and these could include direct drug measurement at the target site of action 
(e.g. lymphocytes) and identification of pharmacodynamic (PD) biomarkers (e.g. IMPDH 
activity).  
Direct measurement of lymphocyte MPA concentrations may provide a better understanding 
of MPA immunosuppressive efficacy and its distribution during graft rejection, compared to 
plasma concentrations. The importance of such an approach has already been demonstrated 
for the calcineurin inhibitors CsA [160, 202-204] and TAC [161, 165] by direct 
quantification in lymphocytes, representing the target site of action. It has been suggested 
that lower lymphocyte CsA [160] and TAC [161] concentrations are associated with 
significantly higher incidences of graft rejection, which were not reflected by whole blood 
concentrations. Indeed, a previous clinical study of 20 kidney transplant recipients 
demonstrated that lymphocyte CsA concentrations (AUC0-12L) were approximately 3-fold 
lower in patients experiencing rejection (35 %) compared to those who did not experience 
rejection (P = 0.004), during the first three months following transplantation [160]. A similar 
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observation has also been reported in 90 liver transplant recipients, where low lymphocyte 
TAC concentrations were associated with a 2-fold higher incidence of clinical rejection (P = 
0.01) in the early post-transplant period, despite adequate concentrations in whole blood 
[161].  
Prior to commencing this study in 2013, little was known regarding the relationship between 
lymphocyte and plasma MPA concentrations. A study in 40 kidney transplant recipients 
failed to find an association between MPA C0P and trough lymphocyte (C0L) MPA 
concentrations (P = 0.17) [166]. However, a later study conducted by the same group 
reported some correlations between plasma and lymphocyte MPA concentrations determined 
at 0, 1.5 and 3.5 hour (hr) on days 2, 4 and 10 post-transplantation [104]. There were 
significant correlations between plasma and lymphocyte MPA concentrations at 1.5 and 3.5 
hr, but not between MPA C0P and C0L concentrations [104]. Despite these two findings, no 
previous studies had investigated the factors that determine lymphocyte MPA 
concentrations. Two important modulators of these concentrations may include the binding 
of MPA to plasma albumin (hence unbound concentrations need to be used) and the possible 
role of uptake and efflux transporters in lymphocytes in modulating concentrations. The 
efflux transporter multidrug resistance-associated protein 2 (MRP2), encoded by the ABCC2 
gene, for which MPA is a substrate [46], is expressed in lymphocytes [205], hence genetic 
variability in ABCC2 gene may influence lymphocyte MPA concentrations and could 
therefore modulate the efficacy and/or safety of MPA therapy.  
The PD monitoring of MPA by the measurement of IMPDH activity has also been 
investigated in whole blood [206] and lymphocytes [103, 104, 106, 107], however only two 
studies have investigated relationships between MPA plasma concentrations and IMPDH 
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activities [103, 104]. A study in 35 renal transplant recipients reported a weak inverse 
correlation between post-transplant pre-dose IMPDH activity and MPA C0P concentrations 
(R2 = 0.24, P = 0.17) [103]. Relationships between MPA plasma concentrations and IMPDH 
activities (samples taken at multiple time points (0, 1.5, and 3.5 hr) on different days (2, 4 
and 10 post-transplant) have also been investigated in a prospective study involving 40 renal 
transplant recipients receiving MMF therapy (1 g daily) [104]. There were significant 
inverse correlations between IMPDH T1.5 activity and MPA C1.5 or AUC0-3.5 (P < 0.01 or P = 
0.027, respectively), however, no correlation was found between MPA C0P concentrations 
and pre-dose IMPDH activities. To the best of our knowledge, no previous studies have 
investigated the utility of determining both lymphocyte MPA concentrations and IMPDH 
activity, and examined their relationship to clinical outcomes after renal transplantation. 
Therefore, this study aimed to investigate the utility of measuring lymphocyte MPA 
concentrations and intracellular IMPDH activity, as predictors of early graft rejection in 
kidney transplant recipients. We hypothesised that determination of lymphocyte MPA 
concentrations within the early post-transplant period may have greater relevance for 
predicting IMPDH activity and the incidence of graft rejection, compared to plasma MPA 
concentrations. Using a general linear model of multivariate regression with step-wise 
addition of factors, the present study also examined variables predictive of rejection and 
lymphocyte MPA concentrations, as well as investigated associations between MPA C0L, 
C0P, C0L/C0P ratio, average (CPav) and unbound (C0u) plasma concentrations with data on 
patient demographics, biological characteristics, and ABCC2 genetics. 
 




4.3.1 Chemicals and reagents 
Mycophenolic acid (MPA), tertiary-butyl methyl ether (t-BME), adenosine 5’-
monophosphate (AMP), inosine 5’-monophosphate (IMP), β-nicotinamide adenine 
dinucleotide hydrate (NAD+), perchloric acid (HClO4) and tetrabutylammonium hydrogen 
sulphate (TBA) were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). MPA-d3 
internal standard was obtained from Toronto Research Chemicals (Toronto, Canada). 
Sodium chloride (NaCl) and hydrochloric acid (HCl) were supplied by Ajax Finechem Pty 
Ltd (Taren Point, NSW, Australia). Sodium dihydrogen phosphate (NaH2PO4) was sourced 
from Chem Supply (Gillman, SA, Australia). HPLC-grade methanol and xanthosine 5’-
monophosphate (XMP) were purchased from Thermo Fisher Scientific Australia Pty Ltd 
(Scoreby, VIC, Australia). Potassium chloride (KCl), potassium dihydrogen phosphate 
(KH2PO4) and potassium carbonate (K2CO3) were obtained from Ajax Chemicals (Auburn, 
NSW, Australia). Ultrapure, de-ionised water (Millipore, ≥ 18.2 mΩ, Cascada AN-water 
purification system, Cheltenham, VIC, Australia) was used throughout the assay.  
4.3.2 Study population, pharmacokinetic and clinical data 
In total, 48 kidney transplant recipients gave written informed consent to participate in this 
prospective clinical study, which was approved by the Royal Adelaide Hospital Research 
Ethics Committee (approval number 130109). Recipients were transplanted between June 
2013 and November 2014 with kidneys from living and deceased donors. They received a 
fixed dose of MMF (1 g twice daily) maintenance immunosuppression in combination with 
TAC and prednisolone. Total (C0P) plasma MPA concentrations were determined (refer to 
Section 4.3.3) using a validated high-performance liquid chromatography (HPLC) method, 
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[93] and unbound (C0u) plasma MPA concentrations were determined by the Analytical 
Chemistry Unit, Pathology Queensland, Royal Brisbane and Women’s Hospital, Brisbane 
QLD, using a validated liquid chromatography-tandem mass spectrometry method 
(unpublished assay). Demographic, pharmacokinetic and clinical data were obtained from 
original patient case notes and the data collected were: recipient and donor ages; sex; 
ethnicity (self-report); donor type (living or deceased); human leukocyte antigen (HLA) 
mismatches; cold ischemia time (CIT); panel reactive antibody (PRA); plasma creatinine; 
albumin and bilirubin concentrations; angiotensin II type-1 receptor (AT1R) antibody levels; 
donor-specific HLA antibodies (DSA); trough whole blood TAC concentrations; and the 
incidences of rejection and delayed graft function (DGF). The incidence of rejection within 
±2 days from sample collection (median (range): 13 (5 – 22) days post-transplant) was 
defined based on clinical assessment and/or histology (e.g. protocol or for-cause biopsies), 
and classified for severity according to Banff 2007 criteria [178] as no rejection, subclinical 
borderline, clinically evident, or severe vascular rejection. The incidence of DGF was 
identified by the lack of spontaneous fall in serum creatinine or haemodialysis within 7 days 
post-transplantation.  
4.3.3 MPA pharmacokinetic calculations  
Briefly, abbreviated AUCP monitoring had been carried out within 5 - 22 days of 
transplantation as part of the recipients’ routine clinical care. Blood samples (patients were 
on a fixed dose at the time of sampling) were collected at pre-dose (C0P), 1, 2, 3, and either 4 
or 6 hr after MMF administration. As there were differences in the last sampling time 
between patients, the average MPA plasma concentration (CPav) was determined as follows: 
CPav= AUC0
n (mg/L) ÷ sampling time (n), where n is the time of the last sample (4 or 6 hr).  
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4.3.4 ABCC2 genotyping and haplotype predictions  
Blood samples collected from transplant recipients were also used for determination of the 
common ABCC2 allele variants (-24 C > T, 1249 G > A and 3972 C > T). A previously 
reported method was used to determine mutations by polymerase chain reaction (PCR) – 
restriction fragment length polymorphism (RFLP) assay [136] and ABCC2 haplotypes were 
inferred by the use of PHASE software version 2.1.1 [192]. The recipients were divided into 
high, wild-type (WT) or low MRP2 expressor groups according to ABCC2 haplotypes as 
reported previously by Laechelt et al. [140]. 
4.3.5 Isolation of lymphocytes from whole blood 
Additional blood samples (2 x 9 mL) were collected in EDTA tubes at the same time as the 
C0P sample (median (range): 13 (5 – 22) days post-transplant) and were processed within 4 
hr after collection to ensure maximal lymphocyte yield. Lymphocytes were isolated with 
LymphoprepTM (Axis-Shield, Oslo, Norway) according to the manufacturer’s protocol with 
several modifications. In brief, 9 mL of patient’s blood was diluted with an equal volume of 
0.9 % ice-cold sodium chloride (NaCl) and 18 mL of this suspension was underlayered with 
9 mL LymphoprepTM and centrifuged without brakes at 1200 x g at 4 °C for 20 minutes 
(min). After centrifugation, lymphocytes were harvested from the plasma/LymphoprepTM 
interface and washed three times with 30 mL of 0.9 % NaCl (centrifugation at 1200 x g at 4 
°C for 10 min). The cell pellets were resuspended with 5 mL of 0.9 % NaCl and 500 μL of 
this suspension was used for cell counting (in duplicate) on a haemocytometer. After final 
centrifugation (1200 x g, 4 °C, 10 min), the two cell pellets for determination of MPA C0L 
concentrations and IMPDH activity, respectively, were kept at −80 °C until analysis. 
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Calibrators and quality control (QC) samples were prepared from blank lymphocytes 
isolated from 150 mL of fresh blood, and treated as 9 mL aliquots as described above.  
4.3.6 Measurement of trough intra-lymphocyte MPA concentrations 
Measurement of C0L concentrations from patient samples was based on our previously 
published liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the 
quantification of MPA in human kidney transplant biopsies (refer to Chapter 2) with slight 
modifications [207]. On the day of the assay, frozen patient and blank lymphocyte pellets 
were thawed at 4 °C and placed on ice. Subsequently, 200 μL of ice-cold phosphate buffered 
saline (PBS) pH 7.4 was added to each thawed patient cell pellet and was mixed thoroughly. 
The calibrators and QC samples were prepared from blank lymphocyte pellets (containing 
107 cells), which had been spiked with MPA working solutions (100 μL of MPA in 50 % 
methanol/50 % water plus 100 μL of PBS solution) prepared from MPA stock solution (100 
mg/L in 100 % methanol) to concentrations of 0.1, 0.2, 0.5, 1.0, 3.0 and 5.0 ng/mL for 
calibrators and 0.3, 1.5 and 2.0 ng/mL for QC samples. To each calibrator, QC and patient 
sample, 60 μL of 0.4 M HCl, 10 μL of 0.2 μg/mL MPA-d3 internal standard and 1 mL of 
tertiary-butyl methyl ether (t-BME) were added. MPA extraction and cell lysis were 
performed by gently mixing on a roller mixer for 10 min. The samples were then centrifuged 
at 1900 x g at 4 ºC for 10 min. After centrifugation, the organic layer was removed, 
transferred to a 5 mL disposable glass tube and evaporated to dryness using an evacuated 
centrifuge at 45 ºC for approximately 20 min. The dried residues were reconstituted with 50 
µL of 50 % methanol/50 % water, vortexed for 2 min and 10 µL of the reconstituted 
solutions injected onto the LC-MS/MS for analysis. Analytical and LC-MS/MS conditions 
are described elsewhere (refer to Chapter 2) [207].  
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The assay was fully validated according to the U.S. Food and Drug Administration (FDA) 
guidelines for bioanalytical methods [174]. The assay was assessed for linearity, accuracy, 
precision, extraction efficiency, matrix effects and stability. The calibration curves were 
linear, with coefficients of determination (R2) greater than 0.99 (n = 5), and within- and 
between-assay inaccuracy and imprecision were less than 15 % (n = 5). MPA extraction 
efficiency displayed a good reproducibility, with coefficient of variations (CVs) ranging 
from 0.1 to 5.2 % and matrix effects were minimal (< 10 %), both assessed at 3 
concentrations (1.0, 5.0 and 20.0 ng/mL) in replicates of 2, using two different blank 
lymphocytes. MPA was stable when spiked into blank lymphocytes, with no significant 
degradation after 12 hr at room temperature or 6 months at –80 °C, nor in post-processing 
samples left in the autosampler (4 °C) for 24 hr. Other immunosuppressants likely to be 
administered with MPA (i.e. TAC, CsA, prednisolone, sirolimus and everolimus) had no 
significant effects on either MPA or MPA-d3 peak areas. The MPA C0L concentrations 
measured were adjusted according to the number of lymphocytes extracted and expressed as 
ng/107 cells. 
4.3.7 Measurement of intracellular IMPDH enzyme activity 
Measurement of intracellular IMPDH activity from lysed lymphocytes was based on 
previously published high performance liquid chromatography (HPLC) methods for the 
quantification of IMPDH activity in peripheral mononuclear cells [106, 208]. In brief, after 
thawing at 4 °C, the lymphocyte pellets were resuspended in 900 μL ice-cold Millipore 
water and insoluble fragments of disrupted cells were removed by centrifugation at 15,800 x 
g for 2 min. The lymphocyte lysate was used for enzymatic assay (50 μL) and protein 
content (20 μL) determinations. The measurement of lysate protein concentration was 
performed with Bio-Rad Protein Assay Reagent (Bio-Rad Laboratories, California, USA) 
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using bovine serum albumin as standard according to the manufacturer’s protocol. IMPDH 
activity in lymphocytes was determined from the conversion of inosine 5’-monophosphate 
(IMP) to xanthosine 5’-monophosphate (XMP) according to methods described previously 
[106, 208]. Briefly, the IMPDH incubation mixture (pH 7.4) consisted of 1 mM IMP, 0.5 
mM NAD+, 40 mM NaH2PO4 and 100 mM KCl. The enzymatic reaction was initiated by the 
addition of 50 μL of the lymphocyte lysate to 120 μL of reaction mixture and incubated at 37 
°C for 2.5 hr. After incubation, the reaction was terminated by adding 20 μL of 4 M ice-cold 
HCIO4, vortexing for 10 seconds (sec), and the deproteinised solution was centrifuged at 
15,800 x g for 2 min. Subsequently, 170 μL of supernatant was neutralised by adding 17 μL 
of 5 M ice-cold K2CO3, vortexing for 10 sec, and storing the samples for at least 30 min at 
−80 °C. After thawing and centrifugation at 15,800 x g for 2 min, 25 μL of the supernatant 
was immediately injected onto the HPLC column for analysis. 
Chromatographic detection of XMP production was achieved using a Synergi HydroRP 80A 
column (4 μM, 250 × 3 mm) (Phenomenex, Lane Cove, NSW, Australia) maintained at 45 
°C on an Agilent HPLC system, with mobile phases consisting of buffer (pH 5.5) containing 
50 mM potassium phosphate (KH2PO4) and 7 mM TBA (Mobile phase A) and 100 % 
methanol (Mobile phase B) [208]. The mobile phases were pumped at a flow rate of 0.7 
mL/min using a semi-gradient program of 94 % mobile phase A and 6 % mobile phase B (0 
– 13.0 min), changed to 80 % mobile phase A and 20 % mobile phase B (13.1 – 23.0 min) 
and then finally back to 95 % mobile phase A and 5 % mobile phase B (23.1 – 40.0 min). 
Injection volume was 25 μL with ultraviolet (UV) detection at a wavelength of 254 nm.  
Specificity was tested in control incubations containing substrate IMP in the absence of co-
substrate NAD+ or containing NAD+ in the absence of IMP. No endogenous XMP was 
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detected in samples incubated without IMP or NAD+ and no interfering peaks were observed 
at the retention time of XMP. Linearity of XMP formation with protein content was 
confirmed by using four serial dilutions of the lymphocyte lysate (protein concentration 
ranged from 0.18 – 2.7 mg/mL). XMP formation (protein concentration 2.7 mg/mL) also 
increased linearly with the time of incubation (0 – 200 min). IMPDH activity was expressed 
as XMP produced (nmol) per incubation time (hr) per mg protein (nmol/hr/mg protein).  
4.3.8 Statistical analyses 
Normality of data distribution was assessed by the D’Agostiono and Pearson omnibus 
normality test. Correlations between MPA C0L, C0P and C0u concentrations and IMPDH 
activity were assessed using a Spearman’s rank correlation. Differences in MPA C0L, C0P and 
C0u concentrations, and IMPDH activity, between patients with and without graft rejection 
were evaluated using Mann-Whitney rank sum test. Receiver operating characteristic (ROC) 
curve analysis was performed to assess the ability of either MPA C0L concentrations or 
IMPDH activity to predict graft rejection. Associations between MPA C0L, C0P and C0u 
concentrations, and IMPDH activity, with the severity of rejection (no evidence of rejection, 
subclinical borderline rejection, and severe cellular or vascular rejection) were assessed 
using Kruskal-Wallis tests (with Dunn’s multiple comparisons post hoc). The Mann-
Whitney rank sum test (CIT, PRA, creatinine, bilirubin, AT1R and TAC C0 concentration), 
unpaired t-test (recipient and donor ages, HLA and albumin) and Fisher’s Exact test (sex, 
ethnicity, DSA post-transplant, donor graft and DGF) were used to investigate the 
differences in demographic and clinical covariates between patients with or without rejection 
episodes. All analyses were performed using Prism version 6.0 (GraphPad Software, Inc, La 
Jolla, CA). Differences between MPA C0L, C0P and C0u concentrations, and IMPDH activity, 
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with the severity of rejection were also analysed using Jonckheere-Terpstra Test (SPSS, 
version 19, IBM, Armonk, NY).  
A step-up linear model of multivariate regression with step-wise addition of factors was used 
to identify predictors associated with rejection incidence as well as variables that determine 
lymphocyte MPA concentrations. Similar models were also used to investigate associations 
between MPA PK (C0P, CPav, C0L and C0u) and IMPDH enzyme activity with genetic and 
clinical variables. The variables included in the step-wise addition procedures were: 
recipient and donor ages; sex; ethnicity; donor graft (living or deceased); genetics (donor and 
recipient ABCC2 phenotypes); HLA mismatches; CIT; PRA; creatinine, albumin and 
bilirubin concentrations; AT1R antibody levels; DSA; trough TAC concentrations, the 
incidences of rejection and DGF, and the severity of rejection. The Chi-square test was used 
to test for each additional factor. Data are presented showing the overall P value and also 
individual P values for each covariate. A P > 0.05 for an individual covariate included in the 
model indicates that, whilst not independently associated with the outcome being 
investigated, the variable significantly improved the overall final linear model. Analysis was 
performed using R [194].  
All data are presented as either mean ± SD for continuous parametric data, median (range) 
for continuous non-parametric data or frequencies (absolute numbers) for categorical data. 
Statistical significance was considered for P-values < 0.05 (two-tailed).  
 




4.4.1 Patient characteristics 
Patient demographic and biological characteristics are shown in Table 4.1. Thirty-nine 
patients (81 %) were Caucasians and nine patients were Indigenous Australians. Sixteen 
patients (33 %) experienced graft rejection during this study at an average ± SD (range) of 
12 ± 5 days (5 – 22 days) post-transplantation. There were no significant differences (P ≥ 
0.066) between the rejection and no rejection groups with respect to recipient and donor 
ages, sex, ethnicity, HLA mismatches, CIT, PRA, AT1R antibody levels, and serum 
creatinine, albumin or bilirubin concentrations; however, TAC C0 whole blood 
concentrations were significantly lower in patients experiencing rejection (P = 0.028) 
compared to those patients in the no rejection group (Table 4.1). 
4.4.2 Correlations between MPA C0L, C0P and C0u concentrations, and 
IMPDH activity 
MPA C0L concentrations ranged from 0.1 to 3.9 ng/107 cells (median = 0.68 ng/107 cells) 
and the corresponding MPA C0P concentrations ranged from 0.45 to 6.5 mg/L (median = 2.1 
mg/L). Trough IMPDH activity ranged from 0.9 to 33.9 nmol/h/mg protein (median = 11.9 
nmol/hr/mg protein). There was no significant correlation between MPA C0L and C0P 
concentrations (Spearman r = 0.18, P = 0.22, Fig. 4.1A), and trough IMPDH activity was not 
significantly correlated with either C0L (Spearman r = 0.23, P = 0.11, Fig. 4.1B), or C0P 
(Spearman r = 0.22, P = 0.13, Fig. 4.1C), concentrations.  
MPA C0u plasma concentrations (n = 34) ranged from 3.6 to 166.4 μg/L (median = 20.8 
μg/L) and were significantly correlated with MPA C0L (Spearman r = 0.36, P = 0.034, Fig. 
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4.2A) and MPA C0P (Spearman r = 0.68, P < 0.0001, Fig. 4.2B) concentrations, but not with 
the trough IMPDH activity (Spearman r = 0.14, P = 0.42, Fig. 4.2C). 
4.4.3 Relationships between rejection and MPA C0L, C0P and C0u 
concentrations, and IMPDH activity 
In the rejection group (n = 16), ten (63 %) patients developed severe cellular or vascular 
rejection, and six (37 %) patients were classified as subclinical borderline at the time of 
protocol or for-cause biopsies. In the total 48 patients recruited, there was no difference 
between either MPA C0L concentrations (P = 0.052, Fig. 4.3A), MPA C0P concentrations (P 
= 0.26, Fig. 4.3B), trough IMPDH activity (P = 0.057, Fig. 4.3C) or MPA C0u concentrations 
(P = 0.57 (n = 34), Fig. 4.3D) with the incidence of graft rejection. However, there was a 
significant concentration-effect relationship between MPA C0L concentrations and the 
severity of rejection (Jonckheere-Terpstra (trend) test, P = 0.030, Fig. 4.4A). There was no 
significant difference between MPA C0P concentrations (trend test, P = 0.18, Fig. 4.4B), 
trough IMPDH activity (trend test, P = 0.075, Fig. 4.4C) or MPA C0u concentrations (trend 
test, P = 0.43, Fig. 4.4D), between patients with no evidence of rejection (n = 32, 67 %), 
subclinical borderline rejection (n = 6, 13 %) and severe cellular or vascular rejection (n = 
10, 20 %).  
Receiver operating characteristic (ROC) curve analyses were performed to provide threshold 
data for both MPA C0L concentrations and IMPDH activity that might predict the risk of 
rejection with optimal sensitivity and specificity. The ROC area under the curve (AUC) for 
the prediction of severe (cellular/vascular) rejection using MPA C0L concentrations was 0.71 
(P = 0.045, Fig. 4.5B), with a C0L threshold of 0.5 ng/107 cells providing 71 % sensitivity 
and 70 % specificity, and a likelihood ratio of 2.37. However, the ROC AUC for the 
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prediction of all rejection using MPA C0L concentrations and IMPDH activity were not 
significant (AUC = 0.67, P = 0.052), Fig. 4.5A, and AUC = 0.67 (P = 0.057), Fig. 4.5C, 
respectively). In addition, the ROC analysis of IMPDH activity for the prediction of severe 
rejection showed a non-significant AUC of 0.66 (P = 0.12, Fig. 4.5D).  
4.4.4 Variables associated with rejection, lymphocyte and plasma MPA 
concentrations 
Rejection 
Variables: recipient and donor ages; sex; ethnicity; donor graft type; ABCC2 genetics; HLA 
mismatches; CIT; PRA; creatinine, albumin, bilirubin and trough TAC concentrations; 
AT1R; DSA; the incidences of rejection and DGF, the severity of rejection, MPA C0P, C0L, 
C0L/ C0P ratio, C0u, CPav and IMPDH activity.  
Of the above variables, MPA C0L concentration was the only independent predictor of 
rejection, such that the occurrence of rejection was associated with a decrease in MPA C0L 
concentrations (P = 0.03). This agrees with the data shown on Fig 4.4A.  
MPA C0L concentrations 
Variables: recipient and donor ages; sex; ethnicity; donor graft type; ABCC2 genetics; HLA 
mismatches; CIT; PRA; creatinine, albumin, bilirubin and trough TAC concentrations; 
AT1R; DSA; the incidences of rejection and DGF, the severity of rejection, MPA C0P, C0u, 
and IMPDH activity.  
 
Zaipul Md Dom, PhD Thesis 2016 
 
128 
Of the above variables, MPA C0P concentration was the only significant variable associated 
with MPA C0L concentration (explaining 12 % of variance, P = 0.009), such that as MPA 
C0P concentration increased by 1 unit, MPA C0L concentration increased by 0.25 units.  
MPA C0P concentrations 
Variables: recipient and donor ages; sex; ethnicity; donor graft type; ABCC2 genetics; HLA 
mismatches; CIT; PRA; creatinine, albumin, bilirubin and trough TAC concentrations; 
AT1R; DSA; the incidences of rejection and DGF, the severity of rejection, and IMPDH 
activity.  
Of the above variables, donor type (living) and recipient age were the only significant 
covariates associated with MPA C0P concentrations, explaining 21 % of variance (P = 
0.002). With regard to individual predictors, patients who had received a graft from a living 
donor had a 1.1 unit decrease in MPA C0P concentrations compared to those who had 
received a graft from a deceased donor (given all other predictors were held constant, P = 
0.015). In addition, as the age of patients increased by 1 year, MPA C0P concentrations 
increased by 0.03 units (P = 0.04).  
MPA C0L/C0P ratio 
Variables: recipient and donor ages; sex; ethnicity; donor graft type; ABCC2 genetics; HLA 
mismatches; CIT; PRA; creatinine, albumin, bilirubin and trough TAC concentrations; 
AT1R; DSA; the incidences of rejection and DGF, the severity of rejection, and IMPDH 
activity.  
The ratio of MPA C0L/C0P concentration was significantly associated with ethnicity, and this 
variable explained 23 % of variance in the ratio of C0L/C0P concentration (P = 0.0004). 
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Patients who were Caucasian had a 0.43 unit decrease in the ratio values compared to those 
who were Indigenous Australians.  
MPA C0u concentration 
Variables: recipient and donor ages; sex; ethnicity; donor graft type; ABCC2 genetics; HLA 
mismatches; CIT; PRA; creatinine, albumin, bilirubin and trough TAC concentrations; 
AT1R; DSA; the incidences of rejection and DGF, the severity of rejection, MPA C0P 
concentrations and IMPDH activity.  
Of the above variables, AT1R score was the only significant factor associated with MPA C0u 
concentrations (explained 13 % of variance, P = 0.02), such that as the AT1R score 
increased by 1 unit, MPA C0u concentrations decreased by 1.1 units. 
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Table 4.1 Patient demographics and biological characteristics of 48 renal transplant recipients. 
 All  
(n = 48) 
Rejection1 group 
(n = 16) 
No rejection group 
(n = 32) 
P-value 
Sex (Male/Female) 25/23 7/9 18/14 0.54 
Ethnicity (Caucasian/Indigenous Australian) 39/9 13/3 26/6 1.0 
Recipient age (years) 49 ± 12 45 ± 10 51 ± 13 0.066 
Donor age (years) 48 ± 15 43 ± 15 41 ± 14 0.12 
HLA mismatches 3.8 ± 1.5 4 ± 1.4 3.7 ± 1.6 0.53 
PRA  0 (0 – 90) 0 (0 – 3) 0 (0 – 90) 0.080 
CIT (hr) 11 (3 – 34) 11 (4 – 26) 10 (3 – 34) 0.95 
Serum creatinine (mL/min) 244 (34 – 913) 244 (55 – 913) 286 (34 – 864) 0.76 
Albumin (g/dL) 31 ± 3.5 31 ± 3.5 32 ± 3.5 0.24 
Bilirubin (mg/dL) 8 (3 – 23) 8 (3 – 23) 8 (4 – 18) 0.62 
AT1R antibody level (U/L) 9 (0 – 40) 10 (0 – 28) 9 (0 – 40) 0.31 
TAC C0 (μg/L) 7.5 (4 – 24) 6.6 (3 – 14) 7.9 (4 – 24) 0.028 
DSA post-transplant (Present/Absent) 13/35 5/11 8/24 0.74 
Donor graft (Living/Deceased) 12/36 5/11 7/25 0.50 
DGF (Yes/No) 19/29 6/10 13/19 1.0 
1Rejection occurred within the period of ±2 days from sample collection.  
Data are given as mean ± SD, median (range) or frequencies (absolute numbers) depending on data type. 
AT1R, angiotensin II type-1 receptor; CIT, cold ischemia time; DGF, delayed graft function; DSA, donor-specific HLA antibodies; HLA, 
human leukocyte antigen; PRA, panel reactive antibody; TAC C0: tacrolimus trough whole blood concentrations. 
 































Figure 4.1 Correlations between (A) trough intra-lymphocyte (C0L, ng/107 cells) and 
corresponding trough plasma (C0P, mg/L) MPA concentrations, and trough IMPDH 
activity (nmol/hr/mg protein) with either (B) MPA C0L concentrations or (C) MPA C0P 
concentrations, in 48 renal transplant recipients.  
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Figure 4.2 Correlations (n = 34) between unbound (C0u) MPA plasma concentrations 
(μg/L) with (A) MPA C0L (ng/107 cells), (B) MPA C0P (mg/L) plasma concentrations, and 
(C) trough IMPDH activity (nmol/hr/mg protein). 
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Figure 4.3 Comparisons between (A) MPA C0L (ng/107 cells), (B) MPA C0P (mg/L) 
concentrations, (C) trough IMPDH activity (nmol/hr/mg protein) and (D) MPA C0u 
concentrations (μg/L) (n = 34), in recipients who did or did not experience graft rejection 






























































































































Figure 4.4 Comparisons between (A) MPA C0L (ng/107 cells), (B) MPA C0P (mg/L), (C) 
trough IMPDH activity (nmol/hr/mg protein) and (D) MPA C0u plasma concentrations 
(μg/L) (n = 34), in recipients who had no evidence of rejection, subclinical borderline 
rejection, or severe cellular/vascular rejection. Lines indicate median values. P-values are 
shown for Jonckheere-Terpstra test for trend. 
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Figure 4.5 Receiver operating characteristic (ROC) curves for the use of (A and B) MPA 
C0L concentrations and (C and D) trough IMPDH activity for the prediction of all 
rejection (A and C) and severe (cellular/vascular) rejection (B and D). 
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Considerable effort has been made into the understanding of MPA PK-PD in an attempt to 
reduce the risk of rejection and MPA-induced toxicity after transplantation. Relationships 
between MPA concentrations in plasma and clinical outcomes have been demonstrated 
supporting dosage individualisation based on target plasma concentration ranges. However, 
plasma concentrations may not be the best indicator of therapeutic efficacy and/or toxicity. It 
has been suggested previously for other immunosuppressants, TAC or CsA, that 
concentrations in lymphocytes may provide greater relevance in predicting efficacy and/or 
toxicity than whole blood concentrations [160, 161, 165]. The present study set out to 
investigate the potential of lymphocyte MPA concentrations and IMPDH activity, versus 
plasma concentrations, to predict the incidence of graft rejection following renal 
transplantation.  
This study provides the first evidence that MPA C0L concentration may be a better predictor 
of graft rejection, compared to either MPA C0P or C0u concentrations. The multivariate 
analysis showed that MPA C0L concentration was the only covariate independently 
associated with rejection, supporting our initial hypothesis that obtaining lymphocyte MPA 
concentrations may have greater relevance for predicting graft rejection compared to 
measuring systemic concentrations alone. This finding was supported in the univariate 
analyses, such that there was a significant-effect relationship between MPA C0L 
concentrations and the severity of rejection, and ROC analysis indicated 70 % specificity 
and 71 % sensitivity for the prediction of severe rejection using a cut-off C0L concentration 
of 0.5 ng/107 cells. Although univariate analysis showed that TAC C0 concentrations were 
significantly lower in patients experiencing rejection, they were not a significant predictor of 
rejection in the multivariate analysis, hence confirming that MPA C0L concentration was the 
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only dominant factor for rejection in our study population. MPA C0P concentrations not 
predicting the incidence of graft rejection supports previous findings in renal transplant 
recipients [80, 82], and suggests that MPA C0P concentrations may not be the best predictor 
of clinical outcomes. The use of AUC0-12 values would be preferred and might be a more 
reliable assessment of total MPA exposure, however the full AUC0-12 monitoring in clinical 
practice is restricted due to being impractical (e.g. requires intense sampling during a 12 hr 
dose interval), labour-intensive and costly. Although univariate regression analysis showed a 
significant correlation between MPA C0L and C0u concentrations, C0u was not a significant 
predictor of rejection, even though it is the unbound MPA which exhibits pharmacological 
effects [30] and is capable of inhibiting IMPDH [17].  
In addition, the present study has also demonstrated that MPA C0u concentrations were 
strongly correlated with total MPA C0P concentrations, although the multivariate analysis 
showed that total MPA C0P concentrations were not a significant predictor of MPA C0u 
concentrations. As such, TDM based on total plasma concentrations may be inappropriate to 
account for changes in percentage of unbound MPA in plasma, and hence, MPA distribution 
into lymphocytes. In the present study, MPA C0u concentrations were not correlated with 
graft rejection (in univariate and multivariate analyses); in agreement with the previous 
findings of Atcheson et al [34]. The AT1R score was the only significant variable associated 
with MPA C0u concentrations in the multivariate analysis, suggesting lower MPA C0u 
concentrations with increasing AT1R antibody levels. A previous study has shown that renal 
transplant patients who had the AT1R antibody level > 10 U pre-transplant had a 1.9-fold 
higher risk of developing acute rejection, independently of other standard immunological 
risk parameters such as HLA mismatch or PRA [209]. It is difficult to provide mechanistic 
answers to the question of how high AT1R antibody levels may have played a role to cause 
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lower MPA C0u concentrations, and how high pre-transplant AT1R antibody levels may 
predispose patients to rejection. However, AT1R antibodies may be directly involved in the 
pathogenesis of rejection by binding to the allograft immediately after transplantation and 
initiating biological processes (e.g. pro-inflammatory actions on vascular cells) leading to 
graft rejection [210].  
The measurement of IMPDH activity directly within lymphocytes may also be a useful 
biomarker as it may correlate more closely to the biological response of MPA than plasma 
concentrations. In the present study, there was a trend for a higher post-transplant IMPDH 
activity (P = 0.057) in patients who experienced rejection compared to those who did not 
experience rejection. Although IMPDH activity was not a significant predictor of rejection in 
the multivariate analysis, our finding may represent a type II statistical error and further 
investigation in larger subject numbers is required to evaluate the added value of monitoring 
IMPDH activity. Determination of pre-transplant IMPDH activity (versus post-transplant) 
may be a promising new approach and help to improve MMF therapy after transplantation. 
Glander et al. reported that patients with high pre-transplant IMPDH activity (hence higher 
IMPDH activity has to be inhibited post-transplant) had a 3.6-fold higher incidence of graft 
rejection compared to patients with low pre-transplant IMPDH activity [103]. The 
investigation of IMPDH messenger RNA (mRNA) could also form an attractive alternative 
method and may provide reliable information to predict rejection. Previous studies have 
shown that increased expression of IMPDH genes resulted in increased IMPDH activity 
[211], and the IMPDH type I and type II mRNA levels were significantly 2.4- and 3.4-fold 
lower in patients with graft rejection, respectively (P = 0.026 and P = 0.007, respectively), 
compared to patients without rejection [212].  
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An alternative explanation of our findings is that there are two types of IMPDH isoforms, 
IMPDH type I, which is expressed in all cell types and IMPDH type II, which is expressed 
only in activated lymphocytes [17]. MPA inhibits both IMPDH isoforms, however, the 
inhibition of IMDPH type II by MPA is approximately 5-fold greater than the type I isoform 
with the Ki values of 0.007 versus 0.033 μM, respectively [17]. However, the use of total 
IMPDH activity in our study may itself be less than ideal such that the overall enzyme 
activity measured may be due to the residual IMPDH type I activity, and therefore could 
have accounted for the lack of significant association between IMPDH activity and rejection. 
In addition, the IMPDH activity in this study may have been limited as only a single 
measurement at pre-dose (C0) taken 5 – 22 days post-transplant was used. The measurement 
of IMPDH activities at multiple time points, which we were not able to assess in this study, 
may possibly be a significant predictive factor of rejection. A previous study in 40 renal 
transplant recipients has shown that the minimum IMPDH activity occurred shortly after 
MMF administration and coincided with the plasma MPA peak concentration (CPmax) at 1.5 
hr, suggesting maximal inhibition of IMPDH activity coinciding with MPA peak levels, and 
there was a striking recovery of IMPDH activity to pre-dose levels over the 3.5 hr dosing 
interval [104]. In addition, it would be interesting to investigate the IMPDH activity in renal 
transplant recipients not receiving MMF as part of their immunosuppression regimen to 
determine if patient characteristics and other clinical covariates have any influence on the 
IMPDH activity in the same way as patients treated with MPA.  
Although MPA C0L was the only independent predictor of rejection, little is known regarding 
the factors that determine lymphocyte MPA concentrations. In the present study, there was 
considerable inter-patient PK variability in lymphocyte (CV = 86 %) and plasma (CV = 54 
%) MPA concentrations. In the multivariate analysis, MPA C0P concentration was the only 
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significant variable associated with MPA C0L concentration, explaining only 12 % of 
variability in lymphocyte MPA concentration; hence this may explain the poor correlation 
observed between MPA C0L and C0P concentrations. The poor correlation found between 
plasma and lymphocyte MPA concentrations may also reflect inter-individual variability in 
plasma protein binding of MPA or transporter-mediated uptake into and efflux from 
lymphocytes. MPA is extensively bound to albumin (97 – 99 %) in patients with healthy 
renal function [30]. The binding of MPA to plasma albumin is influenced by several factors 
including hypoalbuminemia, elevated MPAG concentrations and renal function [30, 37, 66], 
and consequently, this could account for the variability in intracellular MPA concentrations. 
This study confirmed the importance of plasma protein binding in determining lymphocyte 
MPA concentrations, demonstrating a significant but moderate correlation between total 
MPA C0L and MPA C0u concentrations, although MPA C0u concentrations were not a 
significant predictor of MPA C0L concentrations in the multivariate analysis. The 
discrepancy between results from the different analyses (univariate versus multivariate) may 
be due to having to drop out data in the multivariate analysis because of lower number of 
recipients with MPA C0u concentrations, and hence the model is not sufficiently powered to 
pick up the difference, or by introducing more patient characteristics and other clinical 
covariates to the model, MPA C0u concentration may not be the most important predictor in 
determining lymphocyte MPA concentrations. 
Importantly, inter-individual differences in the expression and/or function of drug 
transporters could be a possible additional cause of MPA PK variability. MPA is a substrate 
of the efflux pump, MRP2 [46], so that ABCC2 polymorphisms, coding for MRP2, may be 
an additional cause of variability observed in lymphocyte MPA concentrations by affecting 
the expression or function of MRP2. The CAC (-24C/1249A/3972C) haplotype has 
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previously been shown to be associated with significantly higher protein expression and 
transport activity [140], and may therefore modulate the immunosuppressive efficacy of 
MPA therapy. However, ABCC2 haplotypes were not significantly associated with any of 
the MPA PK parameters and IMPDH activity in the multivariate analysis, and may therefore 
reflect a weak expression of MRP2 in lymphocytes [205]. Determination of differences in 
the expression and/or function of uptake (e.g. organic anion-transporting polypeptide) and 
other efflux pumps (e.g. P-glycoprotein) may help explain some of this PK variability such 
that MPA is also a substrate of P-glycoprotein efflux transporter [213], which is highly 
expressed in lymphocytes [214].  
The present study also investigated the effects of demographics and other clinical covariates 
on MPA PK parameters (C0P, CPav and C0u) and IMPDH activity. Multivariate analyses 
indicated that MPA C0P was associated with donor type (living) and age of the patients. We 
currently have no good explanation for these results; however, kidneys from live donors may 
have a greater chance of maintaining their function than deceased donor kidneys (may have 
poorer function), thus affecting the protein binding of MPA to plasma albumin. Several age-
related factors such as a reduction in liver function with aging may have significant effects 
on the PK of MPA. A previous study employing a population PK approach has shown that 
the clearance of MPA was significantly influenced by the recipient age [197]. Ethnicity of 
the patients was the only significant variable associated with the ratio of MPA C0L/C0P 
concentrations, such that Caucasian patients had a 0.43 unit decrease in the ratio values 
compared to those who were Indigenous Australians. Higher ratio values were observed in 
Indigenous Australians, representing lower and higher lymphocyte and plasma MPA 
concentrations, respectively, compared to Caucasians. These observations may help explain 
the proclivity of Indigenous Australians to experience rejection and infection at the same 
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time following transplantation (RP Carroll, personal communication). The effect of ethnicity 
on MPA PK parameters, however, is an area still poorly researched and thus requires further 
investigation. 
In conclusion, the results from our study suggest that, despite TDM to minimise inter-
individual pharmacokinetic variability in systemic MPA concentrations, lymphocyte MPA 
concentrations may represent an additional tool to further improve individualisation of MMF 
dose following renal transplantation. However, even if lymphocyte MPA concentration was 
a better biomarker to predict graft rejection, facilitating early titration of MMF dosing, its 
clinical application may only practically be feasible as a single test during the early post-
transplant period, where the risk of developing graft rejection is higher, or when the protocol 
or for-cause biopsies are performed at the time of rejection. 
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Chapter 5. General Discussion 
Mycophenolic acid (MPA) has a narrow therapeutic index and large inter-patient 
pharmacokinetic (PK) variability necessitating therapeutic drug monitoring (TDM) to 
individualise dosing following renal transplantation. Although TDM is a necessary measure 
for allowing better individualisation of MPA therapy, early graft rejection and 
immunosuppressant toxicity still occur after transplantation. Consequently, there is a need 
for clinical tools that are better predictors of target tissue MPA concentrations that are not 
necessarily mirrored by plasma concentrations, as currently monitored with TDM. The 
multidrug resistance-associated protein 2 (MRP2) efflux transporter has been established as 
potentially influencing intestinal and biliary excretion of MPA, and hence MPA PK, but also 
regulates MPA distribution into lymphocytes and graft tissue, an area still poorly researched. 
As such, genetic variability in the ABCC2 gene (encoding MRP2) may explain some of the 
additional inter-individual variability in response to MPA.  
Therefore, the primary aims of this thesis were: (1) to establish two new methods for 
determining intra-renal and intracellular MPA concentrations in human kidney biopsies and 
lymphocytes, respectively; and to investigate (2) the impact of recipient and donor ABCC2 
genetic variability (formed by the common -24 C > T, 1249 G > A and 3972 C > T SNPs) on 
MPA PK and distribution, and potential associations with kidney transplant outcomes; as 
well as (3) the utility of measuring lymphocyte MPA concentrations and IMPDH activity, as 
compared to plasma concentrations, as predictors of graft rejection. 
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5.1 LC–MS/MS methods for the quantification of MPA in human kidney transplant 
biopsies and lymphocytes 
In order to fulfill the aims of this thesis, several new and adapted methods had to be 
developed and validated. Firstly, a new robust and reproducible LC-MS/MS method was 
successfully established and validated for the quantification of MPA concentrations in very 
small samples of human kidney biopsies taken as part of routine clinical protocols from renal 
transplant recipients. The biopsies were taken from the kidney cortex tissue at the time of 
validating the method; therefore the assay performance (e.g. sensitivity, specificity) may 
have been different if the biopsy samples were taken from the different region of the kidney. 
The kidney biopsies used in this study were taken in cases of suspected rejection, however, 
the biopsies (protocol biopsies) are now routinely taken immediately pre-transplant, and at 1 
week, 1 and 6 months post-transplant, as well as at times of rejection. All biopsy samples 
were collected for histological assessments. Kidney tissue MPA concentrations were of a 
similar magnitude to the plasma therapeutic range (MPA C0: 1 – 3.5 mg/L). However, we 
were unable to investigate if changes in kidney MPA concentrations reflected those 
concentrations in plasma, as corresponding plasma concentrations were not available at the 
time of validating the method. In addition, the uptake of MPA in kidney biopsy tissues 
during rejection versus non-rejection kidneys could not be assessed, as all kidney biopsies 
used in the study were primarily collected in cases of suspected rejection. Nevertheless, the 
established method was linear, accurate, and precise, with minimal matrix effects. In 
addition, the retrospective analysis of MPA in Mrp2-deficient rats has allowed additional 
validation of the reproducibility of the tissue extraction procedures.  
The method presented in Chapter 2 was the first study to measure tissue MPA concentrations 
in human kidney biopsies and was primarily designed to accurately quantify MPA in routine 
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core needle biopsies of kidney transplant patients weighing as little as 0.1 mg. 
Unfortunately, for the prospective clinical study presented in Chapter 4, we were unable to 
examine the routine core needle biopsies of kidney transplant patients taken as part of the 
clinical procedures, as the protocol allograft biopsies (stored in the last 12 months) may get 
requests for further testing and this extended past the end date of experiments. Nonetheless, 
the establishment of this protocol for accurately quantifying MPA concentrations in excess 
biopsy tissues taken as part of routine clinical care has ensured that our method benefits 
unaltered biopsy sampling and handling, to fit into current clinical practice. This will 
therefore allow further studies directed toward understanding the mechanisms determining 
the tissue PK of MPA and their relationship with clinical outcomes.  
Secondly, prior to commencing this thesis, no protocols for determining intracellular MPA 
concentrations in lymphocytes, representing the target site of action, had previously been 
established. Therefore, for the prospective clinical study of Chapter 4, a new selective and 
sensitive analytical method was successfully developed and validated for the quantification 
of lymphocyte MPA concentrations in renal transplant recipients. This method, like our 
previous method for the detection of MPA in kidney transplant biopsies, demonstrated 
sensitivity, specificity, and reproducibility to allow the accurate and precise measurement of 
MPA concentrations within lymphocytes. 
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5.2 ABCC2 genetic polymorphisms as a determinant of variability in MPA 
concentrations 
One of the major aims of this thesis was to investigate the associations between ABCC2 
genetic polymorphisms with MPA and MPAG PK parameters. More specifically, the 
primary goal was to examine the influence of donor and recipient ABCC2 haplotypes (as 
opposed to individual SNP analysis) on the PK of MPA and its metabolite MPAG, and their 
relationships with kidney transplant outcomes.  
The retrospective clinical study presented in Chapter 3 revealed several new and promising 
findings, with the most significant results related to the CAC (-24C/1249A/3972C, variant at 
1249) haplotype of ABCC2. Recipient carriers of this haplotype, which has been associated 
with increased MRP2 protein expression and transport activity, had 2.3-fold increased MPA 
C0 concentrations, as opposed to recipients with low expressor haplotypes. As such, CAC 
carriers appear to have increased enterohepatic recirculation of MPA, as a result of increased 
biliary excretion of MPAG. Support for these findings was obtained in the multivariate 
analysis, which revealed that MPA C0 concentrations were significantly associated with 
recipient ABCC2 expression phenotypes, and also with rejection and PRA peak. It was also 
found that there was a significant gene-dose effect among the three ABCC2 haplotype groups 
(Jonckheere-Terpstra test for trend), with an inverse step-wise relationship between recipient 
ABCC2 expression and MPA C0 concentrations. In the clinical context, the observed 
haplotype effects were relatively modest, equating to only 17 – 57 % differences in MPA C0 
concentrations; as such, these justify further investigations to elucidate the influence of 
ABCC2 haplotypes on MPA PK. Nevertheless, the findings of Chapter 3 provided the first 
evidence that the recipient’s ABCC2 affects MPA PK in a haplotype-specific manner, 
enabled a more informative haplotype approach to investigating ABCC2 pharmacogenetics 
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(PGx) compared to individual SNP analysis. The consideration of ABCC2 haplotypes in 
place of individual SNPs are more likely to accurately reflect MRP2 expression and/or 
function and should now be part of all studies on ABCC2 PGx.  
In addition to identifying associations between recipient ABCC2 haplotypes and MPA PK, 
the role of donor ABCC2 genetic variability in influencing the PK parameters of MPAG 
metabolite was also investigated (as renal excretion is the primary clearance mechanism for 
MPA metabolites), but revealed no significant relationship between the two. The findings 
suggest that a large change in ABCC2 expression in the donor graft may be required to 
significantly affect the concentrations of MPAG and that the contribution of active tubular 
secretion may be relatively small to overall renal clearance of MPAG. 
Due to the relatively small sample size (n = 5) and low frequency (12 %) of the high 
expressor phenotype, it is difficult to evaluate the usefulness of pre-transplant ABCC2 
haplotype analysis to inform MPA initial dosage prior to transplantation. In addition to 
providing some mechanistic support for the association between the CAC haplotype and 
MPA C0 concentrations, the interpretation is made difficult due to the lack of clear 
understanding of the functional consequences of ABCC2 haplotypes. In the present study, it 
was not possible to actually confirm that MRP2 expression was accurately predicted by the 
assigned phenotypes based on haplotype analysis, and other factors may also have affected 
MRP2 expression. The combined investigation of mRNA expression, MRP2 protein 
expression and transport activity in the recipient and donor graft kidney tissue may provide a 
more useful insight into the exact mechanisms behind the functional consequences of 
ABCC2 haplotypes. Therefore, further investigations are required to determine whether 
ABCC2 haplotypes, along with other genetic and environmental factors, are likely to provide 
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clinical benefit in guiding dosing of MPA prior to transplantation in addition to TDM to 
achieve improved clinical outcomes, including MPA toxicity. 
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5.3 Intra-lymphocyte pharmacokinetic-pharmacodynamic (PK-PD) analyses of MPA 
as predictors of graft rejection 
The final aim of this thesis, as described in the prospective clinical study presented in 
Chapter 4, was to investigate the utility of measuring lymphocyte MPA concentrations and 
IMPDH activity (as opposed to plasma concentrations), as predictors of graft rejection 
following renal transplantation.  
The prospective pilot study provided the first evidence of a positive association between 
lymphocyte MPA concentrations and the incidence of graft rejection. The findings of this 
thesis revealed that MPA C0L concentration was the only significant covariate independently 
associated with rejection in our study population, further confirming that the monitoring of 
lymphocyte MPA concentrations may more accurately predict therapeutic response than 
plasma concentrations alone, as currently monitored with TDM. ROC curve analyses 
revealed that MPA C0L concentration was a better predictor of severe (cellular/vascular) 
rejection compared to IMPDH activity or plasma concentrations. In addition, there was a 
significant concentration-effect relationship between MPA C0L concentrations and the 
severity of rejection. Based on these findings (in univariate and multivariate analyses), it can 
be concluded that MPA C0L concentrations may be a more superior parameter to predict 
clinical outcomes than plasma concentrations. As such, based on the findings of Chapter 4 
and other international studies investigating intra-lymphocyte immunosuppressant 
concentrations, it appears that intra-lymphocyte concentrations may provide information 
regarding mechanisms important to rejection that plasma concentration data do not provide, 
which then may be used as a potential clinical optimisation tool in future individualisation 
procedures that could be incorporated as part of TDM.  
 
Zaipul Md Dom, PhD Thesis 2016 
 
152 
Although the multivariate analysis indicated that MPA C0L concentration was the only 
independent predictor of graft rejection, little is known regarding the factors that determine 
lymphocyte MPA concentrations. A large inter-patient variability in MPA C0L and C0P 
concentrations has been observed in this study. The multivariate analysis indicated that MPA 
C0P concentrations was the only independent predictor associated with C0L concentrations 
(explaining 12 % of variance), thus this may explain the poor correlation coefficient found 
between MPA C0L and C0P concentrations. The pre-dose IMPDH activity was not 
significantly associated with MPA C0L concentrations, suggesting that lymphocyte MPA 
concentrations may not provide any better correlation with IMPDH activity, than plasma 
concentrations. Whilst several studies have previously employed total lymphocytes as a form 
of analysis, the measurement of MPA in specific subsets of lymphocytes (e.g. CD4+ cells) 
would be more beneficial rather in lymphocytes as a whole; however, its application may not 
likely be performed for analytical (e.g. analytical challenge of sensitivity) and practical (e.g. 
the need to draw large blood volumes) reasons.  
MPA exerts its immunosuppressive effect by inhibition of IMPDH within lymphocytes, 
which then inhibits lymphocyte proliferation. It is generally thought that the unbound or free 
MPA is presumed to be the pharmacologically active species and capable of inhibiting 
IMPDH; therefore, the unbound MPA concentrations should have a better correlation with 
IMPDH activity than total MPA plasma concentrations. The present study could not confirm 
the inverse relationship between IMPDH activity and MPA plasma levels as there was no 
significant correlation between IMPDH activity and either total, unbound or lymphocyte 
MPA concentrations. Based on these findings, it remains unclear whether unbound MPA 
concentration or IMPDH activity should be measured for appropriate MPA monitoring, as 
well as whether or not IMPDH activity measured on a single time point is better correlated 
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with total or unbound MPA concentrations. It would be interesting to study the AUC of 
IMPDH activity, as it may likely be better correlated with unbound or total MPA AUC. 
Nevertheless, data collected in this thesis may be used in further PK-PD population analyses 
using total and unbound MPA, and also MPAG and AcMPAG concentrations, in 
combination with the existing data on patient characteristics and other clinical covariates. 
These analyses could therefore provide a better comparison and understanding on which 
concentration of MPA, total or unbound, is related to the inhibition of IMPDH activity. 
The PD monitoring of MPA by the measurement of IMPDH activity would be strengthened 
if IMPDH activity was also a better predictor of graft rejection. The pre-dose IMPDH 
activity was slightly but not significantly higher in patients experiencing graft rejection 
compared to those patients without rejection incidence. In addition, the multivariate analysis 
demonstrated that IMPDH activity was not a significant covariate independently associated 
with rejection in our study population. On the basis of the observed findings, it can be 
speculated that IMPDH activity may not be a more sensitive parameter to predict graft 
rejection than lymphocyte MPA concentration. This needs however to be confirmed in a 
larger prospective study. Previous investigation has shown a correlation between pre-
transplant IMPDH activity and the incidence of rejection although this observation has not 
been confirmed and replicated in larger multi-centre prospective studies. Consequently, it is 
important to further investigate if IMPDH activity (pre- and post-transplant) could 
potentially provide a decision support tool for guiding MPA therapy prior to transplantation, 
in order to achieve an individualised approach to maximising clinical outcomes following 
renal transplantation.  
 




In the light of current findings in this thesis, a revised summary of the hypothetical 
mechanisms originally outlined in Chapter 1, Figure 1.5, of factors affecting MPA PK and 
distribution into lymphocytes and kidney graft, and their association with kidney 









Figure 5.1 Revised summary of the hypothetical mechanisms of factors of both the 
transplant recipient and donor graft that determine concentrations of MPA in plasma, 
circulating lymphocytes and the kidney graft tissue based on thesis findings. 
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In conclusion, this thesis has provided sufficient evidence to justify further prospective 
investigation of the role of ABCC2 haplotypes as an important clinical tool for further 
individualising immunosuppressant regimens. There is a need to move beyond 
individualising dose to attain target plasma concentrations to the situation whereby 
distribution into lymphocytes (and graft kidney tissue) is also factored into dosage 
adjustments. The association between IMPDH activity and clinical outcomes requires further 
investigation before prospective validation of individualised MPA therapy based on PD 
monitoring may be initialised. It is hoped that the research outcomes of this thesis might one 
day allow better tailoring of target concentration ranges based on recipient genotype and 
measurements of intracellular and target tissue MPA concentrations (by more efficient drug 
and dosage selection), and consequently improving clinical outcomes following renal 
transplantation.  
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Tissue MPA  concentrations
Transplantation
a  b  s  t  r  a  c  t
Mycophenolic  acid  (MPA)  has  a low  therapeutic  index  and  large  inter-individual  pharmacokinetic  vari-
ability  necessitating  therapeutic  drug  monitoring  to  individualise  dosing  after  transplantation.  There  is
an ongoing  discrepancy  as to  whether  plasma  MPA  concentrations  sufficiently  predict  kidney  rejection
or  toxicity  and  whether  immunosuppressant  concentrations  within  the  graft  tissue  may  better  predict
transplant  outcomes.  The  aim  of the  study  was  to develop  an LC–MS/MS  method  for  the  quantification  of
MPA  concentrations  in human  kidney  biopsies  taken  as part of  routine  clinical  procedures.  A  total  of  4 sur-
plus  human  kidney  biopsies  obtained  from  4  different  kidney  transplant  recipients  were  available  to use
for  this  study.  MPA  was  also  quantified  in  2 kidney  samples  from  rats  administered  MPA  to assess  tissue
extraction  reproducibility.  Human  kidney  biopsies  and  rat kidneys  were  homogenised  mechanically  and
underwent  liquid–liquid  extraction  before  analysis  by  LC–MS/MS.  MPA-free  human  kidney  tissue  was
used  in  calibrators  and  quality  control  samples.  Analyte  detection  was  achieved  from  multiple  reaction
monitoring  of the  ammonium  adducts  of both  MPA  (m/z  321.1  →  207.3)  and  N-phthaloyl-l-phenylalanine
(PPA, internal  standard,  m/z 296.2 →  250.2)  using  positive  electrospray  ionisation.  The  method  was linear
(calibration  curves  R2 >  0.99,  n = 10),  precise,  and  accurate  with  coefficients  of variation  and  bias  less  than
15%.  Extraction  efficiencies  for MPA  and  PPA were  approximately  97%  and  86%,  respectively,  and  matrix
effects  were  minimal.  In  4 kidney  transplant  recipients,  tissue  MPA  concentrations  ranged  from  1.3  to
7.7 ng/mg  of tissue,  however,  the  correlation  between  blood  (C0) and  tissue  MPA  concentrations  could
not be established.  The  method  was  successfully  applied  to the  quantification  of MPA in human  kidney
biopsies  without  the  need  to alter  current  clinical  protocols.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
Mycophenolic acid (MPA) is a widely prescribed immuno-
suppressant for the prevention of rejection following kidney
transplantation (Fig. 1) [1], usually in combination with other
immunosuppressant drugs, most commonly a calcineurin inhibitor
(cyclosporine or tacrolimus) and prednisolone. Due to a narrow
therapeutic index and significant inter-subject pharmacokinetic
variability [2,3], MPA  requires therapeutic drug monitoring (TDM)
to individualise dosing, ensuring optimal plasma concentrations
∗ Corresponding author at: Department of Clinical Pharmacology, Basil Het-
zel Institute for Translational Health Research, The Queen Elizabeth Hospital, 28
Woodville Road, Woodville, SA 5011, Australia. Tel.: +61 8 8222 6510;
fax: +61 8 8222 6033.
E-mail address: benedetta.sallustio@health.sa.gov.au (B.C. Sallustio).
to prevent organ rejection and minimise the incidence of adverse
events such as leukopenia and diarrhoea [3,4]. MPA pre-dose
trough (C0) concentrations are a relatively good indicator of total
drug exposure [5] and the acceptable plasma therapeutic range
for MPA  C0 is 1.0–3.5 mg/L [3]. Lower plasma C0 MPA concentra-
tions have been shown to correlate significantly with the risk of
rejection whereas high MPA  C0 values were associated with an
increased risk of toxicity [6–8]. Although TDM from plasma is nec-
essary for individualisation of MPA  dosage, both acute rejection and
adverse events still occur after kidney transplantation [9], further
reinforcing that TDM alone may  be inadequate in predicting target
tissue concentrations and consequently therapeutic efficacy and/or
safety. In contrast, MPA  concentrations within lymphocytes or the
graft tissue may  provide more clinically relevant information on the
immunosuppressive efficacy of MPA. Previous studies in liver and
kidney transplant recipients suggest that rejection was associated
with low concentrations of tacrolimus [10–12] and cyclosporine
1570-0232/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
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Fig. 1. Chemical structures of (A) mycophenolic acid (MPA) and (B) N-phthaloyl-l-
phenylalanine (PPA, internal standard). Sites for MPA  glucuronidation are shown by
the  arrows.
[13–15] within the graft tissue, but not with those in whole blood.
To our knowledge, no previous studies have examined tissue MPA
concentrations in human kidney biopsies and determined if the
concentrations within the graft tissue correlate to the outcomes of
rejection and toxicity compared to plasma concentrations.
The aim of this study was to develop and validate a liquid
chromatography–tandem mass spectrometry (LC–MS/MS) method
capable of accurately quantifying MPA  concentrations in human
kidney biopsies from kidney transplant recipients taken as part of
routine clinical procedures. The overall design of the method was
primarily to assess whether MPA  concentrations could be quan-
tified in very small samples of kidney biopsy tissues, which are
shared for histological assessments. In addition, we  also assessed
whether the potential in-source ion fragmentation of the metabo-
lites of MPA  (ether- and acyl-glucuronides) to MPA [16,17] would
result in an overestimation of MPA  concentrations by LC–MS/MS.
2. Materials and methods
2.1. Chemicals and reagents
Mycophenolic acid (MPA), tacrolimus, ammonium acetate,
formic acid, tertiary-butyl methyl ether (t-BME) and N-phthaloyl-
l-phenylalanine (PPA, internal standard (IS)) were sourced from
Sigma–Aldrich (Castle Hill, NSW, Australia). MPA  ether- (MPAG)
and acyl- (AcMPAG) glucuronides were purchased from Roche
Pharmaceuticals (Palo Alto, CA, USA). Cyclosporine and everolimus
were purchased from Novartis Pharmaceuticals Australia Pty. Ltd.
(North Ryde, NSW, Australia), and sirolimus from Wyeth Research
(NJ, USA). HPLC-grade methanol (MeOH) was purchased from
Thermofisher Pty Ltd (Scoreby, VIC, Australia). Sodium chloride
(NaCl), sodium dihydrogen orthophosphate (NaH2PO4·H2O) and
hydrochloric acid (HCl) were supplied by Ajax Finechem Pty
Ltd (Taren Point, NSW, Australia). Sodium dihydrogen phosphate
(NaH2PO4) and ethanol were obtained from Chem Supply (Gillman,
SA, Australia). Potassium chloride (KCl) and potassium dihydro-
gen phosphate (KH2PO4) were purchased from Ajax Chemicals
(Auburn, NSW, Australia). Ultrapure, de-ionised water (≥18.2 m!,
Cascada AN-water Purification system, Pall, Cheltenham, VIC,
Australia) was used throughout the assay.
2.2. Human and animals tissues
Human kidney tissue obtained from a non-transplant nephrec-
tomy patient (The Queen Elizabeth Hospital Ethics of Human
Research Committee, approval number 2008178) who  was not
administered MPA, was  used to prepare the calibrators and quality
control (QC) samples. Two rat kidney samples used as biologi-
cal QCs in this study were obtained from a previous study [18].
Briefly, adult male transport-deficient (TR-) Wistar rats (HRD-AMC
Abcc2) had been purchased from Harlan (Horst, the Netherlands)
and ethics approval had been obtained from the Animal Experi-
ments Committee of the Eramus Medical Center. The rats received
20 mg/kg bodyweight mycophenolate mofetil (the prodrug of MPA;
Cellcept®, Roche Bioscience, Palo Alto, CA, USA) in combination
with 4 mg/kg bodyweight tacrolimus daily (oral microemulsion for-
mulation, 10 mg/mL; Prograf®, Fujisawa Pharmaceutical Co. Ltd.,
Osaka, Japan), starting on day 7 and continuing through day 14
before being sacrificed. Kidney samples were then harvested and
immediately stored at −80 ◦C until the day of assay. All harvested
tissues were divided and assayed as biopsy-sized samples there-
after.
2.3. Measurement of tissue MPA concentrations
On the day of assay, frozen human and rat kidney specimens
were thawed at room temperature and cut into biopsy-sized pieces
as required (approximately 0.5–1.0 mm3), using a clean scalpel
blade and placed in a clean eppendorf tube (Sarstedt AG & Co, Nüm-
brecht, Germany). Patient biopsy specimens stored in TissueTek®
solution (ProSciTech, Thuringowa, QLD, Australia) were removed
from aluminium packaging and placed in an empty eppendorf tube
to thaw. The biopsy specimens were displaced from the TissueTek®
solution with a clean, unused pipette tip to the top of the eppen-
dorf tube. The biopsy specimens were then rinsed with 2–3 drops
of water, blotted dried on lint-free tissue and transferred to clean
eppendorf tubes. Each tissue specimen was weighed before under-
going mechanical homogenisation. Briefly, a chilled mortar and
pestle was used to grind the specimens to a fine powder. At this
stage, 200 !L of phosphate buffered saline (pH 7.4) was added to
each tissue specimen and was  mixed thoroughly around the mor-
tar with the pestle before being transferred into a 5 mL  disposable
glass tube, appropriately labelled. To each sample, 5 !L of PPA inter-
nal standard (0.1 mg/L), 60 !L of HCl (0.4 M)  and 1 mL  of t-BME
were added. Samples were mixed on a roller mixer for 10 min  at a
gentle speed ensuring that the samples were not mixed too vigor-
ously as this may  result in the formation of an emulsion. The tubes
were then centrifuged at 4000 rpm (1900 × g) at 4 ◦C for 10 min.
The aqueous layer was  then snap-frozen in an ethanol/dry ice bath,
the organic layer removed and evaporated using an evacuated cen-
trifuge at 45 ◦C for approximately 20 min. The dried residues were
reconstituted with 50 !L of 50/50 methanol/water, vortexed and
transferred to vial-inserts. Ten microlitres of the reconstituted solu-
tions were injected onto the LC–MS/MS for analysis.
2.4. Preparation of calibration curve standards and quality
control (QC) samples
All calibrators and QC samples were prepared using a blank,
MPA-free, human kidney tissue obtained from the non-transplant
nephrectomy patient. MPA  working solutions for calibration curve
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standards were prepared from MPA  stock solution (100 mg/L in
100% MeOH) and were then used to spike blank human kidney tis-
sue in homogenisation buffer, to final concentrations of 0.6, 1.0, 2.0,
5.0, 10.0 and 20.0 ng/mL. Similarly, QC samples were prepared by
spiking blank human kidney sample in homogenisation buffer with
an independently prepared MPA  stock solution (100 mg/L in 100%
MeOH) to final concentrations of 0.6, 2.0 and 10.0 ng/mL.
As well as spiked controls, two kidney samples obtained from
rats administered MPA  were initially assayed in replicates of 3–6
to determine the concentrations of MPA. Samples from these kid-
neys were then used consistently during method development as
biological QCs to ensure tissue extraction reproducibility.
2.5. LC–MS/MS conditions
Detection of MPA  and PPA IS in rat kidneys and human kidney
biopsies was achieved using an API 3200 tandem mass spec-
trometer (AB Sciex, Mount Waverley, VIC, Australia) operating in
positive electrospray ionisation mode. The spectrometer was  cou-
pled to a Shimadzu UPLC system (Shimadzu USA Manufacturing
Inc, Canby, OR, USA) consisting of a dual Shimadzu LC pump, a
degasser (DGU-20A3), an autosampler (SIL-20AC) and a column
oven (CTO-20AC). The analytical column used was  a 2 × 30 mm
Luna phenyl-hexyl, 5 !m particle size column (Phenomenex, Lane
Cove, NSW, Australia) maintained at 60 ◦C. Mobile phases A and
B consisted of 100% water or 100% methanol, respectively, with
both solutions also containing 2 mM ammonium acetate and 0.1%
formic acid, which assisted the formation of positive ammonium
adducts used for MPA  and PPA detection by the mass spectrom-
eter. The mobile phases were filtered, degassed and pumped at a
flow rate of 0.5 mL/min with the ratio of mobile phase A:B at 50:50
for 0.0–1.2 min  and then changed to the ratio of 5:95 (A:B) for the
remaining 1.2–2.2 min  of the sample run time. The analytical col-
umn  was washed using 50% mobile phase A for a further 30 s prior
to the next sample injection. Ten microlitres of reconstituted solu-
tions were injected onto the analytical column and Analyst v1.5.1
software (AB Sciex, Mount Waverley, VIC, Australia) was used for
data acquisition and quantitation.
The collision energy was set at 25 V, the ionspray voltage was
set at 5500 V and the declustering potential was  set at 25 V and
15 V for MPA  and PPA IS, respectively, allowing optimal detection
of MPA  and PPA by the mass spectrometer. The desolvation tem-
perature was set at 375 ◦C with nitrogen as both the curtain and
collision gas. Analyte detection was obtained from multiple reac-
tion monitoring (MRM)  of the ammonium adducts of both MPA
(m/z 321.1 → 207.3) and PPA IS (m/z 296.2 → 250.2), and calibration
curves were constructed using weighted 1/X least-squares linear
regression analysis of peak area ratios (MPA/PPA internal standard)
versus MPA  concentrations. MPA  tissue concentrations were con-
verted from ng/mL of MPA  in digestion buffer to ng/mg of MPA
in tissue for all unknown human kidney biopsies and rat kidney
samples.
2.6. Method validation
The assay development and validation were performed fol-
lowing the principle of the Food and Drug Administration (FDA)
guidelines for bioanalytical methods [19]. The method was assessed
for accuracy, precision, linearity, extraction efficiency, matrix
effects and stability.
2.6.1. Accuracy, precision and linearity
The highest and lower limit of quantification (LLOQ) calibra-
tors and QC samples were assayed in replicates of 6 in a single
analytical run to obtain intra-day inaccuracy and reproducibility
as well as over 6 consecutive days to obtain inter-day inaccuracy
and reproducibility. The assay was  deemed reproducible if intra-
and inter-day inaccuracy and imprecision for calibrators and QC
samples were both within 15% (or 20% for the LLOQ). Linearity was
assessed and acceptable if the coefficient of determination (R2) for
each of the calibration curves was  greater than 0.99 and calibrator
concentrations did not differ by more than 15% (or 20% for the LLOQ)
from the nominal concentrations. Tissue weighing accuracy and
reproducibility had been assessed previously [15]. Two  rat kidney
tissues were also assayed in 6 replicates within a single analytical
run as well as over 6 separate days to ensure intra- and inter-day
tissue extractions were reproducible. Results were accepted if these
biological QCs had a coefficient of variation below 15%.
2.6.2. Extraction efficiency and matrix effects
Extraction efficiency and matrix effects were estimated using a
post-extraction analyte addition approach, as previously described
[20]. Three sets of samples were prepared at low (2 ng/mL) and
high (20 ng/mL) concentrations. Samples in set 1 consisted of stan-
dards containing the analytes at concentrations of 2 and 20 ng/mL
prepared in 50/50 methanol/water; samples in set 2 consisted of
MPA-free tissue acquired from rat kidney and human kidney tis-
sues, which were spiked with 100 !L of spiking solution to give
final analyte concentrations of 2 and 20 ng/mL, thereafter, the sam-
ples were extracted, as described previously, and the dried residues
were reconstituted in 100 !L of 50/50 methanol/water; samples in
set 3 consisted of MPA-free tissue from the same source as used
in set 2 that were first extracted followed by reconstitution of the
dried residues with 100 !L of 50/50 methanol/water containing the
analytes of interest at amounts of equivalent to the 2 and 20 ng/mL
calibrators. Extraction efficiency was  estimated by comparing MPA
and internal standard peak areas from the samples of set 3 to those
from the corresponding samples of set 2. Matrix effects were deter-
mined by comparing the peak areas of the samples of set 1 to those
from the corresponding samples of set 3. Process efficiency was
determined by comparing sets 3 and 2.
Potential interference from other immunosuppressants that
may  be coadministered with MPA  was also investigated using
post-extraction addition. Based on previous measurement of
cyclosporine [15] and tacrolimus [21] concentrations in human
kidney biopsies, duplicate samples (0.7 mg)  of drug-free human
kidney tissue were homogenised and spiked with 100 !L of 50/50
methanol/water alone or methanol/water containing cyclosporine
(50 ng/mg tissue), tacrolimus, sirolimus and everolimus (all at
1 ng/mg tissue). The samples were then extracted as described
above, and spiked with MPA  and PPA during reconstitution using
50 !L of a 50/50 methanol/water solution containing the equiva-
lent concentrations of a 2 ng/mL calibrator. MPA  and PPA peak areas
in the reconstituted extracts were also compared to direct injection
of the methanol/water spiking solution.
Assessment of matrix effects was  also estimated using a
post-column analyte infusion technique [20,22] that involves post-
column infusion of MPA  and internal standard against injections of
reconstituted blank tissue extract. The sample was  mechanically
extracted and reconstituted in 50/50 methanol/water. Pure solu-
tions of MPA  and internal standard were introduced separately
onto the LC–MS/MS system by an infusion syringe placed after the
chromatographic column and before mass spectrometer ionisation
source in a constant flow [20]. The reconstituted tissue sample
without added analyte was  injected into the LC–MS/MS system,
and the response from the analyte was  recorded and compared to
direct injection of pure 50/50 methanol/water.
2.6.3. Stability
The stability of MPA  in tissues was investigated over a 2
month period in biological QCs that were stored at -80 ◦C, with
replicate samples (n = 3–6) thawed and analysed at 0, 1 and 2
174 Z.I. Md  Dom et al. / J. Chromatogr. B 945– 946 (2014) 171– 177
months together with freshly prepared calibration curves. The sta-
bility of MPA  during chromatographic analysis was  investigated by
repeated injection of an extracted calibrator sample over 24 h.
Stability of MPA  glucuronide metabolites was checked using
authentic MPA  ether- (MPAG) and acyl- (AcMPAG) glucuronides.
Three separate sets of samples were prepared for each MPA  glu-
curonide. Samples in set 1 consisted of pure solutions containing
each of the glucuronides at a concentration of 100 ng/mL prepared
in 50/50 methanol/water and kept at -20 ◦C until ready for injection
onto the LC–MS/MS; samples in set 2 consisted of MPA-free tissue
spiked with AcMPAG or MPAG before being homogenised mechan-
ically; samples in set 3 consisted of MPA-free tissue spiked with
AcMPAG or MPAG after undergoing mechanical homogenisation;
thereafter, samples in sets 2 and 3 were extracted as described pre-
viously and the dried residues were reconstituted in 50 !L of 50/50
methanol/water.
2.7. Clinical application of the method to biopsy specimens from
kidney transplant recipients
A total of 4 excess biopsy specimens obtained from 4 differ-
ent kidney transplant recipients were available for use in this
study. Three of the 4 kidney transplant recipients were taking
MPA, everolimus and prednisolone-, and the other, sirolimus and
prednisolone-based immunosuppression. The kidneys were trans-
planted from living (n = 1) and deceased (n = 3) donors between
February 2006 and April 2010. Informed written consent was
obtained from the recipients and living donor, and where the kid-
ney was obtained from a deceased donor, the recipient was  asked
to provide consent for the use of the biopsy specimen. The study
was approved by the Ethics of Human Research Committee of the
Queen Elizabeth Hospital (approval number 2008178). Biopsies
were taken in cases of suspected rejection, with 1 of 4 biopsies
taken at 8 days post-transplant, 2 taken within the first year post-
transplant, and 1 taken after 4 years post-transplant. Rejection
was defined according to Banff 2007 criteria [23]. Fine core nee-
dle kidney biopsies were routinely divided by pathology staff and
part embedded in paraffin for histological assessment with the
remaining biopsy tissue snap frozen at −80 ◦C in TissueTEK® solu-
tion until the day of the assay.
3. Results
3.1. Assay performance
PPA and MPA  eluted at 1.80 and 1.83 min, respectively, and
total chromatographic analysis time was 2.2 min. Fig. 2(A) shows
a representative chromatogram of an extracted patient kidney
biopsy tissue, with added internal standard (light grey). The
Fig. 2. Representative LC–MS/MS chromatograms from (A) an extracted patient
kidney biopsy tissue (weight 0.33 mg)  with a measured MPA  concentration of
11.0 ng/mL in extraction buffer, equating to 6.7 ng/mg in the biopsy; and MPA-free
human kidney tissues spiked with (B) MPA  ether-glucuronide (MPAG) at the reten-
tion time of 1.51 min, or (C) MPA  acyl-glucuronide (AcMPAG) at the retention time
of  1.63 min. In panels (B) and (C) the MPAG or AcMPAG MRMs are shown in light
grey.
Table 1
Intra- and inter-day inaccuracy (bias) and imprecision of the lowest and highest calibration and low, middle and high QC samples for MPA, and two kidney samples obtained
from  rats administered MPA  (biological QCs).
Intra-day (n = 6) Inter-day (n = 6)
Mean ± SD CV (%) Bias (%) Mean ± SD CV (%) Bias (%)
Calibrators (ng/mL)
0.6 0.61 ± 0.07 10.7 2.2 0.59 ± 0.05 4.6 −0.4
20  20.1 ± 0.66 3.3 0.6 19.9 ± 0.87 4.4 −0.5
QCs  (ng/mL)
0.6 0.60 ± 0.05 8.6 0.1 0.57 ± 0.05 9.5 −5.4
2  1.86 ± 0.25 13.3 −7.3 2.0 ± 0.11 5.5 1.9
10  10.5 ± 0.82 7.8 5.1 10.3 ± 0.49 4.8 2.8
Biological QCs (ng/mg)
A 0.35 ± 0.05 12.8 – 0.35 ± 0.04 12.9 –
B  3.5 ± 0.26 7.3 – 3.6 ± 0.22 6.1 –
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Table 2
Extraction efficiency, matrix effects, and process efficiency of the LC–MS/MS assay in
human and rat kidney samples using the post-extraction analyte addition approach
[20] at MPA  concentrations of 2 (low) and 20 (high) ng/mL.
Human kidney Rat kidney
Low High Low High
Extraction efficiency MPA 97% 98% 94% 89%
PPA 88% 86% 83% 86%
MPA/PPA 103% 104% 100% 103%
Matrix effect MPA  −4% 2% 0% 10%
PPA −2% 9% −5% 10%
MPA/PPA −2% −6% 5% 0%
Process efficiency MPA 94% 99% 95% 98%
PPA 94% 95% 92% 95%
MPA/PPA 101% 105% 103% 105%
calibration curves were linear over the concentration range of
0.6–20.0 ng/mL, with coefficients of determination, R2, greater
than 0.997 (mean ± SD; 0.999 ± 0.00096, n = 10) routinely obtained.
Intra- and inter-day inaccuracy and reproducibility for calibra-
tion curves and QC samples was less than 15% (Table 1). Tissue
extraction reproducibility was determined using two  rat kidneys
from abcc2-deficient rats administered MPA. The mean (± SD) kid-
ney MPA  concentrations (n = 3–6 replicates) were 0.35 (±0.04) and
3.5 (±0.26) ng/mg of tissue. Tissue extraction from the rat kidney
samples was considered reproducible and within acceptable limits
(CV < 13%, n = 6) (Table 1). These rat kidneys were used consistently
during method development and validation as biological QCs.
Extraction efficiency, matrix effects and process efficiency were
all acceptable, as shown in Table 2. There was no evidence for a
matrix effect in human kidney tissue. However, for rat kidney, a
small matrix effect in the form of ion enhancement was  observed
at a higher concentration of MPA  (Table 2), although it was well
Fig. 3. Post-column infusion traces of (A) MPA  and (B) PPA IS following injections
of  analyte-free human kidney tissue extract (light grey) and mobile phase (black).
Expected analyte peak widths are indicated by double arrow on the chromatograms.
Fig. 4. Kidney (!) MPA  concentrations measured in 4 kidney transplant recipients
over 8–1651 days post-transplantation. All recipients also received prednisolone
and one other immunosuppressant (as indicated). Numbers in parenthesis indi-
cate the time biopsies were taken post-transplantation (days) and the shading
(1.0–3.5 mg/L) indicates the plasma therapeutic range for C0.
within the acceptable limit of ±15% as discussed previously [20,24],
and was similar for both MPA  and PPA. Other immunosuppress-
ants likely to be co-administered with MPA  had no significant
effects on either MPA  or PPA peak areas, except sirolimus, which
appeared to interfere with the detection of MPA, decreasing peak
area by 39%. In the post-column infusion technique, Fig. 3 shows
a comparison of an injection of analyte-free human kidney tis-
sue extract (light grey) and mobile phase (black) for MPA  (A) and
PPA IS (B). MPA  and PPA IS co-eluted outside of the area of ion
suppression.
MPA in tissues stored at −80 ◦C was  stable over a 2 month period,
with mean measured MPA  concentrations varying by less than 15%.
MPA  was  similarly stable at room temperature during chromato-
graphic analysis with peak areas varying 4.2–16.5% for repeated
injections over 24 h.
The stability of MPA  glucuronide metabolites was  checked by
comparing the peak areas of both metabolites in pure solution,
before and after undergoing mechanical homogenisation. There
was no difference in the peak areas of MPA  metabolites before and
after mechanical homogenisation and no MPA  peak was  observed
at its retention time on the chromatograms (Fig. 2). In contrast, a
peak was observed in the MPA  MRM  corresponding to the reten-
tion times of MPAG or AcMPAG, 1.51 and 1.63 min, respectively,
as shown in Fig. 2(B) and (C), respectively. This could be due to
in-source ion fragmentation of the glucuronides to MPA  during the
ionisation procedure inside the mass spectrometer. However, since
we were able to separate both glucuronide metabolites from MPA
chromatographically; this in-source fragmentation did not inter-
fere with quantification of MPA.
3.2. Method application to biopsy specimens from kidney
transplant patients
Mean (±SD, range) patient biopsy weights were 0.18 (±0.1,
0.11–0.33) mg,  and tissue MPA  concentrations measured in each
patient biopsy from 4 kidney transplant recipients were 1.25
(biopsy taken at 8 days post-transplant; co-administered with
everolimus), 1.77 (524 days post-transplant; co-administered with
sirolimus), 6.67 (693 days post-transplant; co-administered with
everolimus) and 7.67 (1651 days post-transplant; co-administered
with everolimus) ng/mg of tissue, as shown in Fig. 4. Tissue MPA
concentrations were all within the calibration curve range. Two
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of the 4 MPA  biopsy concentrations were of a similar magnitude
to the plasma therapeutic range for C0 (1–3.5 mg/L) and the other
two biopsies concentrations were above this range. Plasma MPA
C0 concentrations were not available for all patients and therefore
the correlation between plasma (C0) and tissue MPA  concentrations
could not be established in this study.
4. Discussion and conclusions
The quantification of MPA  concentrations within the graft tis-
sue may  provide a better understanding of MPA  distribution
during kidney rejection. Previous studies in liver and kidney trans-
plant recipients showed that intra-graft tacrolimus [10–12] and
cyclosporine [13–15] concentrations are better predictors of trans-
plant outcomes compared to whole blood concentrations. No study
to date has examined tissue MPA  concentrations in kidney trans-
plant recipients to determine whether MPA  concentrations within
the graft tissue may  better reflect or predict transplant outcomes.
This study aimed to develop a method suitable for the quantifi-
cation of MPA  in human kidney biopsies from kidney transplant
recipients taken as part of routine clinical care. Several analytical
methods have been reported for the quantification of MPA  concen-
trations in plasma [25–29]; however, to our knowledge, this is the
first study to measure tissue MPA  concentrations in human kidney
biopsies taken as part of routine clinical procedures.
The method has been comprehensively assessed following
the principle of the FDA criteria for industry on bioanalytical
methods [19] and several aspects of this method are based on
our previous method for the quantification of the calcineurin
inhibitor tacrolimus in human kidney biopsy specimens [21]. Like
tacrolimus, detection of MPA  was also based on MRM  monitoring
of the ammonium adducts, similar to several other published MPA
methods measuring MPA  in plasma [30–32] to enhance greater
overall immunosuppressant assay flow-through on the LC–MS/MS
system. However, several changes to the tacrolimus method were
also necessary to maximise analyte peak intensity and improve
the sensitivity. This method employed mechanical homogenisation
using a mortar and pestle followed by liquid–liquid extraction of
the drug in biopsy samples. Enzymatic tissue digestion had been
used previously for the tacrolimus method [21] and has some
advantages over mechanical homogenisation particularly minimis-
ing sample handling and analyte loss that may  occur in the process.
However, the solubilisation is carried out at alkaline pH and may
hydrolyse the relatively unstable AcMPAG during sample prepara-
tion. This study demonstrated that the mechanical homogenisation
technique prevented degradation of the glucuronides and produced
excellent extraction efficiency (approximately 97%) and high pro-
cess efficiency, and therefore can be considered as an alternative
sample preparation technique for the analysis of small biopsy-sized
samples. Furthermore, the use of biological QCs obtained from rats
administered MPA  also provided additional assessment and vali-
dation of the reproducibility of the tissue extraction procedures.
Liquid–liquid extraction has been used in our sample preparation
as it has been shown to minimise potential matrix interference
in comparison to the solid-phase extraction technique [33] and
this method demonstrated no significant matrix effects in human
samples and practically negligible ion enhancement (≤10%) in rat
kidney samples. Initially, carboxy-butoxy ether mycophenolic acid
(MPAC) had been selected as the internal standard, however MPAC
produced an interfering peak in the MPA  trace (most likely due to
in-source fragmentation) and was replaced by PPA, which provides
overall accuracy, precision and specificity well within acceptable
limits in both human and rat tissues. The use of stable labelled
internal standards (MPA-d3) is highly recommended to adequately
compensate for matrix effects, and may  contribute to improved
performances, however deuterated internal standard was not avail-
able at the time of developing the method.
We  have demonstrated no interference in the quantification
of tissue MPA  concentrations by cyclosporine, tacrolimus and
everolimus, the other commonly co-administered immunosup-
pressants. However, sirolimus appeared to cause underestimation
of MPA  and the method may  require further validation before
MPA  concentrations can be measured in tissues also exposed to
sirolimus. Regarding potential analytical interference from the
metabolites of MPA, the in-source ion fragmentation of drug
metabolites to their respective parent analyte has been discussed
previously [16] and a previous study by Vogeser and colleagues [17]
has demonstrated that the in-source ion fragmentation of MPAG
can interfere with the quantification of MPA. We  have checked with
pure MPAG and AcMPAG solutions that both metabolites did not
interfere with the detection and quantification of MPA. Although
in-source ion fragmentation of the glucuronides into MPA was
observed at the retention times of MPAG and AcMPAG, the chro-
matographic separation of the two MPA  glucuronides from MPA
resulted in no interference with the quantification of MPA. This
factor must be assessed critically during method development to
ensure a correct detection and quantification of the actual MPA
peak, since falsely high MPA  concentrations could lead to lower
dose administration and potentially an increased risk of rejection
in kidney transplant recipients.
The LC–MS/MS method has allowed for the accurate and precise
quantification of MPA  in biopsy-sized tissue samples taken as part
of routine clinical care. As same-day plasma MPA  C0 concentrations
were not available for the biopsy specimens in this small study, we
were unable to investigate any relationships between kidney MPA
concentrations and those in plasma. However, it appears that graft
MPA  concentrations were of a similar magnitude to the C0 thera-
peutic range for MPA. In comparison, we  have previously reported
tissue to blood concentration ratios of 4 and 20 for cyclosporine
[15] and tacrolimus [21], respectively, with no correlation between
their concentrations in whole blood and those within the kidney,
consistent with other published studies [10,11,13]. However, small
sample size was a limitation for this and our two previous studies
[15,21]. In addition, this study may  also have been limited by the
age of the biopsy samples, as the stability of MPAG and AcMPAG
during long-term storage could not be assessed.
In summary, this method has been successfully used for
quantification of MPA  concentrations in core needle biopsies
from kidney transplant recipients taken as part of routine clinical
care. In contrast to previously published studies [11,14], clinical
practice in this study did not allow prospective acquisition of
excess biopsy specimen. In addition, due to shared histological
assessments and processing of biopsy specimens, this method
was primarily designed to quantify MPA  in routine core needle
biopsies of kidney transplant recipients weighing as little as
0.1 mg.  Nonetheless, these limitations have ensured that our assay
benefits unaltered biopsy sampling and handling to fit into current
clinical practice, and therefore will allow further investigations on
the immunosuppressant MPA  concentrations in the transplanted
organ and their relationship with clinical outcomes following
kidney transplantation.
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